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ABSTRACT 
 
                Mastitis is the most prevalent and major cause of economic losses in dairy farms. 
Bovine mastitis caused by strains of S. aureus is a major economically important disease 
affecting the dairy industry worldwide.  S. aureus is one of the most common udder pathogens 
that cause either clinical or sub-clinical mammary gland infections. Different treatment regimes 
have failed to cure S. aureus intramammary infections. Most mastitis vaccination strategies have 
focused on the enhancement of systemic humoral immunity rather than strengthening local 
intramammary immunity. Vaccines aimed at enhancing intramammary immunity of dairy cows 
against S. aureus mastitis have had limited success. Commercially available vaccines show 
various degrees of success and work in research laboratories with experimental vaccines suggest 
that in part, the failure of these vaccines lies in the limited antigenic repertoire contained in the 
vaccine formulations. Moreover, not only does variation in the antigenic composition but also 
presence of capsular polysaccharide in most pathogenic strains and decreased activity of immune 
effectors in milk affect the success of vaccines. In addition to these, the ability of S. aureus to 
attach and internalize into mammary epithelial cells, enables bacteria to escape from the effect of 
immunity and antibiotics by being hidden in the intracellular niche and thereby causing chronic 
recurrent intramammary infection.  S. aureus also has the ability to become electron-transport-
defective and to form slow-growing small colonies that are non haemolytic and less virulent. 
These small colony variants might hide from the immune surveillance in the intracellular area 
and revert to the parental strain causing chronic recurrent infections. If immunization targets 
antigenic molecules that are conserved throughout all pathogenic strains, even the small colony 
variants can be controlled since the immune system will clear the parental strain which causes 
lethal infection. Thus, immunization trials should focus on conserved immunogenic antigen 
molecules among pathogenic strains formulated with an adjuvant and delivered by a route of 
immunization to induce maximum stimulation of the immune system. Moreover, immunization 
should focus on inducing Th1 responses, which is protective against S. aureus mastitis.  It has 
been reported that proteins with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity 
might be used as such antigens to induce protection against parasitic and microbial infections. 
Previous study in our laboratory on mastitis-causing streptococci indicates that GapC proteins of 
S. uberis and S. dysgalactiae have potential as vaccine antigens to protect dairy cows against 
mastitis caused by environmental streptococci. Two conserved cell wall associated proteins with 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, GapB and GapC have been 
identified from S. aureus isolates from bovine intramammary infections. The overall goal of this 
study was to improve our understanding on intramammary immunity using the GapC and GapB 
proteins of S. aureus as model antigens for mastitis and to determine the regulation of expression 
of gapB and gapC genes and their roles in the pathogenesis of bovine S. aureus mastitis. We 
hypothesized that strengthening local intramammary immunity using GapB and GapC proteins 
of S. aureus as antigens will protect against bovine S. aureus mastitis. To test this hypothesis we 
took the approach of using the gapB and gapC genes and constructed plasmids encoding GapB, 
GapC and GapB::GapC (GapC/B) chimeric proteins. We set six objectives to test our hypothesis 
using these proteins to enhance the intramammary immunity. In aim 1 we constructed plasmids 
encoding the GapB, GapC proteins and also constructed a chimeric gene encoding the GapC and 
GapB proteins as a single entity (GapC/B chimera) as the basis for a multivalent vaccine.  In this 
objective the humoral and cellular immune responses to GapC/B were compared to the responses 
to the individual proteins alone or in combination in C57 BL/6 mice. Our results showed that the 
GapC/B protein elicited strong humoral and cellular immune responses as judged by the levels of 
total IgG, IgG1, IgG2a, IL-4 and IFN-γ secretion and lymphocyte proliferation. These results 
strongly suggest the potential of this chimeric protein as a target for vaccine production to 
control mastitis caused by S. aureus. In aim 2 we continued our studies on GapC/B by testing the 
effects of DNA vaccination with plasmids encoding the individual gapB and gapC genes as well 
as the gapC/B protein gene with or without a boost with the recombinant proteins.   The results 
showed that DNA vaccination alone was unable to elicit a significant humoral response and 
barely able to elicit a detectable cell-mediated response to the recombinant antigens but 
subsequent immunization with the proteins elicited an excellent response.  In addition, we found 
that DNA vaccination using a plasmid encoding the GapC/B chimera followed by a boost with 
the same protein, although successful, is less effective than priming with plasmids encoding 
GapB or GapC followed by a boost with the individual antigens.  In aim 3 we optimized immune 
responses in cows by comparing route of vaccination (subcutaneous versus intradermal), site of 
vaccination (locally at the area drained by the supramammary lymph node versus distantly at 
area drained by parotid lymph node. Our results showed that both subcutaneous and intradermal 
immunizations with the GapC/B protein at the area drained by the supramammary and  parotid 
lymph nodes resulted in significantly increased serum and milk titers of total IgG, IgG1, IgG2, 
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and IgA in all vaccinated groups as compared to placebo. The anti-GapC/B IgG1 serum and milk 
titers were significantly higher in all vaccinated group as compared to the placebo group. These 
results indicated that vaccination at the area drained by the supramammary lymph node resulted 
in better immune responses. In aim 4 we tested different formulations of the GapC/B antigen 
with adjuvants such as PCPP, CpG, PCPP + CpG and VSA-3.  We found that the VSA-3 
formulation induced the best immune responses in cows. In this objective we also monitored 
immune responses longitudinally over one lactation cycle to determine the duration of immune 
responses by measuring IgG, IgG1, IgG2, and IgA on monthly blood and milk samples. We 
found that the duration of immune responses was about four months.  In aim 5 we tested the role 
of GapC in the virulence of S. aureus mastitis using the S. aureus wild type strain RN6390 and 
its isogenic GapC mutant strain H330. Our results from both in vitro adhesion and invasion 
assays on MAC- T cells and in vivo infection of ovine mammary glands showed that GapC is an 
important virulence factor in S. aureus mastitis. In aim 6 we examined the role of sar and agr 
loci on the expression of gapC and gapB genes by qRT- PCR using S. aureus RN6390 and its 
isogenic mutants defective in agrA, sarA and sar/agr (double mutant) at exponential and 
stationary phases of growth. Our results showed that both gapB and gapC expression were down 
regulated in the mutant strains, indicating that the expression of the gapB and gapC genes is 
controlled by the universal virulence gene regulators, agr and sar. We also checked the role of 
environmental factors such as pH, growth media, and oxygen tension on the expression of gapB 
and gapC using q-RT-PCR.  Our results showed that the expression of gapB and gapC genes in 
different strains of S. aureus was not consistent under the above-mentioned environmental 
conditions. 
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1. LITERATURE REVIEW 
 
1.1. Mastitis 
 
Mastitis is defined as an inflammation of the mammary gland which is characterized by 
redness, heat, swelling and pain. Mastitis is often expressed as an increased somatic cell count in 
the milk with isolation of potentially mastitis causing pathogens [1, 2]. Microorganisms, irritant 
chemicals and physical or mechanical damage can cause inflammation of a mammary gland. 
Although the impact of mammary gland inflammation by chemicals and physical or mechanical 
damage on dairy productivity is not known, almost all cases of mastitis in dairy farming are 
believed to be caused by pathogenic microorganisms. In dairy cows the cause is nearly always 
pathogenic microorganisms [3], usually contagious (S. aureus, S. agalactiae, Mycoplasma  and 
Arcanobacterium) and environmental  (coliform bacteria group and the environmental 
streptococci) [4-6] bacteria. The main reservoirs of infection for contagious and environmental 
mammary pathogens are infected quarters and the surrounding environment of dairy cows, 
respectively. The genetic selection of cows for milk production has increased milk productivity 
but decreased resistance to mastitis. This decreased resistance to mastitis is believed to be due to 
metabolic stresses associated with milk production [7-9]. Improper use of milking machines, 
intensive indoor housing, and use of bedding materials that support bacterial growth also have a 
significant impact on predisposing dairy cows to mastitis  [10].  Some of the factors known to 
affect the incidence and prevalence of mastitis are lactation stage, parity number, damage to the 
skin of the udder, and season [11-13]. The complex interaction between the intramammary 
pathogens, mammary gland immune effectors and environmental factors that play a role in the 
establishment of intramammary infection as well as protective intramammary immunity should 
be clearly defined for an appropriate immunization strategy to be implemented. 
 
Infection of the mammary gland by pathogenic microorganisms results in either clinical 
or subclinical mastitis. Clinical mastitis is characterized by visible inflammatory changes in the 
mammary gland and changes in milk quality and composition. These changes can be detected by 
physical clinical examination. Bacteriological culture of milk from clinical mastitis is also 
important to identify causative agents. However, bacteriological milk culturing should be done 
early in the development of mastitis since some culture results might be negative since the causal 
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agent could be removed by the host immune system. Local clinical signs of mastitis include a 
swollen udder with hard consistency, changes in milk colour and consistency, and a painful 
udder. Systemic signs of clinical mastitis include increased body temperature, depression, and 
loss of appetite and weight while in subclinical mastitis, there are no grossly visible 
inflammatory changes in both gland tissue and milk. Inflammation can only be detected by the 
presence of increased numbers of somatic cells in the milk.  
 
  Mastitis is a major cause of economic losses in dairy farming [14-16]. These losses are 
primarily due to reduced milk yield [15, 17], rapid spoilage of mastitic milk and the discarding of 
milk with antibiotics [18], treatment and replacement costs [19, 20], lower price of poor quality 
milk [20, 21], increased culling rate or death from infection [22, 23], and decreased fertility [24, 
25]. Mastitis also affects public health due to food spoilage by pathogenic microorganisms in 
mastitic milk [26-28] and production of toxins by these microorganisms [29, 30]. Some potential 
mastitis pathogens such as Mycobacterium, Brucella, and Leptospira and Listeria species are 
zoonotic microorganisms that can infect humans from dairy products [31]. These pathogens can 
be shed through milk either from a primary gland infection or as secondary events to other 
systemic infections in the body. Frequent antibiotic treatment of mastitic cows may lead to 
increased prevalence of antibiotic resistance in animal pathogens and subsequent transfer of 
bacteria or a resistance gene to human pathogens [32-34]. 
 
1.2. Bovine Staphylococcus aureus Mastitis 
 
Taxonomically, S. aureus belongs to the family of Staphylococcaceae and genus 
Staphylococcus. It is Gram-positive, catalase and coagulase positive, nonspore forming, oxidase 
negative, nonmotile, cluster-forming, facultative anaerobe that grows by aerobic respiration or by 
fermentation that yields lactic acid.  It can ferment mannitol which is one of the tests to 
distinguish S. aureus from S. epidermidis. In spite of the fact that the coagulase test is not 
accurate for the identification of S. aureus, more than 95% of all coagulase positive 
staphylococci from bovine mastitis belong to S. aureus [35]. Other coagulase-positive strains are 
S. hyicus and S. intermedius.  S. aureus can grow at a temperature range of 15 to 45 °C and at 
NaCl concentrations as high as 15%. It forms golden yellow colonies on solid growth media. 
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S. aureus is one of the most frequently isolated contagious mastitis pathogens that cause 
either clinical or subclinical mammary gland infection [36, 37]. The prevalence of S. aureus 
mastitis could increase from < 5% to more than 30% in a year, causing significant increases in 
milk somatic cell count [38]. Multiple strains can be involved in causing mastitis in a single herd 
or in different herds from a similar or a different geographical area [39, 40]. An individual cow 
[40, 41] or quarter of the same udder [42] may be infected simultaneously by more than one 
strain of S. aureus. However, in different countries only clones that have a wide geographic 
distribution are responsible for most of the cases of bovine intramammary infections [43]. 
Studies to determine the diversity of S. aureus colonizing cattle and humans indicated that the 
strains prevalent in humans were not similar to the causative agents of bovine mastitis [44]. The 
virulence potential does not differ significantly between human and animal isolates of S. aureus; 
however, S. aureus that causes mastitis in farm animals represent a separate genetic cluster 
dominated by the presence of the toxic shock syndrome toxin encoding gene [45]. 
The main reservoirs of S. aureus are infected quarters and the skin of the udder and the teat [46]. 
The molecular epidemiological analysis of S. aureus strains from diverse clinical and 
geographical origins using pulsed-field gel electrophoresis and binary typing indicated an 
association between distinct genotypes and severity of mastitis [40]. 
  
1.2.1. Staphylococcus aureus Virulence Factors   
 
S. aureus colonizes the teat end and it moves to the intramammary area either by 
progressive colonization or by the changes in intramammary pressure, especially at the end of 
milking [36]. In the intramammary area it can adhere to epithelial cells, multiply and colonize 
the tissue [36, 47, 48]. The pathogenicity of S. aureus is multifactorial and most staphylococcal 
diseases are due to many combined factors rather than a single factor. The S. aureus virulence 
factors comprise cell surface structural components such as proteins, lipids, carbohydrates, 
proteoglycans, glycolipids and secretory products. Based on their biological activities, S. aureus 
virulence factors can be divided into three general functional categories: those that mediate 
adhesion of bacteria to host cells or tissue (adhesins), those that promote tissue damage and 
spread (invasins) and those that protect the bacteria from the host immune system. Thus, the 
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pathogenicity of S. aureus depends on the combined action of cell surface structural components, 
different extracellular toxins and enzymes [49]. The expression of virulence factors of S. aureus 
is dependent on the bacterial growth phase. The cell surface components are expressed during 
exponential growth phase whereas the secretory factors are expressed during post exponential 
growth phase [50-54] (Fig. 1.2.1.7). 
 
1.2.1.1. Staphylococcus aureus cells Surface Proteins, Carbohydrates and Other  
             Structural Components 
 
 
i. Protein A 
  The cell surface of S. aureus comprises the cell wall, the underlying cell membrane 
and in most pathogenic strains the outer layers of exo polysaccharides [55, 56].  Protein A is 
distributed throughout the cell wall in most virulent strains of S. aureus isolated from bovine 
intramammary infections [57] and is believed to have antiphagocytic activity [56-58]. Protein 
A binds to the Fc portion of IgG antibody and prevents the action of anti-staphylococcal 
activity [59]. Structurally, protein A is linked to the cell wall and the N-terminal domain 
which contains five IgG binding repeats is exposed on the bacterial cell surface [60, 61]. The 
five N-terminal repeat domain binds to CH2 and CH3 segments of the Fc portion of IgG [61, 
62] which is at the Cγ2-Cγ3 domain interface region [63, 64]. Staphylococcal protein A also 
binds to the heavy chain variable region of Fab fragment of some monoclonal and polyclonal 
IgM, IgG, IgA and IgE proteins and this site is believed to be different from the antigen-
binding site because the Fabγ fragment of mouse monoclonal antibody was found to bind both 
protein A and antigen at the same time [65]. 
 
S. aureus also expresses many other proteins including extracellular adherence protein 
(Eap) [66-68],  fibronectin binding proteins (FnBPs) [68-70],, collagen binding protein [71], 
fibrinogen binding proteins (FgBP) [72, 73], a vitronectin binding protein [66], and elastin 
binding protein [74]. These surface proteins serve as adhesins to allow the bacterium to attach 
to the host cell surface during early stage of infection to achieve colonization of host tissue 
(Table 1.2.1.1). 
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ii. Glyceraldehyde-3-phosphate dehydrogenase   (GAPDH) 
 
Two conserved proteins that have glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
activity have been identified in S. aureus including bovine clinical mastitis isolates. These 
proteins were named GapB and GapC [75]. Glyceraldehyde-3-phosphate dehydrogenase is a 
known key glycolytic enzyme in both prokaryotic and eukaryotic organisms that reversibly 
catalyses the oxidative phosphorylation of glyceraldehyde-3-phosphate into 1, 3, bi-
phosphoglycerate.  Results from recent studies revealed that this enzyme is localized on the cell 
surface of many pathogenic microorganisms [75-79] and it binds to cellular molecules such as 
plasmin, transferrin, myosin and actin [75, 78-82]. In streptococci, surface located proteins with 
GAPDH activities have been shown to have pathogenic and immunostimulatory roles. Some of 
these proteins induce post-translational modification of eukaryotic proteins including 
phosphorylation and ADP ribosylation [83]. Glyceraldehyde-3-phosphate dehydrogenase also 
serves as a ligand (adhesin) on the surface of pathogenic microorganisms that binds to specific 
receptor molecules on the surface of host cells [84, 85].  
 
iii. Exopolysaccharides  
 
One of the S. aureus cell surface structural components that have a role in virulence is 
capsular polysaccharide. Capsular polysaccharide is an exopolysaccharide layer that covers the 
cell wall of some strains including most clinical isolates of S. aureus from human infections and 
bovine mastitis [86-90]. There are 11 capsular polysaccharide serotypes in S. aureus isolates 
from human infection whereas 12 serotypes had been identified in strains from bovine mastitis. 
Serotypes 1 and 2 are heavily encapsulated and form mucoid colonies on solid media whereas 
serotypes 3–12 are microencapsulated and form non-mucoid colonies on solid media. Strains of 
serotypes 5 and 8 are frequent isolates from bovine mastitis as is the case with human 
endovascular infection [55, 56, 86, 87]. The capsular polysaccharide does not impede deposition 
of antibodies on the highly antigenic epitopes on cell wall; however, it masks recognition of 
antibody by neutrophils and other phagocytic cells [56, 57, 91, 92]. However, if antibody is 
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produced against capsule itself, for example by attaching capsule to immunogenic carrier 
molecule (hapten), it serves as effective opsonins for neutrophils [93, 94] 
 
Slime is an exopolysaccharide component loosely bound to the bacterial surface [56, 91, 
95]. It has the characteristic feature of enabling bacteria to form microcolonies [91, 95] which 
may allow bacteria to evade host defenses and the effects of antimicrobials. Slime production is 
strain dependent and phase variation in slime production is observed [91, 96].  
 
Teichoic acids are a group of polymers in the cell-wall, capsule, or membrane of Gram-
positive bacteria that contain glycerol phosphate or ribitol phosphate residues [97]. There are 
differences between cell-wall linked teichoic acids and plasma membrane linked teichoic acids. 
Cell wall teichoic acids are covalently attached to peptidoglycan that may show glycerol 
phosphate- and ribitol phosphate-containing structures. They are not present in all species of 
Gram-positive bacteria and their presence depends on growth conditions [98]. In contrast, 
membrane teichoic acids are covalently bound to a glycolipid moiety of the plasma membrane. 
They are more relevant structures than cell-wall teichoic acids and their presence is not 
dependent on growth conditions [98]. The covalent attachment of membrane glycerol teichoic 
acids to glycolipid led to the naming as lipoteichoic acid for these polymers [99]. Teichoic acid 
and lipoteichoic acid are reported to serve as receptors for adhesion to epithelial cells of mucosal 
surfaces [100] and are also reported to have role in allowing bacteria to resist host defense 
peptides [101]. Their exact role in bovine S. aureus mastitis is not known. 
  
 
 
1.2.1.2. Secreted Products  
 
Haemolytic toxins (mainly α and β toxins) play a role in the pathogenesis of bovine S. aureus 
mastitis [57, 102-105]. Alpha toxin binds to the plasma membrane of the epithelial cell and 
oligomerises into hollow hexameric complexes, which form transmembrane pores. The 
transmembrane pores result in the leakage of low molecular weight molecules from the cytosol 
and lead to cell death [106, 107]. Beta toxin is a sphingomyelinase C that hydrolyses the 
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sphingomyelin present in the exoplasmic leaflet of the plasma membrane resulting in increased 
permeability [57] with a rapid efflux of K+ and influx of Na+, Cl- and Ca2+
 
 [106] leading to lysis 
of cells.  
Staphylococcal enterotoxins are extracellular proteins mainly composed of a single 
polypeptide chain [43]. There are many serologic types of these toxins, the major ones include A, 
B, C1, C2, C3, D, E, and H [43, 108]. Some of the enterotoxins are known to bind to MHC 
molecules at different site from the peptide binding groove which results in T cell activation and 
cytokine production [109]. This over-stimulation by superantigens leads to systemic shock and 
disseminated intravascular coagulation (DIC) similar to lipopolysaccharides (LPS) of Gram-
negative bacteria. Leukocidin toxin has cytolytic effects on bovine polymorphonuclear 
neutrophils and macrophages [110]. Some of the S. aureus strains from intramammary infection 
have the ability to produce the toxic shock syndrome toxin-1 [111] which causes toxic shock due 
to its superantigenic activity. S. aureus also produces numerous extracellular enzymes which 
have been implicated in the pathogenesis of bovine intramammary infection and human 
infections [49] (Table 1.2.1.1).  
 
1.2.1.3. Adhesion of Staphylococcus aureus to Bovine Mammary Epithelial Cells 
 
S. aureus is one of the most important causative agents of bovine mastitis that is shown to 
adhere to bovine mammary gland cells in vivo [112-114] and in vitro [113, 115-122]. In vitro 
adhesion varies with S. aureus strains, growth medium, growth phase, and the origin of 
mammary epithelial cells. The kinetics of S. aureus adhesion to mammary epithelial cells is not 
well characterized. Adhesion may be achieved through non-specific physiochemical and/or 
specific interactions between a ligand, associated with the bacterial cell surface and a receptor on 
the host cell surface.  
1.2.1.4. Invasion of Staphylococcus aureus into Bovine Mammary Epithelial Cells 
 
Intracellular S. aureus have been demonstrated in mammary secretory epithelial cells of 
experimentally infected mice [123], cultured mammary epithelial cells from cows [113, 115, 
116, 124] and epithelial cells isolated from mastitic milk ([125]. In vitro studies have also shown 
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that S. aureus also invades other non-phagocytic cells such as endothelial, fibroblast and 
osteoblast cells [126-130]. Invasion may occur in a bacterium-specific endocytic process that 
involves the participation of elements of the cytoskeleton and/or through another receptor-
mediated energy-requiring mechanism that involves both eukaryotic and prokaryotic cellular 
functions like de novo protein synthesis [115].  Many bacterial cell surface adhesins seems to be 
involved in adhesion and invasion of mammary epithelial cells [68, 131-134]. S. aureus has also 
been shown to induce apoptosis after being internalized into mammary epithelial cells [135, 
136]. 
 
1.2.1.5. Glyceraldehyde-3-phosphate dehydrogenase of Staphylococcus aureus as a 
Virulence Factor in Bovine Mastitis 
                   
Glyceraldehyde-3-phosphate dehydrogenase is involved in the microbial energy 
metabolism from a glucose source [137, 138]  and it catalyzes oxidative phosphorylation of D-
glyceraldehyde-3-phosphate (G3P) to 1, 3-diphosphoglycerate in the presence of phosphate, and 
NAD+ as follows: 
D-glyceraldehyde-3-phosphate + NAD+ + HPO42- ⇔ 1, 3-diphosphoglycerate + NADH + H+
Studies in the past two decades have demonstrated the presence of GAPDH with non enzymatic 
functions on the cell surface of some pathogenic microorganisms. The GAPDH of Group A 
streptococci (S. pyogenes) binds to plasmin, fibronectin, lyzozyme, myosin and actin [78, 139] 
and it also acts as an ADP-ribosylating enzyme [83, 140]. Streptococcus gordonii, which causes 
endocarditis, highly expressed GAPDH   on its surface at pH 6.5 [141]. Glyceraldehyde-3-
phosphate dehydrogenase of mycobacteria had been shown to bind to  epidermal growth factor 
[142]. Enteropathogenic E. coli (EPEC) was shown to secrete GAPDH as one of the proteins to 
induce signal transduction events in epithelial cells [143].  The expression of GapC of E. coli 
was shown to increase in the natural environment as compared to enriched growth media [144].   
It had also been reported recently that association with host cells increased the expression of the 
gap genes in Neisseria meningitids and N. lactamica with concomitantly increased expression 
and surface deposition of the corresponding protein [145]. In bovine clinical mastitis isolates of 
S. aureus, two proteins with GAPDH activity (GapC and GapB) have been identified [75]. These 
proteins bind to transferrin and plasmin [75]. These authors also showed that the GapC protein 
was present on the surface of all S. aureus strains tested. In human isolates of S. aureus and S. 
.   
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epidermidis a 42 kDa protein with GAPDH activity was found on the cell surface [79, 81]. In 
fungal pathogens such as Candida albicans, Saccharomyces cerevisiae and Kluyveromyces 
marxianus, GAPDH had been shown to be located on the cell surface [76, 146]. GAPDH of 
Candida albicans has been shown to bind to fibronectin and laminin [80].  
 
Recent evidence confirmed that GAPDH is involved in the interaction between 
pathogenic microbes and host cells. In S. pyogenes, SDH (GAPDH) binds to Detroit human 
pharyngeal cells surface-exposed urokinase plasminogen-activator receptor/CD87 [84]. This 
protein was shown to induce apoptosis [147] and to be involved in immune evasion by inhibiting 
C5a-dependent chemotaxis and H2O2 production [148, 149]. A streptococcal SDH (GAPDH) 
mutant strain of S. pyogenes, which could not secrete SDH out of the cell, decreased its binding 
capability to plasminogen and human pharyngeal cells and also lost its immune evasion effect 
[150]. The prevention of cell surface export of SDH affects the pathogenicity of S. pyogenes, 
confirming that SDH is an important virulence factor [150]. Moreover, very recently in S. 
agalactiae GAPDH was found to be a pathogenicity related protein [151]. These authors also 
showed that the enzymatically active recombinant GAPDH protein stimulated expression of 
CD69 on B cells from mice. They also showed an increased number of IgG secreting cells in 
spleen and that a SDH (GAPDH) over-expressing strain is more virulent than the wild type strain 
and these effects were IL-10 dependent. In another  study, in vitro adherence assay data 
demonstrated a significant  reduction in adhesion of Streptococcus suis strain 2 (SS2)  to HEp-2 
cells pre-incubated with purified GAPDH compared to non pre-incubated controls, indicating  
that the GAPDH mediates SS2 bacterial adhesion to host cells [85]. The GAPDH of 
Streptococcus oralis binds to the fimbriae of Porphyromonas gingivalis and leads to P. 
gingivalis colonization of periodontal sites [152]. In Mycoplasma genitalium GAPDH serves as 
an adhesin that bind to mucin for adherence and colonization of host tissue [153]. The secretion 
of GapC of enteropathogenic E. coli as a result of bacterial interactions with host cells [143, 144] 
and the increased expression of a GAPDH gene and its protein deposition on the cell surface of 
Neisseria species [145] shows the involvement of this protein in the pathogenesis of these 
organisms. Moreover, the GAPDH of Leishmania infantum amastigotes allows the parasite to 
resist nitric oxide produced by host phagoyctic cells [154]. More importantly, it has been shown 
that human microflora Lactobacillus plantarum LA 318 adheres to human colonic mucin using 
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its surface GAPDH which might be the case for several other microflora in diverse host 
species[155]. These observations indicated that GAPDH is an adhesin for colonization of tissue 
surfaces including mammary gland both for pathogenic and non-pathogenic normal microflora. 
Based on role of GAPDH in other microorganisms, it is logical to postulate that the 
staphylococcal GAPDH by the virtue of its surface localization may function as an adhesin for S. 
aureus colonization of host tissue surfaces including the bovine mammary gland. 
 
1.2.1.6. Genetic Organization of gapB and gapC in Staphylococcus aureus. 
 
In S. aureus the gapB and gapC genes are located in two different regions of the 
chromosome [156, 157]. Immediately downstream of the gapC gene there are genes encoding 
the glycolytic enzymes phosphoglycerate kinase (pgk), triosephosphate isomerase (tpi), 2, 3-
diphosphoglycerate-independent phosphoglycerate mutase (pgm) and enolase (eno). Immediately 
upstream of gapC is gapR, known to be a regulator of this operon in Streptomyces aureofaciens 
[158]. The presence of a gene located upstream of gapC with high homology to gapR of the 
human strains suggests a similarity in the genetic organization of gapC of bovine and human 
isolates; however, this needs to be determined. 
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Table 1.2.1.1. Summary of virulence factors of Staphylococcus aureus 
Virulence factor  Effects  Reference 
 Cell surface factors    
FnBPA and FnBPB Attachment to fibronectin [159] 
ClfA and ClfB Adhesion to fibrinogen [160] 
Protein A Immune evasion [51, 161-163] 
GAPDH Adhesion to transferin/plasmin [81] 
Collagen binding protein  Adhesion to collagen [164] 
Elastin binding protein Binding to elastin [165] 
MHC analogous protein Binding to extracellular matrix proteins [68, 166 , 167] 
Polysaccharide intercellular 
adhesin  
Intercellular adhesion and biofilm 
formation 
[165] 
Coagulase Binding to fibrinogen [161, 162, 168, 169] 
Capsular polysaccharides (type 
I, 5, and 8) 
Antiphagocytic molecule [170, 171] 
Polysaccharide intercellular 
adhesin and biofilm associated 
protein 
Prevent adhesion and invasion, decrease 
phagocytic ingestion and killing 
[172-174] 
Teichoic acid Protection against human and animal host 
defense peptides and also adhesin 
[101] 
Lipoteichoic acid Induce acute phase proteins, and also 
adhesin 
[175, 176] 
Extracellular factors 
 
  
Staphylococcal 
Enterotoxins: A – E, H  
Evasion of host defences with 
superantigen  function, Food associated 
diarrhea 
[177-179] 
Toxic shock syndrome toxin-1 Evasion of host defenses with superantigen 
properties, cause TSS 
[51, 178] 
Exfoliative  toxins A and B Evasion of host defenses, cause 
staphylococcal scalded skin syndrome 
[165] 
Lipase Evasion of host defense [180] 
V8 protease Tissue invasion and modification of 
surface proteins 
[49, 178, 181] 
Serine proteases Degrade tissue enzymes [162] 
Zinc-metalloproteinase 
(auriolysin) 
Processing enzyme? [49, 181] 
β- lactamase Resistance to β- lactam -type antibiotics [182] 
Methicillin-resistance surface 
protein 
Resistance to methicillin [165] 
Panton-Valentine leukocidin Evasion of host defenses, lysis of 
phagocytes 
[162, 178] 
Staphylokinase Plasminogen activator [51] 
α -hemolysin Tissue invasion, form pores in host cell 
membrane 
[51, 162, 178, 183] 
β - hemolysin Tissue invasion, sphingomyelinase [51 , 161 , 162] 
δ- hemolysin Potentiation of β - hemolysin [51 , 75 , 183] 
γ-hemolysin Potentiation of host cell lysis [162 , 184] 
Phospholipase C Lysis of host cells [49] 
Elastase Tissue invasion [182] 
Hyaluronidase Tissue invasion [161 , 165, 182 ] 
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1.2.1.7. Regulation of Virulence Factors in Staphylococcus aureus  
 
  
Environmental stimuli lead to various changes in microorganisms and these stimuli 
induce changes in cellular activity by inducing transcription of specific genes that are required to 
adapt to changes in the environment. In bacteria, stimuli can be external from the environment or 
internal from their own products. The bacterial products serve as stimuli to induce transcription 
of certain sets of genes which help the whole population of bacterial cells to synchronize their 
activities to adapt to changes at a population level. These products provide mechanisms for cell 
to cell cross talk in a cell quantity dependent manner (quorum-sensing) to better adapt the whole 
population of bacteria to the new changes or stimuli [185-187].           
                      
The pathogenicity of S. aureus is due to the combined action of several cell surface 
structural components and secreted extracellular enzymes and toxins [185-187]. The expression 
of multiple virulence factors of S. aureus is controlled by different global regulatory genes such 
as staphylococcal accessory regulator (sar) [52, 188], and two component regulatory systems 
[49, 165, 189]. There are 16 two component regulatory systems in the S. aureus genome and 
some of these include: accessory gene regulator (agr) [190], S. aureus exoprotein expression 
(saePQRS) locus [191], staphylococcal respiratory response (srrAB) locus [192], autolysis 
related locus (arlSR) [193] and  lytRS systems [194, 195]. Moreover,  the alternative sigma factor 
(sigB) [196] is also involved in the regulation of several virulence factors in S. aureus. These 
global regulatory genes encode many proteins that are involved in the regulation of expression of 
several S. aureus cell surface and extracellular virulence factors in a growth-phase dependent 
manner  [185-187](Figure 1.2.1.7).   
 
Staphylococcal accessory regulator A (SarA)[188] and  its homologues SarR [197], Rot 
[198], SarS [183], SarT[199] and SarU [200] are DNA binding proteins that are known to 
regulate the expression of several cell surface and extracellular virulence genes in S. aureus. The 
sarA operon consists of three overlapping transcripts with similar 3’ end that are under the 
control of three different promoters sarP1, sarP3 and sarP2 (Fig. 1.2.1.7).  All three transcripts 
encode the 14.5 kDa SarA protein [186, 201]. The production of SarA depends on bacterial 
 13 
 
growth phase and maximum production is achieved at late exponential phase. The SarA protein 
binds to the promoter region of agr and induces agr activation and it binds to specific sequences 
in the promoter region of S. aureus cell surface protein genes and regulates their expression. The 
increased production of SarA during post exponential phase [197] is matched with increased 
expression of agr [202]. The sarA locus increases the production of cell surface components 
during early logarithmic phase as well as th at of α-, β-, and δ-toxins during late exponential 
phase [190, 203]. 
 
The sarR encodes a 13.6 kDa protein which has homology with some sequences of SarA. 
The expression of SarR peaks at post exponential growth phase and it induces down regulation 
of SarA [186, 197]. The SarS protein was originally identified as SarH1 [183] and later as SarS 
[204]. The sarS gene is transcribed from two different promoters and SarS up-regulates 
expression of staphylococcal protein A (spa) and down-regulates the expression of alpha toxin.  
Staphylococcal accessory regulator S (SarS) expression is down regulated by both sar and agr 
[183, 186]. The SarT is a 16.1 kDa protein known to down-regulate the expression of hla and is 
down regulated by either Agr or SarA [199]. Staphylococcal accessory regulator U (SarU) is a 
29.3 kDa protein believed to be involved in the agr system, is down-regulated by SarT [200], 
and mutation of sarU decreases expression of agr activated genes. The Rot (repressor of toxin)  
is a 15.6 kDa protein [198] reported to control regulation of several genes in  an opposite manner 
to agr. Rot is believed to be involved in up-regulation of cell surface proteins required for early 
colonization of host tissue and down-regulation of the expression of extracellular toxins and 
proteases during post exponential phase [162]. There are other members of SarA homologues 
such as SarY (29.8 kDa), SarV (13.9 kDa), SarX (16.7 kDa). Staphylococcal accessor regulator-
Y (SarY) is reported to be similar to SarR and SarT whereas SarV and SarX are similar to Rot 
[165, 186].  
  
The agr locus is one of the two component systems of S. aureus that controls the 
expression of virulence factors in a bacterial growth-phase dependent manner. The agr gene up-
regulates the expression of secreted toxins during post exponential growth phase and down 
regulates the expression of cell surface components during the logarithmic phase of growth. The 
agr two component systems consist of two transcripts, RNAII and RNAIII. The RNAII transcript 
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is under the control of the P2 promoter whereas RNAIII is controlled by another promoter, P3 
[203] (Fig. 1.2.1.7). The RNAII transcript encodes four genes agrA, agrC, agrD and agrB [205] 
while the RNAIII encodes the delta hemolysin gene (Fig. 1.2.1.7) and also is believed to control 
most of virulence gene expression in S. aureus through an as yet unknown mechanism. 
  
In the agr two component regulatory systems of S. aureus the bacteria produces the 
autoinducing peptide (AIP) when the bacterial density reaches a certain threshold. The 
autoinducing peptide is encoded by the agrD gene and the propeptide form processed by AgrB 
becomes the active autoinducing peptide.   The AIP with its thiolactone functional domain is 
secreted after binding to AgrC, a transmembrane response-regulator domain. This binding leads 
to a phosphorylation cascade that transfers the phosphate from ATP to histidine and aspartate 
residues of AgrC and AgrA, respectively. Finally, this phosphorylation process results in the 
binding of AgrA to the target gene and induction of transcription processes of the cell [190, 206-
212] (Fig. 1.2.1.7).  AgrA was shown to bind DNA by recognizing a nucleotide consensus 
sequence of 5’ ACAGTTAAG-3’ separated by a 12 bp nucleotide sequence as spacer [213, 214]. 
RNAIII is mainly believed to be the effector of the agr regulon; however, the exact mechanism 
has yet to be defined [190, 215]. The RNAII product of the agr locus was shown to have 
sequence variability in the C-terminal of AgrB, the whole of AgrD and N- terminal of AgrC 
which results in four agr specificity groups [206, 216-218]. The AIP from one group inhibits the 
growth of another group member while it induces two component signal transduction pathways 
in the members of its own group [206]. It has been shown that the N-terminal of AgrB and the C-
terminal of AgrC are much more conserved, whereas the intervening sequences were shown to 
be significantly variable [206, 217]. The variable sequences determine agr specificity. These agr 
group variations are expected to have differences in pathogenicity of S. aureus and each agr 
group might be relevant to a specific disease [217].  Some recent evidence showed that specific 
agr groups are known to cause certain specific diseases. For example menstrual toxic shock 
syndrome causing strain and necrotizing pneumonia  causing strains belong to group III [206, 
219], vancomycin intermediate resistant  strain belongs to agr group II [220] and exfoliatin-
producing strain belong to group  IV [217, 221].  
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The accessory gene regulator (agr) system of S. aureus is induced by autoinducing 
peptide (AIP) produced by bacterial cells when their numbers reach certain level.  Recent studies 
showed that RNAIII autoinducing peptide (RAP) and the target of RNAIII autoinducing peptide 
(TRAP) were also hypothesized to be involved in inducing agr two component signal- 
transduction pathways [222-224]; however, the detailed mechanism has yet to be shown 
experimentally.  
 
In summary the various regulatory network generated at different phases of bacterial 
growth in vitro as well as in vivo allow the bacteria to adapt to their immediate environment very 
rapidly and specifically to achieve infection and/or successful survival in their host. 
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Figure 1.2.1.7. Growth phase dependent regulation of virulence gene expression in S. aureus by 
sar and the agr loci. The agr system comprises RNAII and RNAIII transcripts which are under 
the control of divergent promoters, P2 and P3. RNAII transcript consists of four genes, agrA, 
agrC, agrD and agrB which encodes AgrA, AgrC, AgrD and AgrB proteins, respectively. An 
RNAIII transcript consists of the hld gene that encodes delta hemolysin (Hld) and regulates P2-
P3 promoters functions. The agrD encodes AIP which is the inducer of the agr two component 
signal transduction system at a certain level of bacterial cell density. AIP binds to AgrC, a 
transmembrane protein kinase which is a sensor of the two component signal. This binding leads 
to phosphorylation which transfers phosphate from ATP to histidine and aspartate residues of 
cytoplasmic domains of AgrC and AgrA, respectively. SarA also binds to P2-P3 promoters and 
regulates expression of several virulence genes in a bacterial growth phase dependent manner. 
SarA also directly regulates expression of some virulence factors at exponential and post 
exponential growth phases. 
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1.2.1.8. Role of agr and sar in Biofilm Formation 
 
Biofilms are a multilayered microbial community of cells that are attached to polymeric 
substances and manifest changes in bacterial metabolic reactions, physiology and gene 
expression [225]. A biofilm is formed through multiple steps which includes initial cell-to-cell 
attachment, adhesion and proliferation, maturation and removal from the layer [226].  Biofilm 
formation is an important factor in the pathogenesis of staphylococcal infections since it protects 
bacteria from phagocytic killing by polymorphonuclear phagocytes and antibiotics. In S. aureus, 
poly-N-succinyl-β-1-6-glucosamine (PIA/PNSG) and biofilm-associated protein (Bap) are 
involved in biofilm formation [173]. The PIA/PNSG is encoded by the icaADBC operon [173]. 
Biofilm formation is regulated through quorum-sensing in staphylococci and agr reduces biofilm 
formation and thereby decreases virulence of biofilm forming strains [227]. Moreover, synthetic 
RNAIII inhibiting peptides (RIP) were shown to down-regulate gene expression for biofilm 
formation and toxin production in vitro [228]. Moreover, in vivo prevention of virulence gene 
expression through agr resulted in decreased biofilm formation [229].  
 
In another study an experimental model using indwelling medical device was developed 
to investigate the role of the agr system in biofilm associated infections by S. epidermidis. The 
agr mutant has been shown to colonize the device more than the isogenic wild type strain 
suggesting that agr inactivation increased biofilm formation [230]. These authors also explained 
that the Agr controls production of small peptides called phenol-soluble modulins (PSMS) 
responsible for bacterial detachment from biofilms and these modulins have been indicated to 
have strong proinflammatory properties. The exact role of SarA in biofilm formation is not 
clearly known, however, it has been reported that SarA-defective mutant MRSA and MSSA 
strains lost their biofilm formation capability [231]. The deletion of agr increased biofilm 
formation significantly in some MRSA and MSSA strains while its deletion had no effect in 
others [230-232]. O’Neill et al. [231] concluded that biofilm formation in MRSA strains is not 
affected by Ica; rather it involves a protein adhesin controlled by SarA and Agr.  However, SarA-
controlled PIA/PNAG plays a more important role in biofilm formation by MSSA strains. In 
another study biofilm forming cells was reported to express high levels of SarA which might 
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indicate positive regulation of biofilm formation by SarA [233].  Further detailed investigation is 
required to unravel these discrepancies.  
 
 
1.3. Intramammary Defenses 
 
The mammary gland is protected by non-specific natural defenses as well as innate and 
acquired immune mechanisms. These are highly interactive and coordinated in order to provide 
optimal protection from mastitis. 
 
1.3.1. Natural Defenses 
 
The host is protected from pathogens gaining access to the intramammary area primarily 
by natural defense mechanisms. These natural defense mechanisms include closure of the teat 
canal by a group of smooth muscles called the rosette of Frustenburg, the keratin plug of the teat 
canal, and the antibacterial activity of esterified and non-esterified fatty acids which includes 
palmitoleic, myristic, and linoleic acids [234, 235]. Moreover, bactericidal cationic peptides are 
also indicated to have role in natural defense against intramammary infection. Increased patency 
of the sphincter during milk accumulation prior to parturition and removal of keratin have been 
correlated with increased susceptibility to bacterial colonization and invasion [235-237]. 
Colonization of the udder skin and teat opening and subsequent transfer into the intramammary 
area and establishment of infection can only be achieved when host natural defense systems are 
compromised. 
 
1.3.2. Intramammary Immunity 
 
1.3.2.1. Innate Immunity 
 
Innate intramammary immunity comprises cellular and humoral components that are not 
specific to individual antigen molecules. The innate immune system recognizes the foreign 
antigen or pathogen associated molecular patterns not only by Toll-like receptors [238] but also 
by complement receptors, macrophage mannose binding lectin, ficolins and scavenger receptors 
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(Table 1.3.2.1). The innate immune sytem has three effector mechanisms, including the 
complement system, phagocytic cells, and antimicrobial peptides [239]. The cellular innate 
immunity comprises phagocytic cells (neutrophils and macrophages), natural killer cells and 
dendritic cells whereas humoral innate immunity include the complement system, β-defensins, 
antimicrobial peptides, nitric oxide, lactoferrin, lysozyme, lactoperoxidase, and xanthine oxidase 
[240-242].  
 
i. Cellular Innate Immunity  
 
Macrophages and T lymphocytes comprise a large cell population of the healthy 
mammary gland. Likewise, the number of neutrophils increases together with lymphocyte 
numbers in healthy udders as lactation progresses [243-245]. There is a direct correlation 
between high somatic cell counts and levels of protection against most mastitis causing agents 
[246-249]. In addition to mammary gland tissue has resident cells such as dendritic, natural killer 
and endothelial cells; however, their role in the protection of intramammary infection is not 
known.  
 
The presence of invading pathogens can be detected early in the process of infection by 
innate immune receptors such as Toll-like receptors (TLRs) and others which are present on the 
surface of antigen presenting cells such as macrophages and dendritic cells. Toll-like receptors 
are of germline origin and they are evolved to recognize pathogen associated molecular patterns 
(PAMPs) which are conserved molecules that are specific to microorganisms [250]. The 
detection of invading microorganisms by Toll-like receptors results in the activation of defense 
genes and acquired immune responses [240, 241]. Currently, there are eleven TLR’s known to 
exist in humans and mice which recognize different components of microbes (Table 1.3.2.1). 
Transcription of the genes coding for TLR2, and TLR4 was found to increase during mastitis in 
cattle [240, 241] and also infection with S. aureus increased expression of TLR4 [240, 251]. In 
addition to TLRs there are many other innate receptors on cell surfaces such as  Dectin-1, CD14, 
FMLP (f-methionyl-leucyl-phenylalanyl) receptor, NOD1 (Nucleotide-binding oligomerization 
domain), and NOD2 as well as other  humoral components  such as LBP (LPS binding protein), 
CD14, collectins, properdin, C3b, C3bi, pentraxins [252]. 
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Table 1.3.2.1.  Receptors involved in innate immune recognition of pathogens 
 
SAP = Serum amyloid protein, CRP = C-reactive protein, MBL = Mannan-binding lectin,  
MMR = Macrophage mannose receptor, Scavanger Receptor – A family, MSR = Macrophage 
scavenger receptor, NOD = Nucleotide-binding oligomerization domain, fMLP = f-methionyl-
leucyl-phenylalanyl 
 
 
Neutrophils are actively recruited to the site of infection and are the major cell type 
present in the mammary gland during early phases of S. aureus mastitis [136, 235].  After 
gaining access to the intramammary area S. aureus grows very rapidly and quick recruitment of 
Receptor Ligand Reference 
TLR1 Triacly lipopeptides [253] 
TLR2 PG and LTA [254, 255] 
TLR3 Double stranded RNA of viruses [256] 
TLR4 LPS of Gram-negative bacteria [257] 
TLR5 Flagellin of  bacteria [258] 
TLR6 LTA of Gram-positive bacteria [255] 
TLR7 and 8 Single stranded RNA viruses [259, 260] 
TLR9 CpG containing DNA [261] 
TLR10  and TLR11 Not well known [262] 
Collectins 
(MBL, MMR) 
Binds to terminal mannose residues. Induces lectin- 
mediated complement activation pathway. 
[250, 263-269] 
SR-A family 
(MSR, MARCO) 
Double-stranded RNA, LPS, and LTA. Bacterial cell 
wall and LPS 
[250, 270, 271] 
Pentraxins 
(SAP, CRP) 
Binds to phosphocholine on bacterial surface and serve 
as opsonin, they also binds to C1q and induce the 
classical complement pathway. 
[250, 272-274] 
PKR Double stranded RNA [250, 275] 
NOD proteins 
(NOD1 and NOD2) 
Might bind to C-terminal leucine-rich repeat  (LRR) of 
LPS 
[250, 276, 277] 
fMLP  receptor G-protein receptor on neutrophils, important in 
chemotaxis 
[252, 278] 
LBP and CD14 In their soluble form binds to LPS [252] 
C3b and C3bi Binds to Mac-1/ICAM-1 on phagocytic cells [252] 
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fresh blood neurophils and opsonising antibody of IgG2 isotype is required [251]. These 
recruited neutrophils require bacteria opsonized by IgG2, IgM, or C3bi/C3b for efficient 
clearance of S. aureus infections [279-282]. Normal circulating neutrophils express CD62L (L-
selectin) on their surface whereas activated neutrophils express E-selectin (CD62E) and P-
selectin (CD62P) on vascular endothelial cells at the site of tissue infection [283, 284]. When 
neutrophils come in contact with the endothelium and detect proinflammatory cytokines, they 
become activated and increase expression of Mac-1 [251, 284-288]. This receptor allows 
neutrophils to bind to the endothelium and pass through to the site of injury. Neutrophil 
chemotaxis to the site of inflammation is influenced by several proinflammatory cytokines and 
chemo attractants such as IL-8, TNF-α, IL-1β, IL-6, IL-8, C5a and C3a [251, 289-292]. 
Neutrophil chemotaxis from blood into the mammary gland can takes place within a few hs post 
infection [293-295]. The neutrophil recognizes opsonised bacteria through its FcγR, CR1 and 
CR3 or Mac-1 receptors and phagocytise and degrade them by its pre-formed bactericidal 
components in its intracellular granules or by hydrogen peroxide and/or superoxide produced 
through a respiratory burst from glucose oxidation.  
 
Macrophages are dominant cells in milk and tissues of healthy udders. Macrophages also 
phagocytose and kill bacteria using protease and reactive oxygen radicals [296, 297]; however, 
they are less in number during mastitis and also express  Fc receptors on the cell surface [298]. It 
has been shown that macrophages secrete IL-12, which potentiates the development of IFN-γ 
secreting cytotoxic CD8+ cells [290]. 
 
ii. Humoral Innate Immunity 
 
Antimicrobial peptides are small polypeptides that can have an antimicrobial effect at 
normal physiological levels in the body [299-301]. They exist in several tissues including 
polymorphonuclear leukocytes, macrophages and mucosal epithelial cells. Major antimicrobial 
peptides known to exist in cattle include: defensins, cathelicidins and anionic peptides [302]. 
There are several cationic antimicrobial peptides and a few groups of anionic antimicrobial 
peptides in domestic animals [301]. Other mammalian antimicrobial peptides include histatins 
[303] and dermicidin [304].  Antimicrobial peptides have different mechanisms of killing 
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microbes. For example defensins induce ion channel formation [305], anionic peptides cause 
flocculation of intracellular contents [306] and bactenecins affect  transport and energy 
metabolism [307] (Table 1.3.2.2). 
                    
β-defensins are antimicrobial peptides largely produced by polymorphonuclear cells [240, 
308, 309]. In vitro stimulation of mammary epithelial cells with LPS and LTA induced high 
expression of β-defensin [310] and the transcription of β-defensin-5 increased during mastitis. In 
humans β-defensins form the main class of antimicrobial peptides that exist in  epithelial cells 
[299]. Three β-defensins have been found in human skin including hBD-1, hBD-2 and hBD-3 
[311-313]. Interleukin-1 from resident local monocytes induced the expression of β-defensin-2 in 
inflamed skin [314].  The hBD-1 is believed to be expressed constitutively [315]; however, some 
evidence showed increased expression during inflammation [316]. Despite increased expression 
of hBD-3 in inflamed skin and epithelia [311, 317], its regulation is not known; however, 
microbial molecules activated monocytes and lymphocytes stimulated the epidermal expression 
of all three human defensins [318]. The activation of hBD-3 was through transactivation of 
epidermal growth factor receptor [318].   Although antimicrobial peptides might have role in the 
control of intramammary infections they have not been evaluated for this activity. 
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Table 1.3.2.2. Bovine antimicrobial peptides   
 
Antimicrobial 
peptide 
Source Function Reference 
Cathelicidin    
BMAP27 Bone marrow  myeloid cells Broad  spectrum [319-321] 
 
BMAP28 ‘’  
‘’ 
[319-321] 
BMAP34 Neutrophils, bone marrow 
myeloid cells, testis, spleen 
 
‘’ 
[319,, 321, 322] 
Bac5,  Bac7 Neutrophils Gram-negatives and positives [319, 320, 323-
326] 
Indolicidin Neutrophils Gram-negatives and positives [319, 327, 328] 
Dodecapeptide Neutrophils Gram-positives and negatives [319, 329, 330] 
Defensins    
BNBD-1 – 3, 6 -11, 13 Neutrophils Broad spectrum [331-335] 
BNBD4 Bone marrow, distal small 
intestine,trachea, colon, 
lung, spleen 
 
‘’ 
[332, 334] 
BNBD-5 Bovine alveolar 
macrophages 
 
‘’ 
[334] 
BNBD-12 Bone marrow, distal small 
intestine, trachea, colon 
 
‘’ 
[332] 
TAP Nasal epithelium, trachea, 
broncheoles, alveolar 
macrophages 
 
‘’ 
[336-338] 
LAP Alveolar macrophages, 
tongue 
 
‘’ 
[334, 339] 
EBD Alveolar macrophages, 
intestine 
 
‘’ 
[334, 340] 
Anionic peptides Lung Gram-negative and positives. [302, 306, 341] 
 
Adapted from [301] 
BNBD = bovine neutrophilic beta defensin, BMAP = bovine myeloid antimicrobial peptide, Bac 
= Bactenecin, TAP = Tracheal antimicrobial peptides, LAP = Lingual antimicrobial 
peptides.EBD = epithelial beta defensins. 
 
 
Lactoferrin is an iron-binding bacteriostatic protein produced by epithelial cells and 
leukocytes. It chelates iron and makes it unavailable for microorganisms [235, 242, 342, 343]. It 
also releases lipopolysaccharides from Gram-negative bacteria by interacting with their cell 
membrane [344]. Some in vitro studies showed that E. coli and S. aureus are not affected by 
lactoferrin [345, 346].  
 
Nitric oxide (NO) is a bactericidal agent produced by mammary epithelial cells and 
mononuclear phagocytic cells during mastitis [347-349]. Some reports also indicated that 
 24 
 
enterotoxin-C of S. aureus increased NO production during mastitis [349] and a recent study 
reported that NO had no effect on intramammary defense [348]. The exact role of the NO during 
intramammary infection needs to be defined. 
 
The complement system is a defense mechanism that generates effector molecules 
involved in both innate and acquired immunity through its classical, alternative and lectin 
activation pathways. They serve both as innate and acquired defense molecules. Their effector 
functions include lysis of bacteria, opsonization and the attraction of phagocytes to the site of 
complement activation [242, 350-352]. Complement is activated through three different 
pathways but all result in activation of C3 convertase which is a surface associated enzyme 
complex that cleaves C3. Cleavage of C3 activates deposition of C3b on the surface of 
microorganisms and release of C3a which is a potent chemoattractant for inflammatory cells. 
The C3b and its by product C3bi are deposited on the surface of microorganisms or antigens and 
allow them to be removed by phagocytic cells. Complement is reported to exist in the milk of 
healthy cows [351, 353] but the role of complement protection in the mammary gland is not 
clearly defined. The classical pathway is not functional in the mammary gland due to the absence 
of the C1q complement component.  
 
Lysozyme (N-acetylmuramyl hydrolase) is a bactericidal protein that exists in milk and 
other mucosal secretions. It removes peptidoglycan from the cell resulting in bacterial death; 
however, its role in the intramammary protection is believed to be insignificant [242, 354].  
Lactoperoxidase is a bacteriostatic agent for both Gram-negative and Gram-positive 
bacteria [352, 355]. Some reports indicated that bovine milk has about 30 µg peroxidase/ml 
[354]; however, its role in the intramammary defense is yet to be defined clearly. Xanthine 
oxidase was also reported as bacteriocidal agent in the milk but the specific role of this agent is 
not clearly known [242, 356].             
               
1.3.2.2. Acquired Immunity 
                
The main effectors of mammary gland immune defense against major mastitis-causing 
bacteria are blood derived neutrophils, opsonizing antibodies and effector T cells in cooperation 
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with cytokines [251, 357, 358]. Different cells  in the mammary gland such as dendritic,  natural 
killer, γδ  T,  endothelial, mammary epithelial, neutrophils,  macrophages, CD4+ and CD8+ T 
cells and IgA producing plasma cells play an important role in local inflammatory responses 
[251].  
 
i. Cellular Acquired Immunity 
 
Lymphocytes are able detect antigens by their surface receptors, which determine their 
specificity, diversity, memory and self/nonself recognition [13, 235, 245]. They are divided into 
two main groups: T- and B-lymphocytes. The B-lymphocytes process and present antigen to T 
helper cells as well as produce immunoglobulins through stimulation by cytokines from T helper 
cells such as IL-2, IL-4, IL-6 and IL-10. These cytokines induce proliferation and differentiation 
of B-lymphocytes into either plasmocytes that produce antibodies or become memory cells.  
Their proportions among the total lymphocytes remain constant during mastitis [290]. 
 
The T lymphocytes include αβ CD4+  helper T lymphocytes,  αβ CD8+  cytotoxic or  
suppressor T lymphocytes, γδ T lymphocytes and CD4+, FOXP3+, CD25+ regulatory T 
lymphocytes [359]. The dominant T lymphocytes in the mammary gland tissue and secretions of 
healthy human, porcine and bovine species are CD4+ αβ T lymphocytes [360]. The peripheral 
blood and supramammary lymph nodes of healthy cows predominatly possess CD4+ 
lymphocytes [13, 361, 362]. During mastitis CD8+ T cells become the predominant cells 
recruited into milk. The functional importance for the increased number of CD8+ over CD4+ 
lymphocytes during mastitis is not defined. Based on the type of cytokines produced, the T- 
helper cell can stimulate either a cell-mediated (Th-1 type) or humoral (Th-2 type) immune 
responses [363]. Interleukin-2 (IL-2) and IFN-γ are considered as the dominant cytokines during 
the Th-1 response whereas IL-4, IL-5 and IL-10 are characteristic of a Th-2 response. However, 
it is known that in cattle and humans as opposed to mice, IL-10 can be produced by Th1 and Th2 
cells and regulate all their activities [364]. It is well understood that CD8+ cells can exert either 
cytotoxic or suppressor function [365]. As is the case for CD4+ cells, different cytokines were 
expressed by the two subtypes of CD8+ cells. IL-4 has been associated with the suppressor 
phenotype and IFN–γ with the cytotoxic phenotype [365, 366]. 
 26 
 
 
Ruminants have increased numbers o f γδ T-lymphocytes in the mammary gland 
compared to blood [367, 368]. However, their number decreases during the post partum period 
[369]. The role of these cells in the protection of intramammary infection is not known. Natural 
killer cells have cytotoxic activity and utilize their Fc receptors to achieve antibody-dependent 
cell-mediated cytotoxicity (ADCC). They express CD16 which is the Fcγ receptor for IgG on 
their surface. Their killing activity is mediated through granule exocytosis, release of cytokines 
and receptor mediated antigen recognition [235, 370]. The role of NK cell in protection of 
intramammary infection is not known. 
  
Regulatory T cells are either thymus derived lymphocytes or peripherally activated 
lymphocytes that regulate peripheral immune responses to self and non self antigens. The 
capability of the immune system to distinguish between self-antigens and non-self antigens is 
critical for the maintenance of immune homeostasis.  The immune system has evolved a variety 
of mechanisms to achieve self tolerance. There are two major mechanism of tolerance; these are 
central tolerance and peripheral tolerance. Central tolerance is a clonal deletion of self-reactive T 
and B cells exposed to self antigens at the immature stages of their development [371-373] 
whereas peripheral tolerance is a mechanism by which self reactive T- lymphocytes that escaped 
clonal deletion at the central generative organ have been prevented from causing autoimmune 
diseases [374-376].   
Recently, CD4+ lymphocytes from mammary gland secretions of cows immunized with lectins 
and S. aureus antigen were found to be less responsive to these antigens compared to CD4+ 
lymphocytes from peripheral blood of healthy cows [377]. This decreased response was believed 
to be due to inefficient antigen presentation by mammary gland antigen presenting cells and 
decreased efficiency of mammary lymphocytes. These authors also showed that concurrent with 
the decrease of CD4+ cells there was an increase in the number of CD8+ ACT2+ cells from an 
antigen-challenged gland as compared to peripheral blood lymphocytes from healthy cows. They 
also showed that removal of CD8+ ACT2+ cells stimulated antigen responsiveness of  
lymphocytes from antigen challenged animals whereas stimulation of purified CD4+ 
lymphocytes with different numbers of CD8+ ACT2+ lymphocytes decrease their 
responsiveness in a dose dependent manner.  In another observation, cows with S. aureus 
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intramammary infection showed a change in the ratio of CD4+:CD8+ cells from 1.53 in 
peripheral blood to 0.85 in the mammary gland during S. aureus mastitis, which shows an 
increase in the number of CD8+ cells or decrease in the number of CD4+ cells or both during 
intramammary infection [245, 377, 378]. This CD8+ cell population was shown to have 
increased expression of the activation marker molecule, ACT2. After these early observations, 
these authors focused on S. aureus enterotoxin-C (SEC) due to the high association of SEC with 
mastitis isolates of S. aureus [111]. Staphylococcal enterotoxins, especially SEC, are suspected 
to be primary factors for the induction of CD8+ ACT2+ cells that down regulate the activity of 
CD4+ T cells [379]. Very recently, they showed that bovine peripheral blood mononuclear cells 
stimulated in vitro with SEC increased the number of CD8+ CD26+ cells (ACT3 is the bovine 
orthologue of CD26) and reversion of the CD4+:CD8+ ratio [380, 381]. In another study, bovine 
PBMC cultures stimulated in vitro with SEC to examine T cell apoptosis and proliferation status 
showed that SEC-stimulated bovine PBMC cultures had low nucleic acid synthesis during early 
stimulation but increased nucleic acid synthesis after 5 days of incubation compared to 
stimulation with ConA. On the other hand, nucleic acid synthesis in human PBMC cultures 
stimulated with SEC increased continuously. The bovine CD4+:CD8+ ratio in SEC-stimulated 
PBMC cultures showed increased CD8+ cells with decreased apoptosis compared to CD4+ T 
cells. These authors concluded that SEC induces a prolonged Th-2 biased response and this 
could explain the chronicity of S. aureus intramammary infection [382]. Recent evidence from 
an in vitro study on bovine peripheral blood mononuclear cells (PBMC) cultured with a low dose 
(5 ng/ml) of S. aureus SEC1 enterotoxin for 10 days [383]  clearly showed stimulation of 
regulatory T cells which express typical surface molecules and express immunosuppressive 
cytokines. These authors showed that initially both CD4+ and CD8+ cells proliferate at equal 
rates but later on, CD8+ cells proliferate vigorously with increased expression of genes encoding 
CD25, CD152 (CTLA-4) surface molecules. They also showed an increase of mRNA of IL-10 
and TGF-β in SEC1-stimulated bovine PBMC cultures and they indicated that increased 
transcription of IL-10 and TGF-β comes from the CD4+ CD25+ T cell subpopulations. FOXP3 
mRNA also increased in this culture and this increase correlated with increased expression of 
CD152 and decreased expression of IL-2, which shows regulatory T cell involvement. They also 
showed that both SEC1 stimulated CD4+ and CD8+ cells suppress the proliferation of naïve 
PBMC exposed to heat killed S. aureus which is contrary to the previous observation which 
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indicated suppression of CD4+ cells by SEC-stimulated CD8+ CD26+ cells [382]. However Seo 
et al., [383] showed that SEC-stimulated CD4+ cells induced suppression of naïve PBMCs 
through IL-10 and TGF-β dependent mechanisms whereas CD8+ cells induced suppression did 
not involve IL-10 and TGF-β. These in vitro findings add one more possibility for a mechanism 
of chronic intramammary infection by S. aureus if this can be proven under in vivo conditions. 
 
 
Table 1.3.2.3. Regulatory T lymphocytes 
 
Treg type Origin Phenotype Cytokine 
expression 
Mode of action Reference 
Natural 
Treg 
Thymus CD4+ CD25+ 
FOXP3+, CTLA-4 + 
+/- IL-10 
+/- TGF-β 
Cell contact, membrane 
or soluble TGF-β, 
secreted IL-10 
[384-389] 
Acquired 
Treg 
(Tr1 and  
Th3 cells)  
Periphery CD4+,  FOXP3 
intermediae expression, 
CILA-4  and CD25 
(acquired with 
activation) 
IL-10, IFN-γ 
TGF-β, IL-4 
 Secreted IL- 10, cell 
contact,  membrane or 
soluble TGF-β 
[390-392] 
 
TGF= Transforming growth factor beta, Treg = Regulatory T cells, CTLA= cytotoxic T 
lymphocyte-associated antigen-4, Tr1 = T regulatory 1 cells.  
 
 
ii. Humoral Acquired Immunity 
                     
It is evident that both systemic and local humoral immune responses can contribute to 
mammary gland immune defences. The soluble effectors of the specific immune response are 
antibodies, cytokines and complement. In cattle, there are four classes of immunoglobulins 
known to influence the bacterial defense mechanism of the mammary gland. These are: IgG1, 
IgG2, IgA and IgM [393]. 
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Immunoglobulin A (IgA) secreting B-cells are attracted to the mucosal surfaces after 
stimulation by the antigen at the mucosal associated lymphoid tissues. In humans and 
monogastric species, intramammary immunity is a part of the mucosal immune system so that 
immunization through any mucosal surface will induce immune responses in the mammary gland 
[394-398]; however, in ruminants it is not well defined whether intramammary immunity is part 
of mucosal immune system [399, 400].  Immunoglobulin A (IgA) in the milk is synthesized by 
B-cells, which are resident in the mammary gland. These lymphocytes migrate to the secretory 
epithelia after first interaction with their antigen in the mucosal associated lymphoid tissues. The 
initial recognition of antigen induces expression of specific surface receptors, addressins, also 
known as L-selectin and α4β7 integrin, which binds to homing receptors, MAdCAM-1, present 
on the vascular endothelial cells in secretory epithelia [401].  This event leads to an interaction 
between lymphocytes and endothelial cells which results in migration of mature IgA-secreting 
cells into the lamina propria below secretory epithelial cells [401, 402].  Covalently linked 
dimeric secretory IgA (sIgA) is transported across epithelial cells by the polymeric Ig receptor 
(PIgR) [343, 401]. Some studies reported a significant correlation between IgA concentration in 
milk and phagocytosis of S. aureus by bovine PMNs [251]. Other studies indicated that IgA does 
not act as an opsonin [403]. Nevertheless, all studies indicated that sIgA might have other 
functions such as prevention of the adherence of bacteria to the epithelium of mammary gland 
and/or neutralization of toxins produced by microbial pathogens.  
 
Immunoglobulin-G (IgG) is produced at regional lymph nodes by IgG secreting B-cells, 
and secreted into blood and transferred from blood to the mammary gland across endothelial and 
epithelial layers. The exact mechanism of transportation from regional lymph nodes to the 
mammary gland is not known and some reports indicated that this transportation is achieved by a 
yet unknown prolactin-sensitive mechanism [343, 401]. It has been shown that prolactin inhibits 
IgG transfer into milk and also decreases the expression of an Ig-binding protein on mammary 
epithelial cells [343].  In bovine mastitis, IgG2 and IgM are known to be involved in opsono-
phagocytic clearance of S. aureus from the mammary gland [251]. The IgG1 is the dominant 
immunoglobulin in healthy milk and colostrum, especially during early lactation; however, its 
role as an opsonin for neutrophils is not proven  [404].  Nevertheless, it might be involved in the 
prevention of bacterial colonization and neutralization of toxins [251]. Generally, 
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immunoglobulin-M (IgM) is the most effective opsonin for opsono-phagocytic removal of any 
foreign body or microorganisms but its role in the mammary gland is not clearly known.  
  
Cytokines mediate, regulate and coordinate immune responses in the body through 
stimulation of activities of several cells which are either directly involved in immune effector 
function or produce immune effector molecules (or involve both functions). They form a 
network through which some humoral and/or cellular immune responses are regulated. Immune 
cytokines such as IL-2, IL-12 and IFN-γ are produced by Th1 cells and they promote cell 
mediated immune responses whereas IL-4, IL-5 and IL-10 are produced by Th2 cells and are 
mediators of humoral immune responses. It has been shown that IL-12 is produced by 
macrophages and B-cells and it favors the Th1 type response [405] whereas IL-4 enhances the 
development of Th2 type responses [290, 406].   
 
It is not clearly defined whether a Th1/Th2 bias exists during intramammary infection. 
However, a Th1 response can clear most intramammary infections. Similarly, a Th2 response 
might play role in preventing establishment of intramammary infections [251]. There are some 
reports which show cytokine profiles during S. aureus and/or E. coli mastitis. In an experimental 
infection of cows with S. aureus or E. coli, expression of proinflammatory cytokines such as 
TNF-α and IL-1β have been observed [407]. Analysis of milk and blood samples for cytokine 
expression in dairy cows immunized with S. aureus alpha toxin showed high expression of 
mRNA of IL-1β, IL6, TNF-α, IL-8 and IL-12 in  all milk and blood samples [291]. These authors 
also showed that for milk-derived neutrophils, the expression of CD11b, and CD18 was 
increased which may indicate activation and chemotaxis of neutrophils. It has been shown that  
in vitro stimulation of mammary epithelial cells with lipopolysaccharide (LPS) from Gram-
negative and lipoteichoic acid (LTA) from Gram-positive  bacteria for 24 hs  produced  
increased levels of mRNA expression for IL-1β, IL-8, TNF-α, CXCL6, and β-defensins in LPS-
stimulated cells whereas no significant changes have been detected  in LTA stimulated cells after 
24 hs. However, LTA-treated cells have significantly increased expression of these transcripts 
after 4-6 hs of stimulation which remained elevated up to 24 hs [310]. It has been shown that 
during mastitis, proinflammatory cytokines such as IL-1β, IL-6, IL-8 and TNF-α are produced 
and are involved in the regulation of inflammatory responses [290].  They also increase number 
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of blood and milk neutrophils as well as phagocytosis and bactericidal activity of neutrophils 
[235]. These cytokines regulate the inflammatory responses [408]. They induce vascular 
endothelial adhesion molecule expression locally on endothelial cells thereby enhancing 
neutrophil chemotaxis to the site of infection. Tumor necrosis factor alpha (TNF-α) and IL-1β 
are potent inducers of fever and the acute-phase response. The acute phase reaction results in 
increased production of proteins such as LPS-binding protein (LBP), C-reactive protein, serum 
amyloid A, haptoglobulin by hepatocytes [409]. These acute phase proteins might be involved in 
the defense mechanism of the mammary gland since they have host defense and antimicrobial 
activity and they can be used for early diagnosis of mastitis. 
 
Interleukin-12 is associated with Th1 type responses by stimulating production of IFN-γ, 
which in turn activates neutrophils and macrophages [410]. It increases the activity of 
mononuclear cells, especially lymphocytes including NK cells. Interferon gamma (IFN-γ) 
enhances the activity of Th1 cells and up-regulate production of IgG2 producing plasma cells. In 
the mammary gland experimentally infected with S. aureus, IL-12 increased 24 hs post infection 
[411, 412].  Interleukin-12 (IL-12) is an important cytokine for the differentiation of Th1 CD4+ 
cells [413]. It also enhances IgG2a production [413]. Moreover, significant mRNA transcripts of 
IL-12 have been observed during mid and late lactation, a time during which the mammary gland 
is relatively well protected. In vitro and in vivo studies indicated that recombinant bovine IL-2 
may enhance the function of mononuclear cells within the mammary gland [235].  
 
Colony stimulating factor (CSF)  is produced by several cells such as fibroblasts, 
endothelial cells, macrophages and T cells and its function is to stimulate growth and 
differentiation of several hematopietic cells [414].  Macrophage colony stimulating factor (M-
CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) regulate growth and 
differentiation of granulocytes and macrophages respectively. The roles of these growth factors, 
other than the normal growth initiation of respective cells, are not well known during mastitis. 
 
Dairy cows are more susceptible to mastitis during the peri-parturient and early non-
lactating periods. The increased susceptibility of dairy cows to mastitis during these periods can 
be due to several factors, some of which could be the influence of hormones (cortisol, which is 
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an anti-inflammatory hormone, estradiol, progesterone, etc.), dilution of immune effectors by 
milk, and the interaction between milk components and immune effectors which might decrease 
their activity [235, 251].  During the periparturient period, somatic cell counts increase at 
prepartum and decrease at postpartum; however, the incidence of mastitis is very high during this 
period [235, 251]. During the postpartum period peripheral blood CD8+ lymphocytes mainly 
produce IL-4 and they have less cytotoxic activity [136]. It has been shown that the CD4+ 
enriched cultures of peripheral blood mononuclear cells isolated postpartum have increased IL-4 
and IL-10 mRNA transcript expression [406]. This might indicate either a Th-2 biased response 
or immune suppression by regulatory T cells that leads to a high incidence of mastitis during 
these periods.  In another study, mammary cell cultures isolated during the mid to late lactation 
period, during which incidence of mastitis is low, had increased IL-2 mRNA transcripts [406]. 
These authors also showed that depletion of CD4+ lymphocytes decreased and enrichment of 
CD4+ lymphocytes increased IFN-γ transcripts in cultures of peripheral blood mononuclear cells 
isolated from mid to late lactation cows [406]. The existence of other cells that can secrete IL-4, 
such as CD8+ suppressor cells, might justify the reason why CD4+ depletion did not decrease 
IL-4 transcript levels in these cultures. Cells from mid-lactation dairy cows showed cytotoxic 
activity and they secreted high IFN-γ, while CD8+ lymphocytes from cows at postpartum 
showed no cytotoxic activity and secreted increased level of IL-4 [235, 240]. Studies on 
neutrophils gene activities [415] found that both immune response genes and the basic cellular 
genes for metabolism to generate energy  were affected during the periparturient period [251]. 
 
Intramammary infections by most mastitis causing pathogens can be controlled by rapid 
recruitment of neutrophils from blood into the mammary gland after infection with a 
concomitant increase of IgG2 immunoglobulin in the gland for successful opsonophagocytic 
removal of the infecting microorganism. The protective intramammary immune responses for 
most mastitis causing pathogens are Th-1 dominated responses that express IFN-γ, IgG2 and IL-
2 with rapid recruitment of blood derived neutrophils and efficient opsonophagocytosis [251, 
416-419]. Most mastitis vaccines induced Th-2 dominated immune responses that expresse IL-4, 
IL-10, high IgM and IgG1 with reduced Th-1 type inflammatory responses [251]. These Th-2 
dominated responses did not clear invading intramammary pathogens. Increased numbers of 
stimulated Th-1 cells resulted in increased production of IFN-γ  that activate neutrophils and 
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macrophages to increase their surface Fc receptors and phagocytosis induced respiratory burst 
activity for anibody-dependent and antibody-independent killing of invading pathogens [251, 
416-419]. However, massive infiltration of neutrophils also causes severe damage to the 
mammary gland tissue; therefore, a balanced response that protects against infection with 
minimal damage to the mammary gland tissue is required. 
 
 
1.4. Treatment, Control and Prevention of Bovine Staphylococcus aureus Mastitis 
 
 
1.4.1. Treatment of Bovine Staphylococcus aureus Mastitis 
 
Mastitis due to S. aureus can be prevented or reduced in incidence. Antibiotic therapy can 
be applied to subclinical or clinical cases of mastitis during lactation or during the dry period. 
However, different treatment regimes failed to cure S. aureus intramammary infection [47, 57, 
420, 421]. Antibiotic treatment is ineffective since only 20-70% of the dry period therapy is 
effective and only 10-30% of S. aureus-infected quarters are cured during lactation [422]. S. 
aureus adhesion and invasion into mammary epithelial cells allows the bacteria to escape the 
effect of immunity and antibiotics by being hidden in the intracellular niche and thereby causing 
chronic recurrent intramammary infections. Moreover, the appearance of electron transport-
defective, drug-resistant small-colony variants which can stay in intracellular areas makes the 
control and prevention of S. aureus mastitis more difficult. It has been reported that in a total of 
58 studies that examined results of treatment of S. aureus mastitis the cure rates were 14-100% 
for  dry cow therapy with an average of  63%  and  26-92% for clinical mastitis with  an average 
of 54%  [423]. These authors also reported that out of 16 trials on subclinical S. aureus mastitis 
the cure rate was 17- 95% with an average of 48%. Although dry period therapy seems better as 
compared to lactation therapy the overall success rate of mastitis treatment is not promising 
indicating the need for development of better prophylactic and therapeutic strategies. 
 
1.4.2. Control and Prevention of Bovine Staphylococcus aureus Mastitis 
 
Improved control of bovine S. aureus mastitis can be achieved by combined application 
of dry-cow therapy and milking-time preventive hygienic techniques. Standard hygienic milking 
 34 
 
protocols and dry cow mastitis therapies have been introduced for the control and prevention of 
intramammary infection [424]. Good milking practices include:  wash udder and use one service 
towel per cow to dry the udder, pre- and post-milking teat dipping into disinfectant solutions, use 
of gloves by milkers, and milking unit disinfection. The basic mastitis control program is based 
on five-point mastitis control plans, which include: milking practice with regular testing and 
maintenance of the milking machine, application of a teat disinfectant immediately after removal 
of the milking machine, routine antibiotic therapy for all cows after  each lactation, treatment and 
documentation of all quarters with clinical mastitis, and culling of cows with chronic or recurrent 
mastitis [425] 
 
The goals of this five-point control plan are targeted at reducing exposure, duration and 
transmission of intramammary infection by bacteria. This has markedly reduced the incidence of 
contagious mastitis but has had little effect on the incidence of environmental mastitis [426]. 
This may be due to inadequate knowledge of the pathogenesis of the infection, insufficient 
clearance of the infection during treatment or inadequate awareness of the importance of 
different strains of S. aureus as well as vectors and mechanism of spread. It also may relate to the 
manifestation of certain strains of highly transmissible S. aureus [38].  Some studies suggest that 
there are strains that are common to several herds, even in separate states [427, 428] or countries 
[429].  
 
The isolation and culling of infected cows is also an effective control procedure for S. 
aureus mastitis [423]. However, these techniques are time-consuming, labour intensive and 
expensive. Therefore, a better strategy is needed to reduce the prevalence of S. aureus mastitis in 
dairy herds.          
 
     
1.4.2.1. Vaccination 
 
Despite several successful vaccine trials conducted with different commercialized [430, 
431] and non-commercialized vaccines [93, 432] (Table 1.4.2.1) all field trials with these 
vaccines have been unsuccessful [6].  These include vaccines developed from live attenuated or 
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killed S. aureus cells, toxins (α and β hemolysins), capsular polysaccharide, protein A and 
fibronectin-binding proteins [433-438]. Vaccination with autogenous whole cell bacterins and 
specific antigen fractions do not elicit heterologous protection [6, 93, 109, 439-442]. However, 
vaccines containing combined antigenic factors [170] from S. aureus surface components have 
shown promise if the antigen, adjuvant and route of delivery are appropriate.  Major problems 
affecting the successful development of protective S. aureus vaccines against bovine S. aureus 
mastitis are strain variation, the presence of capsular polysaccharide in most pathogenic strains 
which does not allow recognition of antibody coated S. aureus by phagocytic cells, dilution of 
immune effectors by milk [6, 443], interaction between milk components and immune effectors 
[444] that reduce their effectiveness, and the  ability of S. aureus to attach and internalize into 
mammary epithelial cells. There is an increasing need for the development of better vaccines that 
overcome these problems. A better understanding of the natural and acquired immunological 
defenses of mammary gland coupled with detailed knowledge of the S. aureus pathogenesis 
should lead to the development of improved methods of reducing the incidence of mastitis in 
dairy cows. 
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Table 1.4.2.1. Staphylococcus aureus vaccines tested 
 
 
 
 
S. aureus vaccine Type of 
vaccine 
Immunogenic effects Reference 
Whole S. aureus cell lysate 
encapsulated in biodegradable 
microspheres 
Whole cell 
lysate 
Induced antibodies that were more opsonic for 
neutrophils and inhibited adhesion to mammary 
epithelium. 
[93] 
Whole cell lysate from two 
strains (α and   α + β 
hemolytic) plus supernatants 
from non-hemolytic strain 
Whole cell 
lysate from 
two strains 
Vaccinated cows had 70% protection from 
infection compared to less than 10%  protection 
in control cows 
[439] 
MASTIVAC I Whole cell  
lysate 
 Improved  udder health in addition to specific 
protection against S. aureus infection 
[431] 
Live pathogenic S. aureus 
through IM route  
Live 
pathogenic S. 
aureus 
Induce activation of immune cells in mammary 
gland and blood. 
[109] 
Fibronectin binding protein 
and clumping factor A 
DNA primed 
and protein  
boosted 
Induced cellular and humoral immune 
responses  that provide partial  protection 
against S. aureus 
[445] 
Protein A of S. aureus with 
green fluorescent protein 
DNA Induced humoral and cellular  immune  
responses 
[446] 
Plasmid encoding bacterial 
antigen β-gal 
DNA Induced humoral  and cellular immune  
responses 
[447] 
Polyvalent S. aureus bacterin 
 
Protein Eliminated some cases of chronic 
intramammary S. aureus infections  
[448] 
Five-isolate-based S. aureus 
bacterin (Lysigin), three-
isolate  experimental bacterin 
and five-isolate experimental  
bacterin 
Bacterin Lysigin reduced the clinical severity and 
duration of clinical disease. None of 
experimental bacterins has significant effect.  
[430] 
Polyvalent S. aureus bacterin 
combined with antibiotic 
therapy. 
 
Bacterin S. aureus intramammary infection cure rate 
increased 
[449] 
Whole cell trivalent vaccine 
containing CP types 5, 8 and 
336 with adjuvants (FICA or 
Alum 
Whole cell 
lysate 
Elicited  antibody responses specific to the 3 
capsular polysaccharides (increased  IgG1 and 
IgG2 in all vaccinated animals 
[432] 
CP conjugated to a protein 
and incorporated in poly 
microspheres and emulsified 
in Freud’s incomplete 
adjuvants 
CP types 5, 8 
and  336 
Cows in both groups produced increased 
concentrations of IgG1, IgG2 antibodies, 
neither groups produced an increase in IgM. 
Sera from cows immunized with conjugates in 
microspheres induced sustained increased 
phagocytosis. Immune sera from both groups 
decreased bacterial adherence to bovine 
mammary epithelial cells.   
[170] 
Polysaccharide-protein 
conjugates emulsified in 
Freund’s incomplete adjuvant. 
Polysacchari
de-protein 
conjugate 
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1.4.2.2. DNA Vaccines.  
 
Most vaccination strategies for prevention against mastitis have focused on the 
enhancement of humoral immunity. The developments of vaccines that induce a protective Th1 
type cellular immune response in the mammary gland have not been well investigated. The 
ability to induce cellular immunity, especially neutrophil activation and recruitment into the 
mammary gland is one of the key strategies in the control of S. aureus mastitis. One such 
strategy is use of DNA vaccines that contain pathogen-specific genes with known antigen-
presentation ability for quick activation of Th1 immune responses and that also induce increased 
production of opsonizing IgG2 antibody by B cells. It has been shown that genes in a plasmid 
vector can be injected into animals with the subsequent expression of the encoded protein [450] 
and  that an immune response could be induced to the proteins [451-454]. In another study 
intradermal injection of DNA encoding a green fluorescent protein (GFP) gene resulted in the 
production of antibody to GFP [455]. In addition it has been shown that DNA-based vulvo-
mucosal immunization in cattle stimulated both cellular and humoral immune responses [456, 
457]. These authors also showed that the circulating antigen presenting cells of the dermis 
migrated to the injection site, indicating their involvement in antigen presentation [457].   
 
DNA vaccines have many advantages over other conventional vaccines. They are easy 
and economical to produce, have no requirement for an adjuvant [458] and thus, no injection site 
reaction problems due to adjuvant occur [459], induce balanced Th1/Th2 like immune responses 
which is important for the control  of several viral infections [460, 461], can induce immune 
responses in neonates without interference by maternal antibody [462, 463], and can be given in-
utero [464]. Despite all these advantages, DNA vaccines are less efficient in humans and large 
animals and induce weaker humoral responses. The reason for this low efficiency is believed to 
be due to poor transfection of host cells by DNA. The improvement of DNA delivery with 
appropriate vector selection is expected to improve the efficacy of DNA vaccines in large 
animals. It has been hypothesized that immune  responses to DNA vaccines  in large animals can 
be improved by improving three major components which are a promoter of the gene, gene of 
interest for immune induction and back bone of the plasmid for delivery of construct into cells 
[461]. These authors also proposed a model system where an improved promoter with 
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appropriately enhanced antigen expression system combined with an optimal delivery route, will 
induce balanced Th1/Th2 responses in large animals and humans. For example, as one means to 
optimize DNA immune response in large animals, it has been successfully shown that gene gun 
or suppository delivery of bovine herpes virus -1 glycoprotein-D (BHV-1 gD) to the vaginal 
mucosa induced protective immune responses both in the vaginal and nasal mucosa, indicating 
that vaccination at vaginal mucosa can induce protection at other common mucosal surfaces 
[461]. These authors also showed that simultaneous injection of two plasmids encoding different 
antigens did not result in significant interference.  They suggested that various combinations of 
antigen delivery protocols could increase immune response to DNA vaccines in large animals. In 
another study DNA vaccination with an improved bicistronic plasmid  encoding a fusion of two 
sequences from fnbP and clfA genes separated by an Internal Ribosomal Entry Site (IRES), 
followed by a booster vaccination with respective proteins, resulted in both cellular and humoral 
immune responses that gave partial protection of mammary gland from staphylococcal mastitis 
[445]. 
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2. HYPOTHESIS, OVERALL GOALS AND SPECIFIC OBJECTIVES  
  
2.1. Hypothesis: Strengthening Local Intramammary Immunity Will Protect against 
Bovine S. aureus Mastitis  
 
 
Our hypothesis is based on the fact that most of the previous S. aureus mastitis 
vaccinations were focused on inducing protective systemic humoral immune responses rather 
than enhancing local immune responses in the mammary gland. Vaccination strategies that can 
also enhance cell-mediated immunity in the mammary gland have not been pursued. Moreover, 
most S. aureus vaccines were composed of killed bacterial cells or bacterial products that elicit 
protection against a limited number of strains.  It is evident that both systemic and local humoral 
immune responses can contribute to the mammary gland immune defenses. However, we believe 
that strengthening local immune responses using highly immunogenic molecules conserved 
among pathogenic strains of S. aureus combined with the best adjuvant and appropriate selection 
of the route of  administration that induce maximum stimulation of the immune system will 
protect against bovine S. aureus mastitis.     
 
2.2. Overall Goals and Rationale of this Study 
 
 
The complex interaction between the intramammary pathogens and mammary gland 
defense mechanisms are not well understood. Moreover, the protective host immune responses 
needed to eliminate pathogens from the mammary gland and how to enhance protective 
intramammary immunity before mastitis is established are not well defined. Therefore, the 
overall goals of this study were:  
A. To improve our understanding of intramammary immunity using GapB and GapC proteins of 
S. aureus as model antigens  
 
B. To determine the regulation of expression of the gapB and gapC genes and their role in 
virulence. 
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2.3. Specific Objectives  
 
1. To test immune response to GapB, GapC and GapC/B proteins in mice. 
 
2. To test immune responses in mice after vaccination with plasmids, gapB, gapC and 
gapC/B encoding GapB, GapC and GapC/B proteins respectively. 
 
3. To optimize the immune response in the mammary gland of cows 
 
4. Monitor duration of immune responses in cows with the best immunogenic proteins and 
adjuvants selected from the above mentioned mice experiments (GapC/B and VSA3). 
 
5. To determine the role of GapC in the virulence of S. aureus. 
 
6.  To determine the role of environmental conditions and global virulence regulators 
(agr/sar loci) in  the regulation of expression of the gapC and gapB genes in S. aureus  
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3. MATERIALS AND METHODS 
 
3.1. Bacterial Strains, Culture Media, Growth Conditions and Preparation of  
       Competent Cells  
 
3.1.1. Bacterial Strains and Growth Conditions 
 
The S. aureus strains SA10 and SA12 were isolated from clinical bovine mastitis cases in 
dairy farms in Saskatoon, SK, Canada [75]. S. aureus strain 16 (SA16) was also from a bovine 
clinical mastitis case and it was obtained from Dr. Lorraine M. Sordillo Department of Large 
Animal Clinical Sciences, Michigan State University, East Lansing, MI, USA). The S. aureus 
strains RN6390 and its isogenic gapC mutant strain H330 (RN6390 gapC::tet ) [79] were 
obtained from Dr. David Heinrichs (Microbiology & Immunology, University of Western 
Ontario, London, Ontario, Canada), The S. aureus strain ALC132 (RN6390) and its isogenic  
mutants  agrA,  ALC133 (RN6390 agrA::erm),  sarA, ALC136 (RN6390 sarA::erm), agr/sar, 
ALC135 (RN6390 agr/sar::tet/erm) were obtained from Dr. Ambrose L. Cheung (Department of 
Microbiology, Dartmouth Medical School, Hanover, NH, USA). The identities of the strains 
were confirmed at VIDO using the API Staph kit (bioMérieux, Marcy-l’Étoile, France). The S. 
aureus strains were grown in tryptic soy broth or agar (DIFCO, Becton-Dickinson, Sparks, MD, 
USA), tris minimal succinate (TMS) broth (defined growth media containing succinate as carbon 
source) [465], tris minimal glucose (TMG) broth (defined media with glucose as carbon source) 
and whey. Whey was prepared from whole milk as described in section 3.1.2 and filter-sterilized. 
Tris minimal succinate medium contains: 4% (v/v) of a sterile tris salt stock (NaCl 145 g/L), KCl 
(92.5 g/L), NH4Cl (27.5 g/L), Na2SO4  (3.55 g/L), KH2PO4 (6.8 g/L), tris base (12.1 g/L), 
sodium succinate (16.6 g/L), adjusted to pH 7.4 and supplemented with filter sterilized 
tryptophan (0.02 g/L), cysteine (0.022 g/L), thiamine (0.0169 g/L), nicotinic acid (0.00123 g/L), 
pantothenic acid (0.0005 g/L), biotin (0.00001 g/L), MgCl2 (0.0953 g/L) and CaCl2 (0.0111 
g/L). Tris minimal glucose media has the same components as TMS and prepared exactly as for 
TMS except for the replacement of succinate with glucose (5 g/L). S. aureus strains were grown 
in tryptic soy broth and whey at pH 5 and pH 7.4 when necessary. Tryptic soy broth at pH 7.4 
was prepared with 0.1 M of 3-(N-morpholino) propanesulfonic acid (MOPS) and continuously 
buffered with MOPS during bacterial growth. To maintain anaerobic and microaerophilic 
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conditions cultures were grown in an aerobic jars containing BBL™ Gaspack™ with anaerobic 
and microaerophilic system envelopes respectively (BD Company, Sparks, MD, USA). The 
gapC mutant strain H330 (RN6390 gapC::tet) [79] was grown in TMS broth or agar at 37 oC in 
the presence of antibiotics (tetracycline 4µg/ml), when necessary. The TMS solid medium was 
obtained by the addition of Bacto agar (DIFCO, 15 g/L). Escherichia coli strains E. coli BL21 
(DE3) (Novagen Inc. Madison, WI, USA), SG13009 (pREP4) [466] and DH5-α were grown in 
Luria-Bertani broth or agar (DIFCO) at 25 oC or 37 o
Table 3.1.1.1. Bacterial strains and plasmids used in this study 
 
C, in the presence of antibiotics (100 µg of 
ampicillin per ml or 50 µg/ml of carbencillin or 50 µg/ml of kanamycin per ml) when necessary. 
Name Description Reference 
S. aureus strains   
SA10 , SA12 Bovine mastitis clinical isolates [75] 
SA16 Bovine mastitis clinical isolates VIDO 
RN4220 Restriction enzyme deficient 8325-4 mutant [467] 
RN6390 Prophage cured wild type strain, human isolate [205] 
H330 RN6390 gap:: tet; Tc [79] r 
ALC133 RN6390 agrA:: erm; Em [468] 
 
r 
ALC136 RN6390 sarA:: erm; Emr 
ALC135 RN6390 sar/agr:: tet/Emr, Tcr,Emr 
E. coli strains   
DH5-α Host for plasmid Laboratory stock 
BL21(DE3) Used to express the histidine-tagged Gap protein genes. Laboratory stock 
SG13009 (pREP4) F- [466]  his pyrD ∆lon-100 rpsL 
Plasmids   
pBISIA-24 Eukaryotic cell expression vector [469] 
pQE-30 Prokaryotic cell expression vector Qiagen 
 
 
 
3.1.2. Preparation of Whey from Milk 
 
Whey was prepared as follows: Milk from 4 quarters of the cow was pooled in equal 
amounts and 1 rennet tablet, purchased from a health food store (Mom’s nutrition, Saskatoon, 
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Canada), was homogenized in 40 ml of water or ¼ tablets in 10 ml. A 100 µl aliquot of the 
rennet mix was added to 2 ml of milk or 500 µl to 10 ml of milk. Samples were stirred with a 
wooden applicator stick. The tip of the stick was broken off so that the lid would fit back on the 
tube and the tubes were incubated for 2-6 hs (usually 4 hs) at 37 °C until a milk clot formed.  
After the milk clot formed, the tubes were centrifuged at 3000 X g for 20 min and the milk 
formed three layers as follows: fat, whey and curd at the top, middle and bottom of the tube 
respectively.  The whey was collected carefully using a Pasteur pipette after removing the top fat 
layer. 
 
3.1.3. Growth Conditions of Staphylococcus aureus Strains RN6390 and H330 for in vitro 
Adhesion and Invasion Assays and in vivo Challenge Trials. 
A 50 ml aliquot of tryptic soy broth (TSB) and tris minimal succinate (TMS) broth was 
inoculated with an overnight culture of 0.5 ml of S. aureus strains RN6390 and H330 
respectively, in 125 ml flasks and incubated at 37 °C with shaking. The optical density (OD) of 
the cultures was taken at a wavelength of 600 nm using a spectrophotometer (Fisher Scientific 
Company, Ottawa, Ontario, Canada) and growth curves of OD600 versus time were constructed. 
When cells were at the exponential phase (OD600 of 0.4-0.5, usually within 2:30-3:30 hs) the 
growth was stopped by placing the flask on ice. Cells were collected by centrifugation at 3000 X 
g for 10 min at 4 ºC.  The cell pellet was suspended in 45 ml cold sterile PBS and centrifuged at 
3000 X g for 10 min at 4 ºC. Finally, the cell pellet was suspended in 5 ml cold sterile PBS, 
counted and diluted to 2 X 107 
3.1.4. Infection 
CFU/ml in MAC-T media {Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) (DIFCO), 5µg/ml insulin, and 
1µg/ml hydrocortisone (Sigma, St. Louis, MO, USA)} without gentamicin, and kept on ice until 
infused into the mammary gland. The serial dilutions of the bacterial suspensions were plated on 
TSA and TMS agar plates for RN6390 and H330 respectively to determine viable counts. 
 
To determine the number of attached and internalized RN6390 and H330, into MAC-T 
cells, the bacterial suspensions were used to inoculate MAC-T cell cultures at a multiplicity of 
infection (M.O.I) of around 20 to 50 CFU of S. aureus strains RN6390 or H330 per 1 MAC-T 
cell as follows: The spent media was removed from the 6 wells plate containing MAC-T cells 
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and a 2 ml aliquot of fresh MAC-T culture media was added to each well. Finally, 0.5 ml of the 
S. aureus suspension were added to each well and incubated at 37 ºC in a 5% CO2
3.1.5. Determination of the Number of Total RN6390 and H330 Attached and Internalized 
into MAC-T Cells 
 atmosphere 
for 1 h.  
 
 
After MAC-T cells were co-incubated with S. aureus strains RN6390 or H330 for 1 h, 
aliquots of the culture supernatant were removed, serially diluted and plated for viable counts. 
The wells were washed 3 times with 2.5 ml of cold PBSA (PBSA = 8 g/L NaCl, 0.2 g/L KCl, 
1.15 g/L Na2PO4, 0.2 g/L KPO4
3.1.6. Determination of the Number of Invasive RN6390 and H330 
 to 1000 ml distilled water) each time. Finally, 1ml of a solution 
containing 0.5% saponin and 0.025% trypsin (Sigma) was added to each well and plates were 
incubated at 37 ºC for 10 minutes to lyse MAC-T cells. The lysate was serially diluted and plated 
for viable counts. 
 
 
After 1 h of incubation of RN6390 or H330 with MAC- T cells, aliquots of the culture 
supernatants were removed, serially diluted and plated for viable counts. Each well was washed 
3 times with pre-warmed MAC-T media with gentamicin (50 µg/ml). To kill extracellular 
bacteria 2.5 ml of media containing gentamicin (200 µg/ml) (Sigma) and penicillin (20 µg/ml) 
(Invitrogen Canada Inc., Burlington, Ont, Canada) was added to each well and incubated at 37 ºC 
for 1 h. To monitor bacterial killing aliquots of the supernatants were taken, serially diluted and 
plated for viable counts. To determine the number of intracellular bacteria each well was washed 
3 times with 2.5 ml of cold PBSA  and MAC- T cells were lysed by treating  with 1 ml of a 
solution containing 0.025% trypsin and 0.5% saponin in PBS and incubated for 10 minutes at 37 
ºC. Serial dilutions were made of the suspension and plated for viable counts.  
 
3.1.7. Preparation of Staphylococcus aureus Cells for Electroporation and Electroporation 
Protocol  
 
An overnight culture of S. aureus strain RN4220 was diluted 100 fold in 500 ml TSB and 
incubated with  shaking at 37°C until the culture reached an OD600 of 0.4-0.5 (exponential 
phase). S. aureus cells were washed  3 times with  ice cold 500 mM sucrose and  suspended in a 
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final volume of 2 ml 500 mM sucrose. The S. aureus cell suspensions were aliquoted into pre-
chilled microfuge tubes (60 µl each) and frozen in a liquid nitrogen or dry ice/ethanol bath. 
Staphylococcus aureus cells suspensions were electroporated in a 0.2 cm gap cuvette (Bio-Rad, 
Life Science Research, Mississauga, Ont, Canada) at a voltage of 2.5 Kv, capacitance of 25 µF 
and resistance of 100 Ω. A 50 ng of DNA was used for electroporation of S. aureus. The bacteria 
were recovered in non-selective medium, in this case TSB for 4 hs. Erythromycin was added to a 
0.05 µg/ml and cells were allowed to recover for an additional 2 hs. Finally, aliquots of the 
suspension were plated on TSA with 3 µg/ml erythromycin.   
 
3.1.8. Preparation of Escherichia coli for Electroporation and Eletroporation Protocols 
 
All E. coli transformation experiments involved electroporation. To prepare E. coli cells 
for electroporation an overnight culture in Luria Bertani broth (LBB) was diluted 1:100 in 500 
ml of fresh broth and grown to early logarithmic stage (OD600 = 
3.2. Culturing of Bovine Mammary Epithelial Cells 
~ 0.2). E. coli cells were 
collected by centrifugation at 4424 X g for 15 minutes at 4 °C. The cells were washed 3 times in 
500 ml ice-cold sterile deionized water, suspended in 10% cold glycerol and stored in 50 µl 
aliquots at -70 °C until use. Bacterial  cells were transformed by electroporation using  a 1 mm 
gap cuvette (Bio-Rad) at 1.8 kV, 25 µF, 200 Ω  by a gene pulser (Bio-Rad)  using 50 µl of 
bacterial cells prepared as described above. A 50 ng of DNA was used for transformation of E. 
coli.  
 
 
Transformed mammary epithelial cells (MAC- T ) [470] were cultured as described [471] 
in 75 cm2 tissue culture flasks (Corning Inc. Corning, NY, USA) to confluent monolayers. Cells 
were treated with 0.5% (w/v) trypsin (GIBCO BRL) in versene buffer (0.2 g/L sodium-EDTA, 8 
g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4, 0.2 g/L KH2PO4, 0.2 g/L glucose), resuspended in 
fresh DMEM containing 10% (v/v) of fetal bovine serum (FBS) (GIBCO BRL) and diluted to 5 
X 105 cells/ml with DMEM. For adhesion and invasion experiments, 106 cells were added to 
each well of 6-well tissue culture plates and incubated at 37 °C in a 5% CO2
 
  (v/v) atmosphere 
for 18 hs. 
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3.3. DNA Preparation, Plasmid Construction and Manipulation 
 
 
3.3.1. Genomic DNA, PCR and Plasmid Purification Protocols 
 
Genomic DNA from strains of S. aureus was purified with a Nucleospin Tissue Kit 
(Clontech, Palo Alto, CA, USA) with the addition of 5U/ml lysostaphin (SIGMA, St. Louis MO, 
USA.) and used as PCR template.  PCR reactions were carried out using specific primers for 
gapC and gapB (Table 3.3.1).  The PCR conditions were as follows: initial denaturation step at 
95 oC for 4 minutes; followed by 40 cycles of 95 oC 1 minute, 50 oC 1 minute, 72 oC 1 minute 
each, and finished by incubation at 4 o
 
C for 1 h.  Aliquots of the PCR reactions were loaded on a 
1% agarose gel, separated by electrophoresis, and stained with ethidium bromide. The PCR 
fragments were purified with the QiaQuick PCR purification kit (Qiagen, Mississauga, ON, 
Canada) and analyzed on a 1% agarose gel. Plasmid DNA was extracted using the Qiagen 
plasmid purification kit (Qiagen) following the manufacturer’s instructions and analysed by 
restriction endonucleases as well as by sequencing of the inserted DNA 
  
3.3.2. Construction of Plasmids Encoding GapC, GapB and GapC/B Used for DNA 
Immunizations.  
 
The plasmids used in DNA immunizations were constructed using a derivative of 
pBISIA-24 [469].  This plasmid has regulatory sequences for expression of genes in eukaryotic 
cells, including the HCMV-IE1 promoter, intron A and the polyadenylation signals from the 
bovine growth hormone gene.  The plasmid also contains CpG ODN motifs which have 
previously been shown to enhance the quality and quantity of the immune response following 
vaccination with plasmid DNA [469].  The S. aureus gapB gene, contained in a 1032 bp 
fragment obtained by PCR using the primers Sa7a and Sa8a (Table 3.3.1), was ligated to the 
4393 bp EcoRI/XhoI fragment of pBISIA-24.  The resultant plasmid was named pBISIA-gapB.  
The S. aureus gapC gene, contained in a 1025 bp SmaI/XhoI fragment obtained by PCR using 
the primers Sa5 and Sa10 (Table 3.3.1) was ligated to the 4406 bp SmaI/XhoI fragment of 
pBISIA-24.  The resultant plasmid was named pBISIA-gapC.  The 1938 bp BamHI/SalI 
fragment of pQE-SAgapCB2 encoding the S. aureus gapC/B chimeric gene [472] was ligated to 
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the 4357 bp BamHI/XhoI fragment of pBISIA-24 and the resultant plasmid was named pBISIA-
gapC/B. 
 
3.3.3. Construction of Plasmids Encoding GapB, GapC and Chimeric GapC/B 
Recombinant Proteins for Expression and Purification in Escherichia coli. 
 
The PCR pair Sa-1 and Sa-2 (Table 3.3.1.) was used to amplify a ca. 1.1 kb DNA 
fragment from SA10 encoding the gapC gene and this fragment was digested with BamHI and 
KpnI.  The resultant 1048 bp fragment was cloned into pQE-30 (Qiagen), an E. coli expression 
vector that adds a 6 x histidine tag at the NH2 
3.3.4. Construction of a Plasmid Expressing the T-cell Plasminogen Activator Signal 
Sequence. 
terminus of the GapC protein for purification by 
affinity chromatography.  The resultant plasmid was named pQE-SAgapC.  The primer pair Sa-
3a and Sa-4 (Table 3.3.1) was used to amplify a ca 1 kb DNA fragment of SA10 encoding the 
gapB gene without the first 39 bp of the coding region. This fragment was digested with KpnI 
and SalI and cloned into pQE-SAgapC to generate plasmid pQE-SAgapC/Ba encoding a 2,064 
bp ORF encoding a 688 amino acids GapC/B fusion protein with a predicted Mr of 74,385 Da 
and an isoelectric point (pI) of 5.86. 
 
 
To construct a vector expressing the T-cell plasminogen activator signal sequence (Tpa), 
the 99 bp HindIII-BglII fragment encoding Tpa, obtained by annealing of the complementary 
oligonucleotides Tpa-1 and Tpa-2 (Table 3.3.1) was ligated to the 4390 bp HindIII/BglII 
fragment of pBISIA-24.  The resultant plasmid was named pBISIA-Tpa (Fig.4.2.2.1).  To 
construct a plasmid expressing the S. aureus GapC protein on the cell surface, the 90 bp 
EcoRI/BamHI synthetic Tpa-fragment, obtained by annealing of Tpa-2F and Tpa2-R 
oligonucleotides (Table 3.3.1), was ligated to the 5310 bp EcoRI/BamHI fragment of pBISIA-
gapC.  The resultant plasmid was named pTPA2-gapC (Fig.4.2.2. 1). This plasmid possesses an 
ORF of 1116 bp encoding a Tpa:GapC protein with an estimated Mr of 40,016 Dalton (Da) and 
pI of 4.0.  To construct a plasmid expressing the S. aureus GapC/B chimeric protein on the cell 
surface, the 90 bp EcoRI/BamHI synthetic Tpa fragment,  obtained by annealing of Tpa-2F and 
Tpa2-R oligonucleotides (Table 3.3. 1), was ligated to the 6291 bp BamHI/EcoRI fragment of 
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pBISIA-SAgapC/B.  The resultant plasmid was named pTPA2-gapC/B (Fig.4.2.2. 1).  This 
plasmid possesses an ORF of 2112 bp encoding a Tpa:GapC/B protein with an estimated Mr of 
76,000 Da and a pI of 5.33.  Finally, to construct a plasmid expressing the S. aureus GapB 
protein on the cell surface, the 5331 bp fragment of pTPA2-gapC/B, obtained by digestion with 
KpnI, blunting with T4 DNA polymerase, followed by digestion  with NheI and blunting with the 
Klenow fragment of DNA polymerase I was self ligated.  The resultant plasmid was named 
pTPA2-gapB (Fig.4.2.2. 1).  This plasmid possesses an ORF of 1128 bp encoding a Tpa:GapB 
protein with an estimated Mr of 40,615 Da and a pI of 6.4. Plasmids were purified using the 
Endofree® Plasmid Maxi Kit (Qiagen, Mississauga, ON, Canada) and the determination of 
endotoxin content was carried out as before [472].  
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Table 3.3.1. Synthetic oligonucleotides used in this study 
Name Sequence Description 
Sa-1 5’AACATAGGATCC Forward primer.  It binds to the 30-51 bp region 
of his-gapC in pET-GapC [75] 
AGCAGCGGCCTGGTGCCGCGC 
Sa-2 5’AAATTAGGTACC Reverse primer.  It binds to  the 987-1008 bp 
region of gapC 
TTTAGAAAGTTCAGCTAAGTAT 
Tpa-1 5'-AGCTT Forward oligonucleotide used to construct 
pBISIA-tpa 
GCAATCATGGATGCAATGAAGAGAGGGC 
TCTGCTGGTGCTGCTGCTGTGTGGAGCAGTCTTCGT 
TTCGGCTAGCCCCGGGTGATAAGGATCCA 
Tpa-2 5'-GATCT Reverse  oligonucleotide  used to construct  
pBISIA-tpa 
GGATCCTTATCACCCGGGGCTAGCCGAA 
ACGAAGACTGCTCCACACAGCAGCAGCACACAGC 
AGAGCCCTCTCTTCATTGCATCCATGATTGCA 
Tpa-2F 5’-GATCC Forward oligonucleotide used to construct Tpa 
fusion plasmids 
AGCTTGCAATCATGGATGCAATGAAGAG 
AGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAG 
TCTTCGTTTCGGCTAGCCCACG 
Tpa-2R 5’AATTC Reverse oligonucleotide used to construct Tpa 
fusion plasmid 
GTGGGCTAGCCGAAACGAAGACTGCTCCACA
CAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCA
TCCATGATTGCAAGCTG 
Sa-3a 5’-ATGGGTGGTACC Forward primer.  It binds to the 40-59 bp region 
of gapB 
GGAAGAATGGTATTACGTAT 
Sa-4 5’-GATCCGTCGAC Reverse primer.  It binds to the 1010-1026 bp 
region of gapB 
GTATTAACTTGCACTTACAG 
Sa7a 5’AAAAAAGAATTC Forward primer used to amplify the S. aureus 
gapB gene 
ATGTCAACCAATATTCCAATTAAT
CCTAGG 
 
Sa8a 5’- TTTTTTCTCGAGTTAACTTGCACTTACA Reverse primer used to amplify the S. aureus 
gapB gene 
Sa5 5'-AAAAAACCCGGG Forward primer used to amplify the S. aureus 
gapC gene 
AGCCATATGGCAGTAAAAG 
Sa10 5'-AAATTACTCGAG Reverse primer used to amplify the S. aureus 
gapC gene 
TTTAGAAAGTTCAGCTAAGTAT 
Sa12 5’-CCCTAACTCAACAGGTGCTGCTAAAG Forward qRT-PCR primer used to amplify part 
of gapC gene 
Sa13 5’-TACAGGAACACGTTGTGCACCACCATC Riverse  qRT-PCR primer to amlifiy part of 
gapC gene 
SA14 5’-TTCCTACTTCTACTGGTGCGGCGAAA Forward qRT-PCR primer used to amplify part 
of gapB gene 
SA15 5’-GGTACACGTAATGCCATGCCGTGTAA Riverse  qRT-PCR primer to amplifiy part of 
gapB gene 
551F 5’-GGCAAGCGTTATCCGGAATT Forward qRT-PCR primer used to amplify part 
of 16s rRNA gene of S. aureus 
651R 5’-GTTTCCAATGACCCTCCACG Riverse  qRT-PCR primer to amplifiy part of 
16s rRNA gene of S. aureus 
 
The sequences of the primers used to amplify the S. aureus gapB and gapC genes are shown 
together with the complementary oligonucleotides encoding the T-cell plasminogen activator 
secretion signal (Tpa).The underlined nucleotides indicate the recognition site for the restriction 
endonucleases used in the cloning.  In the case of the Tpa-1, Tpa-2, Tpa-2F and Tpa2-R the 
respective residual HindIII, BglII, EcoRI, and BamHI sites are shown. The primer pairs (Sa12, 
Sa 13), (Sa14, Sa15) and   (551F, 651R) are specific for gapC, gapB and 16s rRNA genes, 
respectively and were used in qRT-PCR reactions.  
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3.3.5. qRT-PCR                  
                   
To determine the effects of environmental conditions on gapC and gapB gene expression, 
the bovine clinical mastitis S. aureus strains SA10, SA12 and SA16 and the S. aureus strain 
RN6390 [205], were grown under different environmental conditions.  The conditions tested 
were pH: tryptic soy broth and whey kept at pH 5, and 7.4 by continuous buffering during 
bacterial growth; oxygen tension: aerobic, anaerobic, microaerophilic, and high CO2 levels, for 
high CO2, cultures were grown in CO2 incubater at 5% CO2 level; Growth media:  Tris minimal 
glucose media , tris minimal succinate media ,  trypticase soy broth,  and whey.  Total RNA was 
extracted from cultures grown for 7, and 12 hs using RiboPureTM bacterial RNA isolation kit 
(Ambion Inc, Austin, Texas, USA) following manufacturer’s instruction. The gapC and gapB 
cDNA were synthesized using gapC (sa12, sa13) and gapB (sa14, sa15) (Table 3.3.1) specific 
primer pairs with the SuperScript ™  One-Step RT-PCR System (Invitrogen Canada Inc., 
Burlington, Ont, Canada) following the manufacturer’s instruction. The gapC and gapB gene-
expression levels under the above mentioned different environmental conditions were quantified 
using qRT-PCR (Invitrogen).  The 16s rRNA gene of S. aureus was amplified with specific 
primer pairs (551F and 651R) (Table 3.3.1) and used as an internal control for qRT-PCR.  
 
To determine the role of sar and agr loci on the expression of gapC and gapB genes in S. 
aureus, total RNA was extracted from wild type strain RN6390 and its isogenic mutants agrA, 
sarA and sar/agr (double mutant) [468] at the exponential and stationary phases of growth using 
the RiboPureTM 
Briefly, amplification was carried out in a total volume of 15µl in 96 well plates using an 
iCycler qPCR instrument (Bio-Rad). The reaction was carried out using platinum SYBR Green 
qPCR SuperMix UDG (Invitrogen Canada Inc., Burligton, Ontario) according to the 
manufacturer’s instruction using 3 step amplification cycles with following the parameters: 95 
°C 15s, 55 °C 30s, and 72 °C 30s. The amplification of the product was determined by 
bacterial RNA isolation kit (Ambion Inc. Austin, Texas, USA) following 
manufacturer’s instructions. To determine the expression of gapC and gapB genes cDNA was 
synthesized by RT-PCR using specific primers for gapC and gapB. The cDNA products were 
used in the qRT-PCR reaction (Invitrogen).  The 16s rRNA gene is used as an internal control. 
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measuring the amount of SYBR Green I dye incorporated in the PCR product and plotted as 
fluorescence versus cycle number. The CYBR Green I dye is a double stranded DNA binding 
dye that emits fluorescence as the double stranded DNA accumulates. The fluorescence intensity 
increases proportionally to the double stranded DNA concentration [473]. Data from qRT-PCR 
can be analysed either by relative quantification or absolute quantification methods.  Absolute 
quantification determines the input copy number by relating the PCR signal to a standard curve 
whereas relative quantification detects the PCR signal of the target transcript in a treatment 
group to that of another sample such as untreated control. For all conditions tested, cells grown 
in TSB were considered as the control. The relative difference in gapC and gapB gene 
expressions under the above-mentioned conditions was compared to the expression of these 
genes in TBS under similar environmental conditions. The relative difference in gene expression 
was calculated as fold change using a formula 2-∆∆ct [474], where the Ct was defined as the cycle 
number at which the first detectable fluorescence increase above the threshold  was observed. 
∆Ct = Ct value of target gene minus Ct value of internal control (Ct value of 16s rRNA).  The 
∆∆Ct = ∆Ct of test minus ∆Ct of control. The qRT-PCR reactions were carried out in triplicate 
and the data showed fold change in mRNA which is 2 -∆∆ct
3.4. Purification of Proteins and Western Blots Analysis 
 [474]. 
 
 
  
 
3.4.1. Whole Cell Protein Extraction Procedure 
 
Cultures containing S. aureus were centrifuged at 4424 X g for 10 min to collect the cells. 
The cell pellets were suspended in PBS and the suspensions centrifuged as above. The cell 
pellets were suspended in 5 ml lysis buffer (buffer T1) (100µl of 1M tris-HCl (pH8), 20 µl of 
0.5M EDTA, 500 µl of 10% Triton-X, 100 µl of lyzozyme at 100 mg/ml final concentration, and 
sterile water added to bring the final volume to 5 ml). To this solution lysostaphin, RNase I and 
DNase I were added at concentrations of 100 µg/ml, 10 mg/ml and 10 mg/ml respectively. The 
suspension was incubated at 37 oC for 1 h. The cell debris was removed by centrifugation at 
26712 X g for 15 mins and the supernatant was collected in a clean tube. 
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3.4.2. Determination of Protein Concentration in the Whole Cell Lysate 
 
The protein concentration in the whole cell lysate was determined using the Bio-Rad 
microplate assay protocol following the manufacturer’s instruction. Briefly, a series of tubes 
containing 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600 and 1800 µg/ml of  BSA in sterile 
distilled water was used to construct a standard curve.  Since our lysis buffer contained 
detergent, a 20 µl aliquot of reagent S (Bio-Rad) was added to each ml of reagent A to make 
reagent A’. All samples were diluted to 1:25 in sterile distilled water. 5 µl of standards and 
diluted samples were placed into a micro titer plate. 25 µl of reagent A’ and 200 µl reagent B 
were added to each well sequentially. The absorbance was read after 15 min at a wavelength of 
750 nm in a spectrophotometer (SpectraMax, Molecular Devices Corporation, Sunnyvale, CA, 
USA). The total amount of protein in each sample was calculated by comparing the A750 of 
unknown to the A750 of the standards and using the forecast utility of Microsoft Excel©
 
 
(Microsoft corporation, WA, USA). 
 
3.4.3. Recombinant Protein Purification Procedure from E. coli 
 
The E. coli BL21 (DE3) cells carrying the plasmids containing the gapB (pETgapB) or 
gapC (pETgapC) genes of S. aureus BM10 [75] were cultivated to mid-log phase at 37 oC or 25 
oC for the strain E. coli M15 (pQE-SAgapC/Ba) carrying the chimeric plasmid.  Expression of 
genes encoding the 6xHis-GapB, 6xHis-GapC, and 6xHis-GapC/B proteins was induced by the 
addition of 0.2 mM isopropyl- -D-thiogalactopyranoside (IPTG) and cells were harvested 3hs 
post-induction.  Purification of the recombinant proteins was carried out by affinity 
chromatography to Ni-NTA as described before [75]. For immunological analysis, proteins 
separated by SDS-PAGE were transferred onto a nitrocellulose membrane (Bio-Rad) and probed 
with anti-GapB or GapC polyclonal antisera as described below.  In this text, the 6xHis-GapB, 
6xHis-GapC, and 6xHis-GapC/B proteins are referred to simply as GapB, GapC and GapC/B 
respectively. 
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3.4.4. Western Blot 
 
SDS polyacrylamide electrophoresis [475] of whole cell total protein extracts was carried 
out as follows: whole cell extracts containing 20µg total protein were added into eppendorf tubes 
and the same volume of 2X protein loading  dye (100 mM tris HCl, 200 mM dithiothreitol 
(DTT), 4% SDS, 0.2% bromophenol blue, 20% glycerol) were added to each sample and the 
mixture was boiled for 5 min and loaded into each lane of a 12% SDS-PAGE. The proteins were 
separated at 130 volts in a gel apparatus (Bio-Rad). For immunobloting, proteins were 
transferred from the gel to the nitrocellulose membrane (Bio-Rad) using a power supply 
(PowerPac200, Bio-Rad).  Briefly, after protein separation the gel was soaked in a transfer buffer 
(3 g/L tris, 1.41 g/L glycine, 200 ml methanol, distilled water to a final volume of 1000 ml, pH 
9) for 5 min.  A piece of nitrocellulose matching the size of the gel was cut and soaked in the 
transfer buffer for 5 min.  The nitrocellulose filter was placed on top of the gel and two pieces of 
pre-cut Whatman filter papers were placed on both the gel and the nitrocellulose sides. This 
sandwich was placed in between two thick membrane supports and the whole assemble was 
placed in a holder and into a tank containing pre-chilled transfer buffer. The buffer was kept cold 
by using a plastic reservoir with ice and a stirrer bar was used to keep buffer circulating. The 
proteins were transferred at a current of 400 mA for 1 h with stirring. After proteins were 
transferred to nitrocellulose, the membrane was removed from the apparatus and blocked with  
3% bovine serum albumin in 0.1M PBS, 0.05% Tween-20 (pH 7.2) (PBS-T) overnight at 4 oC. 
After overnight incubation, the membrane was washed three times with PBS-T and incubated 
with primary antibodies (Rabbit anti-GapB and -GapC sera) as described before [75] at 1/500 
dilution for 1 h. After incubation with primary antibodies, the membrane was washed three times 
with PBS-T and incubated with a secondary antibody conjugated to alkaline phosphatase (Goat 
anti-rabbit IgG (H+L) (KPL, Gaithersburg, MA, USA). After incubation with the secondary 
antibody the membrane was washed once with PBS-T and additional once with alkaline 
phosphatase (AP) buffer (0.1 M tris base and NaCl, each, 0.0051 M  MgCl26H2O  adjusted to 
pH 9.5  and  autoclaved). The membrane was incubated with 10 ml of AP buffer for 15 min.  
Finally, the membrane was incubated with nitroblue tetrazolium (NBT) salt and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) (Sigma) 165 µg/ml each, until color developed [476]. The 
membrane was dried by blotting off excess liquid on Kim-wipes.  Developed membranes were 
scanned with white light fluorescent light and imaging was done using AlphaEase software.  
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3.5. Transfection of MAC-T Cells and Immunohistochemistry 
 
After 2 days of incubation, confluent monolayers of MAC-T cells were harvested, 
digested with 0.5 % trypsin, and suspended in culture medium to 1 X 105 cells/ml. One ml of the 
cell suspension was used to seed each of 4 wells of Permanox® slides and after overnight 
incubation at 37 oC in 5% CO2, the cells were transfected with 1 µg of plasmid DNA using the 
Lipofectamine-Plus® reagents (Invitrogen) following the manufacturer’s recommendations. 
Transient expression of the gapB, gapC and gapC/B genes was detected by 
immunohistochemistry (IHC) after incubation at 37 o
3.6. Mice Immunizations Protocols 
C for 16 hs.  IHC was carried out as 
follows: cells were fixed with PBS: Acetone (2:3) for 10 min at room temperature. The slide was 
then washed by three successive immersions in PBS.  Antigen-specific antibodies were diluted in 
PBS-3% horse serum and incubated with the MAC-T cells for 2 hs at room temperature in a 
humid chamber. After 3 consecutive washes in PBS, the cells were incubated with a 1:2000 
dilution of horse anti-mouse IgG conjugated to horse-radish peroxydase for 1 h at room 
temperature.  After washes, the reaction was developed using the ABC and DAB reagent kits 
(Vector, CA, USA) following manufacturer’s instructions. 
 
 
 
3.6.1. Immunizations with Recombinant Proteins. 
 
The immune responses to the Gap proteins were determined in C-57BL/6 mice 
immunized with the purified GapB, GapC and GapC/B proteins. Proteins (20 µg dose) were 
formulated in 30% VSA3 as adjuvant and administered via the intramuscular route.  In all cases, 
vaccinations were carried out 21 days apart. The first trial consisted of a total of 32 mice divided 
into 4 groups of eight each. Three groups were immunized with GapB (Group 2), GapC (Group 
3) or GapC/B (Group 4) respectively. A placebo group (Group 1) was included.  Serum samples 
were collected at days 0, 21 and 42 and tested by ELISA for the presence of total IgG, IgG1 and 
IgG2a antibodies against the GapB, GapC and GapC/B proteins using alkaline-phosphatase-
conjugated polyclonal antibody against mouse IgG and monoclonal antibodies against mouse 
IgG1 and IgG2a (KPL, Gaithersburg, MA, USA).  Serum titres were calculated by the 
intersection of least-square regression of A405 versus logarithm of dilution.  
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The second trial consisted of 40 mice divided into 5 groups of 8 each. The groups consisted 
of:  Group 1 (placebo); Group 2 (GapB); Group 3 (GapC); Group 4 (GapB + GapC) and Group 5 
(GapC/B) (Table 3.6.1.1). Humoral immune responses (total IgG, IgG1 and IgG2a) were 
measured by ELISA assays and titres calculated as described above. After 45 days, the spleens 
were collected from the immunized animals and lymphocytes were recovered by disruption of 
the spleen followed by washes and suspension into AIMV culture media. The number of IFN-γ 
and IL-4 producing cells were determined using the ELISPOT assay (section 3.9.2) after seeding 
1x106
Table 3.6.1.1. Vaccination of mice with recombinant proteins  
 
 cells in tissue-culture wells pre-coated with anti-IFN-γ or anti-IL-4 specific antibodies.  
The proliferation of lymphocytes was determined as described in section 3.9.2. 
 
Group Antigen (Ag) Ag Dose Adjuvant Route 
1 Placebo - 30% VSA3 IM 
2 GapB 10 µg 30% VSA3 IM 
3 GapC 10 µg 30% VSA3 IM 
4 GapC + GapB 10 µg (each) 30% VSA3 IM 
5 GapC/B 10 µg 30% VSA3 IM 
 
The group assignments, vaccine formulation, and route of immunization are described. 
 
3.6.2. Immunizations with DNA-Recombinant Proteins Combinations. 
 
The immune response to the Gap proteins was determined in C-57 BL/6 C mice (5 
groups of eight animals each) first immunized with plasmid DNA encoding GapB, GapC and the 
GapC/B chimera formulated in PBS, 10 µg/dose, I.D. route as shown in Table 3.6.2.1. Serum 
samples were collected at days 0, 28 and 56 and antigen-specific total IgG, IgG1 and IgG2a titres 
against purified recombinant GapB, GapC and GapC/B proteins were determined as described 
before [75] using alkaline-phosphatase-conjugated polyclonal antibody against mouse IgG, and 
monoclonal antibodies against mouse IgG1 and IgG2a. Serum titres were calculated by the 
intersection of least-square regression of A405 versus logarithm of dilution. At day 97 after the 
start of the trial, four mice from each group were humanly sacrificed, the spleens were collected 
and lymphocytes were recovered and the number of cells of IFN-γ and IL-4 producing cells were 
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determined by ELISPOT assay. The proliferation of lymphocytes after stimulation with the 
recombinant antigens was determined as described in section 3.9.2. 
 
Table 3.6.2.1. Immunization of mice with DNA-recombinant proteins combination 
 
Group DNA (10 µg)  Protein (20 µg) Route Vaccination(day) Assay 
(day) 
1 pBISIA-tpa None ID 0, 28, 56 91 
1a pBISIA-tpa GapC/B ID/IM 0, 28, 56, 98* 119 
2 pTPA2-gapB None ID 0, 28, 56 91 
2a pTPA2-gapB GapB  ID/IM 0, 28, 56, 98* 119 
3 pTPA2-gapC None ID 0, 28, 56 91 
3a pTPA2-gapC GapC ID/IM 0, 28, 56, 98* 119 
4 pTPA2-gapC/B None ID 0, 28, 56 91 
4a pTPA2-gapC/B GapC/B ID/IM 0, 28, 56, 98* 119 
5 None None ID 0, 28, 56 77 
5a None None ID/IM 0, 28, 56, 98 119 
 
The different immunization groups are shown.  The vaccination routes were i.d.: Intradermal and 
i.m.: Intramuscular.  The vaccination column indicates the days of the immunizations and the 
asterisk denotes the day of the protein boost for groups 1a, 2a, 3a, and 4a.  The assay column 
refers to the day the animals were sacrificed. 
 
3.7. Optimizing Antibody Response in the Mammary Gland of Cows  
 
This trial consisted of 40 dairy cows divided in to 5 groups of 8 animals each and 
immunized with the GapC/B chimera via the subcutaneous (SQ) and intradermal (ID) routes in 
areas drained by the parotid lymph (PLN) and supramammary lymph (SMLN) nodes (Table 
3.7.1). 
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Table 3.7.1. Vaccination protocol for optimizing antibody response in the mammary gland of 
cows  
 
Group Antigen 
(Ag) 
Ag 
Dose 
(µg) 
Adjuvant  Adj. 
Dose 
Route/Target Total 
volume/dose 
1 Placebo - VSA3 30% SQ 2 ml 
2 GapC/B 100  VSA3 30% SQ/PLN 2 ml 
3 GapC/B 100  VSA3 30% SQ/SMLN 2 ml 
4 GapC/B 100      VSA3  30% ID/PLN 1 ml 
5 GapC/B 100  VSA3 30% ID/SMLN 1 ml 
 
3.8. Monitoring Duration of Immunity in Cows 
 
This animal trial was designed to determine the duration of the immune response to the  
best antigen selected from the mouse experiment and to test vaccine formulations containing the 
adjuvant PCPP (Poly [di(carboxylatophenoxy) phosphazene], synthetic polymer and the 
immunomodulator CpG ODN 2135 (cytosine-phosphate-guanosine). The trial consisted of 40 
dairy cows divided into 5 groups of 8 animals each and immunized via the subcutaneous route 
(SQ) with 2 ml of vaccine (Table 3.8.1). 
 
Table 3.8.1. Vaccination protocol for monitoring duration of immune response in cows   
 
Group Antigen 
(Ag) 
Ag Dose 
(µg) 
Adjuvant  Adj. Dose Route Total 
volume/dose 
1 Placebo - VSA3 30% SQ 2ml 
2 GapC/B 100  VSA3 30% SQ 2ml 
3 GapC/B 100  CpG 250 µg SQ 2ml 
4 GapC/B 100  PCPP 750 µg SQ 2ml 
5 GapC/B 100  CpG/PCPP 250/750 µg SQ 2ml 
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3.9. Analysis of Humoral and Cellular Immune Responses 
 
 
3.9.1. Enzyme-Linked Immuno-Sorbent Assay (ELISA)               
 
Proteins were diluted to 1 µg/L in a 50 mM sodium carbonate buffer (1.5 g/L of NaCO4, 
2.93 g/L NaHCO4, to the final volume of 1000 ml with distilled water and pH adjusted to 9.6) 
and 100 µl of this diluted solution was used to coat each well of a 96-well plate. The plates were 
covered with a lid, wrapped with saranwrap and placed inside a plastic bag to avoid drying, and 
incubated overnight for 16 hs at 4 oC. After incubation, the coating solution was removed and 
plates were washed 5 times with tris-buffered saline (TBS, 0.85% NaCl (w/v), pH7) containing 
0.5% (v/v) of Tween 20 (TBS-T) using an automated plate washer.  The wells were blocked with 
200 µl/well of TBS-0.5% Tween 20 containing 0.03% gelatine (v/v) (TBS-TG) for 2 hs at room 
temperature. Both serum and whey were serially diluted in four-fold increments from 1:100 to 1: 
1, 638, 400 and 1:10 to 1:1, 280 respectively in TBS-TG and incubated for 1h. After five washes, 
alkaline phosphatase-conjugated polyclonal sheep anti-bovine IgG and monoclonal sheep anti-
bovine IgG1 and IgG2 (Kirkegaard and Perry laboratories, Gaithersburg, MD, USA) were 
diluted to 1:5000 in TBS-TG and 100 µl of diluted antibody was added to each well and 
incubated for 1h.  After five washes, 100 µl of freshly prepared para-nitrophenyl phosphate 
(PNPP, 1 mg/ml, Sigma) substrate solution in DE buffer (10.5 ml of 1 M Diethanolamine, 1 ml 
of 0.5 M MgCl26H2O and 990 ml of distilled water) was added per well and incubated for 45 
min at room temperature. Finally using a microtitre plate reader, the absorbance was read at 
405nm with reference at 490 nm. The serum titer was calculated by the intersection of least-
square regression of A405 
3.9.2. ELISPOT and Lymphocyte Proliferation Assays 
versus logarithm of dilution. 
 
 
The production of cytokines (IFN-γ and IL-4) by spleen lymphocytes was determined by 
ELISPOT assay. Cells were diluted to a density of 1x106 cells/well in AIM V media, pre-coated 
with anti-IFN-γ or anti-IL-4 specific antibodies (BD Biosciences, Sparks, MD, USA).  Purified 
GapB, GapC or GapC/B (200ng/well) was added and incubated overnight at 37 °C in 5% CO2. 
After washes, biotinylated anti-mouse IFN-γ or IL-4 (BD Biosciences, Sparks, MD, USA) were 
added to the wells and incubated for 2 h. After washes, alkaline phosphatase (AP)-conjugated 
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streptavidin (Invitrogen, Burlington, Ont, Canada) was added and incubated for 2h. After 
washes, the alkaline phosphatase (AP) substrate Sigma-Fast (Sigma) was added, incubated 30 
min, washed and air dried overnight. The number of IFN-γ or IL-4 secreting cells (spots) was 
determined by counting in a microscope 
 
The proliferation of lymphocytes was determined by seeding 3 X 105 cells/well, addition of 
GapB, GapC or GapC/B (200 ng/well) and incubation for 72 hs at 37 oC in 5% CO2.  A solution 
containing 0.4 µCi/well of 3H-thymidine (Sigma) was added and the cells incubated 18 hs at 37 
oC in 5% CO2. Cells were harvested and the amount of incorporated 3
3.9.3. Peripheral Blood Mononuclear Cell Isolation and Assessment of Phagocytosis by 
Phagocytic cells. 
H-thymidine was 
determined in a scintillation counter. 
 
 
Blood was collected from the jugular vein of sheep (2 X 20 ml) in 0.3% EDTA (Sigma-
Aldrich) and centrifuged at 2500 X g for 20 min at room temperature. After this step, the buffy 
coat was removed and resuspended in 8 ml of PBSA/EDTA (5.4 ml of 0.5 M EDTA (pH 8) to 
1000 ml of PBSA, and layered on to 5 ml of Ficoll-Hypaque (GE Health Care  Biosciences AB, 
Uppsala, Sweden) and centrifuged at 3000 X g  for 20 min. The supernatant was removed and 
the pellet of PBMCs was resuspended in 8 ml of PBSA/EDTA and centrifuged at 1200 X g for 
10 min at 4 °C. The pellet was resuspended in 10 ml of PBSA/EDTA and centrifuged at 1000 X 
g for 10 min at 4 °C. The cell pellet was resuspended in 4 ml of cell culture media (minimum 
essential medium (MEM supplemented with dexamethazone at 1 ng/ml, gentamicin at 50 µg/ ml, 
10% of fetal bovine serum (GIBCO BRL), 1% of  L-glutamine (Sigma)  and 0.1% of 50  mM 
solution  of 2-mercaptoethanol/) and 40 µl was taken and added to 20 ml of Isoton®II  diluent 
(Beckman Coulter Inc., Ca, USA) and counted with an automated Coulter particle counter model 
Z1 (Beckman Coulter Inc., Ca, USA). Cells were diluted to a density of 1X 106 cells/ml. 
 
To determine whether phagocytic cells were phagocytising and removing bacteria.  
Peripheral blood mononuclear cells (PBMCs) were isolated 48 hs post challenge and incubated 
in a 6 well tissue culture plates at a density of 1X 106 cells/ml for 2 hs to allow cells to settle 
down  and attach to the plates. After 2 hs of incubation the supernatants were removed and media 
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with 200 µg/ml gentamicin (Sigma) and 20 µg/ml penicillin (Invitrogen) were added and further 
incubated for 1 h to kill extracellular bacteria.  After incubation, aliquots of supernatants were 
taken and plated for viable counts and cells were washed gently with growth media without 
antibiotics. Cells were then lysed by adding 1 ml of distilled water to each well. Lysates were 
serial diluted and plated for viable counts.   
 
 
3.10. Milk Sample Collection Procedure, Processing and Somatic Cell Count 
 
 
3.10.1. Hygienic Milk Collection Procedure. 
 
Prior to the sampling, quarters of cows and udder halves of sheep were washed and dried. 
The teat tip was wiped with 70% alcohol and the first few streaks of milk were discarded.  About 
5-20 ml of milk from sheep and 20-100 ml of milk from cows was collected in sterile 50 ml 
tubes and 100-500 ml bottles respectively. 
         
3.10.2. Somatic Cell Count 
 
After collected milk was thoroughly mixed, somatic cells in the milk were fixed by 
mixing 10 ml of milk with 0.2 ml of the fixative liquid (mixture of 0.02 g of eosin, 9.4 ml of 
35% formaldehyde solution and  water to 100 ml) [477]. Well mixed samples were kept for 24 hs 
at 22 ºC (room temperature). Then a 0.1 ml of milk test sample was transferred to a tube and 
diluted with 10 ml of emulsifier electrolyte mixture (125 ml of 96% ethanol, 20 ml of Triton X-
100 and 855 ml of 0.9% sodium chloride (saline) solution) [477]. The diluted milk was heated to 
80 oC for 10 min and then cooled down to 15-20 o
3.11. Statistics 
C. The test portion of the milk was transferred 
to a measuring vessel taking care that no air bubbles were produced.  Somatic cells were counted 
by an automated Coulter particle counter model Z1 (Beckman Coulter Inc., Ca, USA). 
 
 
Statistical analysis of the humoral and cell-mediated immune responses (One way analysis of 
variance (ANOVA) and Bonferroni post-test analyses) were performed using GraphPad Prism on 
logarithmically-transformed data 
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4. EXPERIMENTAL RESULTS 
 
 
4.1. Immune Responses to a GapC/B Chimera and Use as a Component of a  
       Multivalent Vaccine against Staphylococcus aureus Mastitis 
 
4.1.1. Introduction 
 
S. aureus and coagulase-negative staphylococci are the most prevalent infectious bacteria 
isolated from bovine mammary gland secretions. Infections with these micro-organisms account 
for a large percentage of mastitis cases and the economic losses suffered by the dairy industry are 
in the millions of dollars per year [14]. Combinations of intramammary and systemic treatments 
or extended therapy to combat this disease results in success rates between 0% and 80% [420, 
421] emphasizing the need for alternative control measures. One of these measures is vaccination 
with killed bacterial cells or bacterial products [442], however with few exceptions they have not 
always resulted in protection against new infections or do not elicit heterologous protection [439-
442, 478].  These findings suggest that isolates from different sources encode distinct products 
and that a vaccine composed of all the different antigens would be impractical to produce. 
Recently, a new approach consisting of DNA or DNA/Protein vaccination resulted in partial 
protection against a S. aureus experimental challenge in mice and dairy cows [445, 479].  The 
DNA vaccines were based on the more conserved epitopes of the fibronectin-binding protein and 
clumping factor A adhesins of S. aureus and elicited both humoral and cellular immune 
responses.  Thus, identification of protective antigens should focus on conserved proteins and on 
means to elicit Th1 and Th2 responses.  Previous work on GapC proteins of environmental 
streptococci at VIDO resulted in the identification of potential targets for vaccines [480, 481]  
and the construction of a GapC chimera composed of the S. uberis GapC as backbone and non-
identical regions of the S. agalactiae and S. dysgalactiae GapC proteins [481]. The mastitis 
research was extended to include S. aureus and recently our laboratory reported the isolation of 
surface-located GapB and GapC proteins that have homology to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) [75]. 
 
In this work, a similar approach of constructing chimeric proteins that can serve as 
antigens in the formulation of multivalent vaccines was used. A S. aureus GapC-GapB chimera 
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comprised of most of their amino acid residues was constructed and the protein expressed in E. 
coli. The GapC/B chimera was compared to the individual GapB and GapC proteins for its 
ability to elicit humoral and cellular immune responses in mice. The results indicate that the 
GapC/B chimera is immunologically indistinguishable from its individual components. In 
addition, the chimera is able to elicit both humoral and cellular immune responses as determined 
by the presence of IgG1 and IgG2a in serum and for the secretion of IFN-γ and IL-4 by 
stimulated lymphocytes. 
  
4.1.2. Construction of the Chimeric gapC/B Gene 
 
The goal of this research was to compare the immune response to GapB and GapC 
proteins of S. aureus to the response obtained with the GapC/B chimera.  A protein chimera was 
constructed by PCR amplification of the gapB and gapC genes of a mastitis-isolate of S. aureus 
described before [75] followed by tandem ligation of the PCR products.  The gapC/B chimeric 
gene was cloned in front of a histidine tag for purification and the resultant construct encoded a 
ca. 74 kDa protein that reacted to polyclonal antibody against GapC (Fig. 4.1.2.1) and GapB 
(Data not shown).  This protein was purified and used in vaccination trials.  
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Figure 4.1.2.1. Construction of a S. aureus GapC/B chimera. 
 A: The gapC and gapB genes were amplified by PCR with primers containing BamHI (B), KpnI 
(K) and SalI (S) restriction endonuclease sites and cloned into the expression vector pQE-30 
digested with BamHI and SalI. B: Composite western blot of E. coli extracts containing plasmids 
expressing 1: GapB; 2: GapC; 3: GapC/B chimera. M: Molecular weight standards.  The arrows 
point to the location of the GapB, GapC and GapC/B proteins. 
 
 
4.1.3. Humoral Immune Responses to the GapB, GapC and GapC/B Proteins 
 
The use of the GapC/B chimera as a multivalent antigen would be possible only if the 
immune responses to the protein are comparable to the responses obtained when the individual 
antigens are used in single or combined vaccine formulations.  The chimeric protein GapC/B was 
constructed, expressed in E. coli as a histidine-tagged protein (Fig. 4.1.2.1) and purified by 
affinity chromatography. The endotoxin content of the recombinant GapB, GapC, and GapC/B 
proteins was determined to be 4.7, 29.2, and 1.2 EU/µg of protein, respectively. Mice were 
immunized with the recombinant proteins and their immune responses to the three proteins were 
determined by measuring total IgG, IgG1 and IgG2a in serum. The results are presented in Fig. 
4.1.3.1. Compared to the placebo group, the GapC-specific total IgG, IgG1, IgG2a, titers 
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significantly increased in mice immunized with GapB (p<0.001) (Fig. 4.1.3.1A) and a weak but 
significant (p<0.01) cross immune response to GapC was observed as an increase of total IgG 
and IgG1 GapB titers in mice vaccinated with GapC. Compared to the placebo group, the GapC-
specific total IgG, IgG1, IgG2a titers increased significantly (p<0.001) in mice immunized with 
GapC (Fig. 4.1.3.1.B) and in contrast to GapB-titers in mice vaccinated with GapC, a weak but 
not significant (p>0.05) total IgG and IgG1 response of GapC was observed in mice immunized 
with GapB. Finally, compared to the placebo group the total IgG, IgG1 and IgG2a serum titers to 
GapC/B increased significantly (p<0.001) in mice immunized with GapB or GapC (Fig. 
4.1.3.1C). The results of immunization with GapC/B did not completely correlate to the results 
after vaccination with either GapB or GapC. Compared to the placebo group, the total IgG and 
IgG1 serum titers to GapC/B increased significantly in mice immunized with GapC/B (p<0.001) 
albeit they were 10-fold  lower (on average) than the titers against the individual proteins; 
however the IgG2a titers were not significantly different (p>0.05) to the placebo group (data not 
shown). It has been determined that the reason for the differences in serum titers was a partially 
degraded GapC/B protein and thus we prepared a new batch of the GapC/B protein and stored it 
in the presence of protease inhibitors and used it in a second mice immunization experiment to 
confirm our serology findings. This time we also included a vaccination group that received the 
individual GapB and GapC or the chimeric GapC/B proteins and the results are presented in Fig 
4.1.3.2. Compared to the placebo group, immunization with GapB-containing vaccines resulted 
in a significant increase (p<0.001) of the total IgG titers in the Groups 2, 4, and 5 (GapB, GapB 
+ GapCor GapC/B groups, respectively) while immunization with GapC (Group 3) resulted in 
higher but not significantly different GapB titers (p>0.05) than the placebo group (Group 1) (Fig 
4.1.3.2A) but significantly lower (p<0.001) than the GapB, GapB + GapC or GapC/B groups. 
The IgG1 titers to GapB were significantly different to the placebo group (p<0.001) except in the 
GapC- immunized mice (p>0.05) and not significantly different (p>0.05) between the groups 
that received any form of GapB (Groups 2, 4, and 5). Like the GapB total IgG titers, the IgG1 
levels in the GapB, GapB + GapC or GapC/B groups were significantly higher than the titers in 
the animals that received GapC (Group 3) Fig. 4.1.3.2A). Immunization with GapB resulted in 
significantly higher (p<0.001) GapB-IgG2a titers in the animals immunized with any form of 
GapB (Groups 2, 4, and 5) compared to the placebo and GapC groups (Goups 1 and 3 
respectively). Unexpectedly, the GapB-IgG2a titers in mice immunized with GapB + GapC were 
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significantly lower than the titers in the GapC/B group (p<0.001) (Fig 4.1.3.2A) which might 
suggest interferences between the GapB and GapC proteins when not in the same molecule.  
 
Compared to the placebo group, immunization with any form of GapC (Groups 3, 4, and 
5) resulted in significantly higher GapC-total IgG titres (p<0.001) (Fig. 4.1.3.2B).  Contrary to 
the GapB titers in the GapC-immunized group (Group 3) (Fig. 4.1.3.2A), the GapC titres in the 
GapB-vaccinated group (Group 2) were also significantly different from the placebo (p<0.001), 
suggesting a stronger cross-reaction between GapC antibodies against GapB.   As observed 
before (Fig 4.1.3.2A), there seemed to be interference between the GapB and GapC proteins in 
the GapB + GapC group (Group 4) since the total IgG titers to GapC were lower (p<0.05) in this 
group compared to the titers in the GapC/B group (Group 5) (Fig.4.1.3. 2B).  The IgG1 titers to 
GapC in groups 2, 3, 4, and 5 were significantly different than the placebo group (p<0.001, 
however contrary to the total IgG levels, the GapC-IgG1titers in the GapB-vaccinated group 
were lower (p<0.05) than the titers in the GapC-immunized and the GapC/B-vaccinated groups 
(p<0.001). Moreover, the GapB IgG1 titers were higher (p<0.05) in the GapC/B-vaccinated 
group compared to the GapB + GapC group (Groups 5 and 4 respectively).  The GapC-IgG2a 
titers were significantly higher than the placebo group in all the vaccinated animals (p<0.001 for 
Groups 2, 3, and 5; p< 0.01for group 4, respectively) (Fig. 4.1.3.2B). There were no significant 
differences (p>0.05) between the IgG2a titers in the   GapB-, GapC- and GapC/B-immunized 
groups but like before, the titers in the GapB + GapC-vaccinated group (Group 4) were 
significantly lower than the other vaccinated groups (p<0.001), suggesting again interferences 
between these two proteins when not in the same molecule.  
 
Compared to the placebo group, immunization with GapC/B resulted in a significant 
increase (p<0.001) of total IgG titers against GapC/B not only in group 5 but in the groups that 
received GapB (Group 2), GapC (Group 3) and the GapB + GapC (Group 4) combination (Fig 
4.1.3.2C).  A similar picture was observed with the GapC/B-IgG1 titers (Fig.4.1.3. 2C). The 
GapC/B IgG2a titers in the GapB-immunized group were not different than the titers in the 
GapC/B group (p<0.05).  Unexpectedly, the IgG2a-GapC/B titers in the GapC-immunized mice 
were lower than the titers in the GapB-vaccinated animals although this difference was not 
significant and as observed before for the IgG2a titers against GapB and GapC  in the GapB + 
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GapC-immunized animals (Fig. 4.1.3.2A and B), the IgG2a-GapC/B titers in the GapB + GapC 
group (Group 4) were significantly lower than the titers in the GapB (Group 2)-, GapC (Group 
3)-, and GapC/B (Group 5)-immunized mice (p values: <0.001; <0.05 and <0.001 respectively) 
(Fig. 4.1.3. 2C). 
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Figure 4.1.3.1.  Humoral total IgG, IgG1 and IgG2a titers against GapB, GapC and GapC/B. 
Humoral immune responses to GapB, GapC, and GapC/B (trial I), titers were measured 42 days 
after the first immunization. The immunoglobulin isotypes and vaccine groups are indicated on 
the X-axis while the titers to GapB, GapC, and GapC/B are shown in the panels A, B, and C 
respectively. The symbols are mean + S.D. of the titers. The asterisks above the columns 
represent statistically different titer levels between groups. 
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Figure 4.1.3.2.  Humoral immune responses to GapB, GapC and GapC/B. 
Humoral immune responses to GapB, GapC and GapC/B (Trial 2), titers were measured 42 days 
after the first immunization. The immunoglobulin isotypes and vaccine groups are indicated on 
the X-axis while the titers to GapB, GapC, and GapC/B are shown in the panels A, B, and C 
respectively. The symbols are means + S.D. of the titers. The asterisks above the columns 
represent statistically different titer levels between groups.  
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4.1.4. Cellular Immune Responses to the GapB, GapC and GapC/B Proteins 
 
 
Cytokine expression assays were performed after stimulation with the GapB, GapC or 
GapC/B proteins. Compared to the placebo group, stimulation with GapB resulted in 
significantly higher IL-4 expression in mice vaccinated with  GapB or GapB + GapC (p< 0.01 
and p< 0.05 respectively) while GapC stimulation was significantly higher (p<0.05) than the 
placebo group only in mice vaccinated with GapB + GapC (Fig 4.1.4.1A). Stimulation with 
GapC/B in animals vaccinated with it resulted in higher numbers of spots as compare to the 
placebo group, however, due to the variation in the assay, this difference was not significantly 
different (p>0.05).  Secretion of IFN-γ after stimulation with GapB was significantly higher than 
the placebo group in GapB- and GapC/B- immunized animals and different from the placebo 
group in GapB- and GapC/B-immunized animals only (Groups 2 and 5) (p<0.001). Stimulation 
with GapC resulted in significantly higher IFN-γ expression in mice immunized with GapB, 
GapC/B (groups 2 and 4; p<0.01 and p<0.001 respectively) (Fig. 4.1.4.1B). The levels of IFN-γ 
expression in the groups vaccinated with GapC or GapB + GapC were similar to the level in the 
GapB-vaccinated group, however due to the variability of the assay these numbers were not 
significantly different from the placebo group (p<0.05). Stimulation with GapC/B promoted 
significant IFN-γ secretion in mice vaccinated with GapB (Group 2, p<0.001) and GapC/B 
(Group 5, p<0.001) only (Fig. 4.1.4.1B). 
 
Activation of cell-mediated immunity was also evaluated by measurement of the lympho-
proliferation responses to the recombinant proteins. Stimulation with GapB induced significant 
blastogenesis only in mice immunized with GapB (p<0.001) (Fig.4.1.4.1C) while GapC 
significantly induced proliferation of splenocytes of mice immunized with GapB (Group 2, 
p<0.05), GapB + GapC formulation (Group 4, p<0.001) and with the GapC/B chimera (Group 5, 
p<0.001) (Fig.4.1.4.1C).  Finally, stimulation with the GapC/B chimera resulted in significant 
levels (p<0.001) of lymphocyte proliferation in the GapB-, GapB + GapC- and GapC/B-
immunized groups (Groups 2, 4, and 5 respectively) (Fig 4.1.4.1C). 
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Figure 4.1.4.1.  Cellular immune responses to GapB, GapC and GapC/B. 
The production of IL-4, IFN-γ, and stimulation index of splenocytes with GapB, GapC, or 
GapC/B is shown. (A) IL-4 expression; (B) IFN-γ expression; (C) Lymphocyte proliferation. 
Significantly different IL-4, IFN-γ or stimulation indexes between vaccine groups are shown by 
asterisks. The production of IL-4, IFN-γ, and stimulation index of lymphocytes with GapB, 
GapC or GapC/B is shown.  A: IL-4 expression; B: IFN-γ expression; C: Lymphocyte 
proliferation.  Significantly different (*: p<0.05; ***: p<0.001) IL-4, IFN-γ or stimulation 
indexes between vaccine groups are shown by asterisks.  See text for more explanation. 
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4.1.5. Antibody Recognition of Native GapC and GapB Proteins  
 
The recombinant forms of GapB, GapC or GapC/B contains the 6 X histidine tag for 
purification by affinity chromatography [75] (Fig 4.1.2.1.) and as expected, sera of mice 
immunized with these proteins reacted with purified recombinant proteins on the ELISA assays 
(Fig 4.1.3.1 and 4.1.3.2). To determine if these immune responses were detected to the GapB and 
GapC portion of the recombinant proteins and not to the histidine tag, we tested whether the 
mice immune sera would also react with native GapB and GapC extracted from the surface of 
several isolates of S. aureus. We prepared extracts from the human isolates of S. aureus Sa2 and 
from bovine mastitis isolates S. aureus Sa4, Sa5, Sa7, Sa10 (source of the gapB, and gapC 
genes; [75] and Sa12 and performed ELISA assays using pooled mice anti-GapC/B sera as the 
primary antibody anti-mouse IgG1 and IgG2a as secondary antibodies.  The results (Fig. 
4.1.5.1A) showed that pooled mice immune sera recognized the native proteins as judged by the 
IgG1 and IgG2a titers. Dairy cows are the ultimate target for a vaccine containing GapC and 
GapB as one of its components. To assess whether these proteins were recognized by the 
immune system of cows naturally exposed to S. aureus, we carried out a western blot against the 
GapB proteins using serum from a cow with a history of chronic mastitis due to S. aureus. The 
results (Fig. 4.1.5.1B) indicated that the serum was able to recognize the recombinant proteins. 
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Figure 4.1.5.1A and B.  Antibody recognition of GapC and GapB proteins.  
(A) GapC/B titers against cell surface extracts. The mouse GapC/B IgG1 (black bars) and IgG2a 
(white bars) titers against the surface extracts are presented. The day 0 (pre-immune serum) was 
used as negative control. (B) Western blot of purified GapB and GapC proteins with serum from 
a cow with chronic mastitis due to S. aureus. 
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4.1.6. Discussion 
 
Mastitis caused by S. aureus remains the most costly disease for dairy farmers.  Although 
antibiotic therapy and culling of infected animals are the most effective approaches to control of 
the disease, the success rate of treatment against S. aureus infections varies considerably.  When 
the treatment costs and losses due to reduced milk production, discarding of the milk and culling 
of the animals are factored, it is obvious that new approaches to control the disease such as 
vaccination are needed. The family of proteins with GAPDH activity are conserved at the DNA 
and protein sequence level and have been shown to be potential components of vaccines against 
a variety of bacterial, mycotic, and parasitic infections [77, 480-484].  The identification of 
GapB and GapC on the surface of S. aureus [75] allowed us to construct a GapC/B chimera for 
producing a single multivalent antigen. The protein was expressed in E. coli and it reacted to 
specific GapC (Fig 4.1.2. 1) and GapB antisera (data not shown).  As to the rationale of using a 
chimera composed of GapB and GapC, we felt that while the role of GapC as a protective 
antigen is well documented, the addition of another surface-expressed protein could increase the 
potential role of the vaccine to protect against S. aureus infections.     
  
The use of the GapC/B chimera as a single antigen would be possible only if the immune 
responses to the protein are comparable to the responses obtained when the individual antigens 
are used in single or combined vaccine formulations.  On the first mice immunization trial, we 
observed significant total IgG, IgG1, and IgG2a antibody levels against the GapB and GapC 
proteins on all vaccinated groups (Fig 4.1.3.1). Immunization with GapC/B however, results in 
approximately 10 fold less total IgG and IgG1 titers on average as compared to immunization 
with GapB or GapC and practically undetectable IgG2a titers (data not shown). We determined 
that the amount of GapC/B protein used was lower than originally estimated and this might have 
had a moderate effect on the antibody titers. Nevertheless, the IgG2a titers against GapB and 
GapC are suggestive of a cellular immune response and thus we decided to repeat the mice 
immunization experiment and to measure cell mediated and humoral immune responses. 
 
Immune responses to GapB, GapC and GapC/B were determined and with minor 
exceptions, the results indicate that in general, there are no differences between the total IgG and 
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IgG1 titres when the GapB or GapC or GapC/B proteins are used compared to titers resulting 
from immunization with a mixture of the GapB + GapC proteins (Group 4). It would be logical 
to expect no differences in the serum titers against the three proteins; however the animals that 
received the GapB + GapC mixed formulation developed a comparably lower IgG2a response to 
the individual proteins and the GapC/B chimera (although significantly higher than the placebo 
group) (Fig 4.1.3.2). This suggest interference between these two proteins, since degradation of 
the vaccine components was discounted after analysis by Western blots of the remainder of the 
vaccine after it was sent back to the laboratory (data not shown).  
 
The GapB and GapC proteins share 47% identity [75], thus some degree of immune-
cross-reactivity between these proteins was expected. Overall we detected cross-immune 
responses but not to the levels observed with the cognate antigens. In the first trial, GapC-
vaccinated animals apparently developed significantly higher antibodies titers against GapB 
compared to the placebo group but the opposite was not true (Fig 4.1.3.1A and B). In the second 
trial, mice that received the GapB protein only (Group 2) developed a significant response to 
GapC (Fig 4.1.3.2B) but the opposite was not true (Fig 4.1.3.2A). This apparent contradiction 
between trials can be explained by comparing the titers to GapB in the placebo groups in the two 
trials. Comparison of GapB titers between the placebo groups indicates that the titers in the first 
trial are approximately 10 fold lower than the titers in the second trial (Fig 4.1.2.1A and 
4.1.3.2A) perhaps due to different mice lots used for the trials. The lower placebo titers might 
account for the statistical significance (p<0.01) observed between the GapB titer of mice of the 
placebo and Group 3 in the first trial (Fig 4.1.2.1A). 
 
Published evidence of the role of proteins with homology to GAPDH as protective 
antigens and the results obtained here after vaccination with GapC (i.e. high serum titres against 
GapB and GapC) would suggest that a vaccine solely composed of this protein would suffice and 
the GapC/B chimera would not be needed. Previous results with the GapC protein of S. 
dysgalactiae suggest otherwise.  Immunization of dairy cows with S. dysgalactiae GapC (closely 
related to S. uberis GapC) resulted in a lack of protection against a S. uberis experimental 
challenge [480]  indicating that despite close relationships, immunization with proteins sharing a 
high degree of homology is not a guarantee of cross-protection.  
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More supporting evidence for the addition of GapB to a vaccine formulation comes from 
the results obtained here when markers of cellular immune responses were analyzed. In general, 
GapB is better than GapC in inducing IL-4 expression (Fig 4.1.4.1). This was somewhat 
unexpected since the total IgG and IgG1 serum titers to both proteins are not different between 
all the groups (except the placebo). Formulation that contains GapB (either as individual protein 
or as part of the GapC/B chimera are able to stimulate IL-4 production in cells obtained from 
mice immunized with GapB or GapB + GapC (Fig 4.1.4.1A) while stimulation with GapC is 
only significant in mice vaccinated with the GapB + GapC combination (Fig 4.1.4.1A), perhaps 
due to cross-reaction. Stimulation with GapC/B also shows a higher number of IL-4 secreting 
cells than the placebo in groups 2, 4, and 5 (Fig4.1.4.1A); however in none of these groups is the 
number of IL-4 producing cells significantly different from the placebo. This is also unexpected 
since vaccination with GapC/B resulted in an increase of serum titers in all the test groups (Fig. 
4.1.3.2). In our hands the IL-4 ELISPOT assay seems to be more variable and sometimes the 
antibody titers do not correlate with the number of IL-4-secreting cells [485]. GapB also 
performs better than GapC at inducing IFN-γ expression and promoting blastogenesis (Fig. 
4.1.4.1B and C) despite showing similar GapB- or GapC-specific IgG2a titers (Fig. 4.1.3.2A and 
B). Since the GapC-vaccinated mice show high GapB-IgG2a levels (Fig. 4.1.3.2B) it is not 
totally surprising to detect IFN-γ-secreting cells or a proliferative response in cells from mice 
from group 2 after stimulation with GapC. The effects of IFN-γ and blastogenesis on cells from 
mice vaccinated with GapC/B followed by stimulation with the cognate antigen can also be 
attributed to the GapB portion of the protein since significant levels of IFN-γ and stimulation 
indexes are seen in cells from the GapB- and GapC/B-vaccinated animals (Fig. 4.1.4.1B and C). 
The possibility of contaminating endotoxin affecting the results was discarded since GapC 
(which had the highest endotoxin amounts) does not induce production of IL-4 or IFN-γ and 
neither promotes splenocyte proliferation as well as GapB or GapC/B (Fig. 4.1.4.1).  Although it 
appears that GapB is a better antigen in several laboratories including ours, GapC in GAPDH-
related sequences were shown to be protective [77, 480-484].  As to whether to use a mixture of 
GapB + GapC or a chimera protein containing approximately 50% residues from GapB and 50% 
residues from GapC, we believe that GapC/B is a better choice. The animals that received the 
GapB + GapC mixed formulation developed a comparably lower IgG2a response compared to 
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the individual proteins (Fig. 4.1.3.2) and this correlates  with low number of IFN-γ-secreting 
cells collected from these mice after stimulation with any of the three antigens (Fig. 4.1.4.1B). 
Thus a chimeric protein composed of GapB and GapC sequences not only will reduce the cost of 
antigen production but also has a greater potential to offer protection than the individual proteins.  
Although we cannot completely discard the contribution of the histidine tags in the recombinant 
proteins to the immune responses in mice, we are confident that it is negligible since mice sera 
was able to recognize proteins extracted from the surface of several S. aureus strains, including  
a human isolate (Fig. 4.1.5.1A). Moreover, serum from a cow naturally exposed to S. aureus 
reacts with the recombinant GapB and GapC proteins (Fig. 4.1.5.1B), again suggesting that the 
histidine tag plays no role in the development of antibodies to these two proteins. More 
importantly, recognition of these proteins by the target species indicates that they are available to 
the cow’s immune system in the native state, i.e., as components of the surface-located proteins 
of S. aureus.  
A comparison of the amino acid sequence of the GAPDH proteins of S. aureus to the 
bovine and mouse GAPDH proteins indicate that overall there is 43% identity between the S. 
aureus and bovine GAPDH and 44% between the mouse and S. aureus GAPDH (data not 
shown). A close inspection at the homologous regions between these proteins reveals that most 
of the identity lies near or at the GAPDH active site (residues 145 to 223 of S. aureus GapC). We 
concede that the GapC protein of S. aureus as a whole might not be the ideal candidate for 
vaccination since the potential exists for developing an auto-immune disease after vaccination 
with GapC. There is no information available however as to whether this problem exists in cows 
chronically exposed to S. aureus or to other bacteria that possess GAPDH-related sequences. 
Nevertheless it might be necessary to construct derivatives lacking undesirable regions before the 
ultimate vaccine prototype can be tested.  
 
Immunization of dairy cows represents an economical alternative to control mastitis 
caused by S. aureus and experimental vaccines containing various antigen preparations have 
been tried, however with ambiguous results [439-442, 478].  The use of conserved epitopes in a 
DNA/Protein vaccination approach partially protected against an experimental challenge with S. 
aureus [445, 479] which suggests that the use of conserved antigens as part of a single protein 
molecule as a vaccine component is a viable alternative.  Thus, we believe that our approach of 
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using GapB and GapC protein-sequences assembled in a GapC/B chimera as a potential target 
for developing of a vaccine to protect dairy cows from mastitis caused by S. aureus would 
increase the arsenal available to combat this economically important disease.  
 
4.2. DNA-Protein Immunization against the GapB and GapC Proteins of a Mastitis Isolate 
of Staphylococcus aureus 
  
 
4.2.1. Introduction 
 
Vaccination with DNA has been proposed as an alternative to using bacterins or 
recombinant proteins as the antigenic components of a vaccine [107, 454]. The advantages and 
pitfalls of the use of DNA for vaccination were recently reviewed [486].  DNA or DNA/protein 
vaccination against S. aureus resulted in partial protection against a S. aureus experimental 
challenge in mice and dairy cows [445, 479, 487].  The DNA vaccines were based either on the 
penicillin-binding protein (PBP2a) encoded by the mecA gene or on more conserved epitopes of 
the fibronectin-binding protein and clumping factor A adhesins of S. aureus and elicited both 
humoral and cellular immune responses.  
 
In this study the GapB, GapC and GapC/B antigens were tested as candidates for DNA 
vaccination by constructing plasmids expressing these proteins. The humoral and cell-mediated 
immune responses in mice were determined after immunizations with either plasmids alone or a 
combination of priming with plasmid DNA followed by a boost with the recombinant proteins. 
 
4.2.2. Construction of Plasmids Encoding a Protein Export Signal and Protein Expression 
on the Surface of MAC-T Cells 
 
The tests to determine the immune responses to the S. aureus proteins encoded by 
derivatives of pBISIA-24 were conducted first. This plasmid has been used successfully to elicit 
immune responses to viral antigens [469].  The plasmids pBISIA-gapB, pBISIA-gapC and 
pBISIA-gapC/B were used to immunize mice and serum and cell-mediated immune responses 
were determined.  The results indicated that vaccination with these plasmids was not enough to 
mount a detectable immune response to the S. aureus antigens (data not shown). The reason for 
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the low immune response could be that the S. aureus proteins were present in the cytoplasm of 
the cells and no or few antigen molecules were expressed on the cell surface where they could be 
detected by antigen-presenting cells.  To express the proteins on the cell surface, a pair of 
complementary oligonucleotides (Table 3.3.1) encoding the protein-export sequence from the T-
cell plasminogen activator (Tpa) was inserted in front of the gapB, gapC and gapC/B genes 
resulting in the plasmids pTPA2-gapB, pTPA-gapC and pTPA2-gapC/B respectively (Fig. 
4.2.2.1).  We transfected MAC-T cells and used immunohistochemistry (IHC) to assess the 
expression of the GapB, GapC and GapC/B antigens on the cell surface.  The results 
(Fig.4.2.2.2) indicated that these antigens were expressed on the cell surface of MAC-T cells.  
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Figure 4.2.2.1. Construction of plasmids encoding protein export signal. 
To express the proteins on the cell surface, a pair of complementary oligonucleotides (Table 
3.3.1) encoding the protein-export sequence from the T-cell plasminogen activator (Tpa) was 
inserted in front of the gapB, gapC and gapC/B genes resulting in the plasmids pTPA2-gapB, 
pTPA2-gapC and pTPA2-gapC/B respectively. A vector carrying only signal sequence (pBISIA-
tpa) also constructed. 
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Figure 4.2.2.2. Expression of proteins on the surface of MAC-T cells. 
The plasmids pTPA2-gapB, pTPA2-gapC and pTPA2-gapC/B encoding the gapC, gapB, and 
gapC/B genes respectively, were transfected into MAC-T cells and the presence of the proteins 
was detected by immunohistochemistry (IHC) as described in section 3.5. Negative MAC-T cells 
with vector alone, pTPA2-gapB, pTPA2-gapC, and pTPA2-gapC/B: MAC-T cells expressing 
GapB, GapC and GapC/B, respectively. The arrows point to the location of MAC-T cells 
expressing the proteins. 
 
4.2.3. Immune Responses to DNA Vaccination 
 
 
To determine the immune response to the GapB, GapC and GapC/B antigens encoded by 
pTPA2-gapB, pTPA-gapC and pTPA2-gapC/B respectively, mice were immunized with plasmid 
DNA by the intradermal route (Table 3.6.2.1).  The immune responses were first assessed by 
measuring antibody titers to the proteins followed by ELISPOT and cell-proliferation assays.  
The results of the ELISA tests indicated that there was no significant total IgG, IgG1 and IgG2a 
serum response to the three antigens (data not shown). When the cell-mediated immune response 
was measured by ELISPOT and lymphoproliferation tests in four mice from each group, the 
results showed low production of IL-4 (Fig. 4.2.3.1A) and IFN-γ (Fig. 4.2.3.1B) and low 
stimulation indexes (Fig. 4.2.3.1C) in all of the vaccinated groups with respect to the control 
group. 
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Figure 4.2.3.1. Cellular immune responses to GapB, GapC and GapC/B after immunization with 
plasmid DNA.  
The production of IL-4, IFN-γ, and stimulation index of splenocytes with GapB, GapC or 
GapC/B is shown. A: IL-4 expression; B: IFN-γ expression; C: Lymphocyte proliferation. The 
symbols are mean + S.D. The vaccine groups are indicated on the X-axis while the recall 
antigens are indicated by the brackets below the X-axis. Group 1 animals received pBISIA-TPA, 
while groups 2- 4 were immunized with pTPA2-gapB, pTPA2-gapC and pTPA2gapC/B, 
respectively. Group 5 (placebo) received a PBS solution. 
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4.2.4. Immune Responses to DNA-Protein Vaccination 
 
The low humoral and cell-mediated responses obtained after immunization with plasmid 
DNA indicated that these plasmids alone were not adequate to mount an immune response.  A 
previous report indicated that mice immunization with plasmid DNA encoding the CTLA-ClfA 
hybrid protein followed by a boost with ClfA resulted in a higher humoral response compared to 
the response in mice vaccinated with the plasmid alone [479].  Therefore, the remaining four 
mice from each group were boosted with the recombinant proteins as indicated in Table 3.6.2.1. 
The serum total IgG, IgG1, and IgG2a levels as well as the number of IL-4-, IFN-γ-secreting 
cells and lymphoproliferation indexes were measured after stimulation with the respective recall 
antigens.  
 
A boost immunization with GapB (Fig. 4.2.4.1A) resulted in significant increases of total 
IgG titers in the group primed with pTPA2-gapB and boosted  with GapB (Group 2a) compared 
to groups primed with pTPA2-gapC  and boosted with GapC (Group 3a, p<0.05), primed with 
pTPA2-gapC/B and boosted with GapC/B (Group 4a, p<0.01) and placebo (Group 5a, p<0.001) 
while no significant differences were observed between the serum titers of groups 2a and 1a 
which received a GapC/B boost after vector only immunization.  GapB-specific IgG1 titers 
significantly increased in groups 1a and 2a with respect to the placebo group (Fig. 4.2.4.1A).  
The titers in group 2a were also significantly different from the GapB antibody levels in groups 
3a (p<0.05) and 4a (p<0.01) respectively.  The GapB-specific IgG2a titers were elevated in all 
the vaccinated groups (Fig. 4.2.4.1A) but these titers were different (p<0.05) in group 2a with 
respect to the placebo group 5a.  
 
A different result was observed when the GapC-specific serum titers were measured after 
a boost immunization with GapC. Vaccination with this protein resulted in a significant increase 
(p<0.001) only in the animals primed with pTPA2-gapC and boosted with GapC (group 3a, Fig. 
4.2.4.1B). Similar results were observed when the GapC-specific IgG1 titers were measured. In 
this case GapC-specific IgG1 titers were significantly elevated (p<0.001) in group 3a with 
respect to groups 1a, 4a and 5a (Fig. 4.2.4.1B).  The IgG1 GapC-specific serum titers in group 3a 
were also significantly different (p<0.05) to the titers in mice primed with pTPA2-gapB (Group 
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2a).  In addition, the IgG1 GapC-specific titers in animals that received a GapC/B boost after 
vector only immunization (Group 1a) were significantly different (p<0.01) than the placebo, 
(Group 5a) titers.  Finally, GapC-specific IgG2a titers were also significantly different in group 
3a with respect to group 1a (p<0.001), group 2a (p<0.05) and groups 4a and 5a (p<0.01) 
respectively. 
 
A boost immunization with GapC/B resulted in significantly elevated total IgG in animals 
of groups 1a (p<0.001), 2a (p<0.001), 3a (p<0.001) and 4a (p<0.01) with respect to the placebo 
group 5a (Fig. 4.2.4.1C). In addition the group 2a GapC/B-specific total IgG was significantly 
different (p<0.01) than the titers in group 3a.  A similar picture was observed with the GapC/B-
specific IgG1 titers.  In all the vaccinated groups, a significant increase of the serum titers was 
observed in groups 1a, 2a, and 3a (p<0.001) and in group 4a (p<0.01) compared to the placebo 
group (Group 5a). The titers in group 4a however, were significantly lower than the titers in 
groups 1a, 2a and 3a (p-values <0.05, p<0.01, and <0.05, respectively).  As observed with the 
total IgG titers against GapC/B, the IgG2a titers in groups 1a, 2a and 3a were significantly 
different than the titers in group 4a (p-values <0.05; <0.01 and< 0.05), respectively.   
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Figure 4.2.4.1. Humoral immune responses to GapB, GapC and GapC/B after vaccination with 
plasmid DNA and boost with recombinant proteins.  
Titers to GapB, GapC, and GapC/B (measured 119 days after the first immunization) are shown 
in panels A-C, respectively. The vaccine groups are indicated on the X-axis. The symbols are 
mean + S.D. of the titers. The asterisks above the columns represent statistically different titers 
level between groups. Group 1a animals received a boost of GapC/B, while groups 2a, 3a, 4a 
were boosted with GapB, GapC and GapC/B, respectively. Group 5a (Placebo) received a PBS 
solution. 
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4.2.5. Cell-mediated Responses in Animals Boosted with the Recombinant Proteins 
                  
 
Contrary to the results obtained when mice were immunized with plasmid DNA only 
(Fig. 4.2.3.1) increased cell-mediated immune responses were observed in animals primed with 
DNA and boosted with proteins (Fig. 4.2.5.1).  Stimulation with GapB resulted in an increase of 
the number of IL-4-secreting cells in all immunized animals (Fig. 4.2.5.1A). The number of IL-
4-secreting cells of animals of the group 2a (Primed with pTPA2-gapB and boosted with GapB) 
was significantly higher (p<0.001) than the placebo group 5a only. The number of IL-4 secreting 
cells of the animals primed with pTPA2-gapC and boosted with GapC (Group 3a) was 
significantly higher than the number of cells of  group 1a (Primed with pBISA-TPA and boosted 
with GapC/B, p<0.001), the group 2a (Primed with pTPA2-gapB and boosted with GapB, 
p<0.01),  group 4a (Primed with pTPA2-gapC/B and boosted with GapC/B, p<0.001), and group 
5a (Placebo, p<0.001).  In addition, a significant number of IL-4-secreting cells were observed in 
the group 1a compared to the placebo group 5a (p<0.05).  Priming with pTPA2-gapC/B followed 
by a boost immunization with GapC/B did not significantly increase the number of IL-4-
secreting cells after stimulation with GapB.  Stimulation with GapC (Fig. 4.2.5.1A) resulted in a 
significant increase in the number of IL-4-secreting cells in group 3a (Primed with pTPA2-gapC 
and boosted with GapC) compared to groups 4a (Primed with pTPA2-gapC/B and boosted with 
GapC/B, p<0.01) and 5a (Placebo, p<0.01) and to group 1a (Primed with pBISIA-TPA and 
boosted with GapC/B, p<0.05). Priming with pTPA2-gapB or pTPA2-gapC/B followed by boost 
immunizations with GapB or GapC/B (Groups 2a and 4a respectively) did not significantly 
increase the number of IL-4-secreting cells compared to the placebo group 5a after stimulation 
with GapC.  Stimulation with GapC/B resulted in a significant increase of the IL-4-secreting 
cells of all vaccinated groups with respect to the placebo group 5a (1a: p<0.001; 2a: p<0.05; 3a: 
p<0.001 and 4a: p<0.001). No differences however were detected amongst the different 
vaccinated groups.  
 
The numbers of IFN-γ-secreting cells were determined after stimulation with GapB, 
GapC or GapC/B and the results are presented in Figure 4.2.5.1B. Stimulation with GapB 
resulted in an increase of the number of IFN-γ-secreting cells in all immunized animals with 
respect to the number of cells of the placebo group 5a (p<0.001).  As observed before for the IL-
 85 
 
4-secreting cells, the number of IFN-γ−secreting cells of group 3a (Primed with pTPA2-gapC 
and boosted with GapC) was significantly higher than the number of cells of group 4a (Primed 
with pTPA2-gapC/B and boosted with GapC/B, p<0.01) and higher (Albeit not significant, 
p>0.05) than the number of cells of group 2a (Primed with pTPA2-gapB and boosted with 
GapB).  The number of IFN-γ−secreting cells of group 3a however, was significantly higher than 
the number of cells secreting IFN-γ of group 4a (Primed with pTPA2-gapC/B and boosted with 
GapC/B, p<0.05).  Stimulation with GapC resulted in a significant increase of the IFN-γ-
secreting cells of group 3a animals (Primed with pTPA2-gapC and boosted with GapC) 
compared to groups 1a, 2a, 4a and 5a (p<0.001) and no other differences were found amongst the 
groups.  As observed before for the number of IL-4-secreting cells, stimulation with GapC/B also 
resulted in a significant increase (p<0.001) of the IFN-γ-secreting cells in all the vaccinated 
animals with respect to the placebo group 5a (Fig. 4.2.5.1B).  In this case, however, cells from 
group 2a (Primed with pTPA2-gapB and boosted with GapB) showed a significant decrease in 
the number of IFN-γ-secreting cells when compared to the number of cells of the groups 3a 
(Primed with pTPA2-gapC and boosted with GapC, p<0.001) and 4a (Primed with pTPA2-
gapC/B and boosted with GapC/B, p<0.01) respectively. 
 
The results of the lymphoproliferation assays after stimulation with GapB, GapC or 
GapC/B are presented in Figure 4.2.5.1C. Stimulation with GapB resulted in significant 
proliferation indexes in cells obtained from animals of group 2a (Primed with pTPA2-gapB and 
boosted with GapB) compared to the indexes in groups 1a (Primed with pBISIA-TPA and 
boosted with GapC/B, p<0.001), 4a (Primed with pTPA2-gapC/B and boosted with GapC/B, 
p<0.001) and 5a (Placebo, p<0.001) but not when compared to the stimulation index in group 3a 
(Primed with pTPA2-gapC and boosted with GapC, p>0.05).  In addition, cells from group 3a 
showed significant differences (p<0.001) in the stimulation index when compared to the placebo 
group 5a only. The stimulation index of the cells of groups 1a and 4a did not show a significant 
increase with respect to group 5a (Fig. 4.2.5.1C).  A comparable result was obtained when GapC 
was used as the recall antigen.  In this case, the stimulation index was significantly higher 
(p<0.001) in group 3a animals (Primed with pTPA2-gapC and boosted with GapC) when 
compared to the indexes in groups 1a, 2a, 4a, and 5a (Fig. 4.2.5.1C).  As seen before for GapB, 
addition of GapC to the cells of group 2a (Primed with pTPA2-gapB and boosted with GapB) 
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resulted in a stimulation index significantly higher than the index observed in the placebo group 
5a (p<0.01) only.  Addition of GapC/B resulted in significant stimulation indexes in cells from 
all vaccinated groups compared to the placebo group 5a (Fig. 4.2.5.1C) although these indexes 
were smaller than the ones observed after stimulation with either GapB or GapC (Note the 
difference on the scale of Fig. 4.2.5.1C). Compared to the placebo group 5a, the highest 
stimulation indexes were observed in groups 2a (Primed with pTPA2-gapB and boosted with 
GapB, p<0.001), 3a (Primed with pTPA2-gapC and boosted with GapC, p<0.001), followed by 
the group 1a (Primed with pBISIA-TPA and boosted with GapC/B, p<0.01) and finally group 4a 
(Primed with pTPA2-gapC/B and boosted with GapC/B, p<0.05). No differences however were 
detected amongst the different vaccinated groups. 
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Figure 4.2.5.1. Cellular immune responses to GapB, GapC, and GapC/B after vaccination with 
plasmid DNA and boost with recombinant proteins.  
The production of IL-4, IFN-γ, and stimulation index of splenocytes with GapB, GapC or 
GapC/B are shown. A: IL-4 expression; B: IFN-γ expression; C: Lymphocyte proliferation. Note 
the different scale used for the stimulation indexes after addition of the GapC/B recombinant 
protein. The symbols are means + S.D. The asterisks above the columns represent statistically 
different values between groups. The vaccine groups are indicated on the X-axis while the recall 
antigens are indicated by the brackets below the X-axis. The vaccine groups are the same as of 
Fig. 4.2.4.1. 
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4.2.6. Discussion 
 
In the last few years it has been proposed that immunization with plasmid DNA might be 
a viable alternative to the more traditional approach of using proteins or whole cell lysates as the 
antigenic component of a vaccine (reviewed in [486]).  The objective of the present study was to 
compare the quantity and quality of the immune response to S. aureus antigens encoded by 
plasmid DNA. This work was started by constructing plasmids encoding the GapB, GapC and 
GapC/B genes of S. aureus SA10 [75, 472] using a vector possessing eukaryotic promoter and 
enhancer regions together with 3 tandem copies of the CpG ODN 2135 which had previously 
been used to increase cell-mediated immune responses in bovine species [469, 488, 489]. Since 
there is experimental evidence suggesting that low levels of surface-exposed or secreted antigens 
results in sub-optimal immune responses [489, 490], these plasmids were modified by addition 
of a synthetic segment of DNA encoding a derivative of the T-cell plasminogen activator protein 
export sequence (Table 3.2.6.1) to promote expression of antigens on the cell surface [490].  
Using the modified plasmids, expression of recombinant GapB, GapC and GapC/B on the 
surface of transfected MAC-T cells was detected (Fig.4.2.2.2) but no significant humoral and 
very low cell mediated immune responses were observed even after three rounds of 
immunizations (data not shown, and Fig. 4.2.3.1,  respectively). Despite the low immune 
responses to the antigens encoded by the plasmids, an additional boost with the recombinant 
proteins was conducted to determine if this would enhance the quality and quantity of the 
immune responses in mice.  
 
In a previous trial, immunizations with GapB or GapC resulted in significant increases of 
total IgG, IgG1 and IgG2a serum titers against the cognate antigen and the recombinant GapC/B 
chimera, while immunization with GapC/B resulted in significant serum titers against the three 
proteins.  In addition, GapC titers in GapB-immunized animals were also elevated suggesting 
cross-reaction between these antibodies [472]. In addition, GapC titers in GapB- immunized 
animals were also elevated suggesting cross-reaction between these antibodies [491]. In the trials 
reported here, the GapB- and GapC-specific total IgG, IgG1 and IgG2a titers are significantly 
higher than the placebo group in the groups immunized with pTPA2-gapB or pTPA2-gapC and 
boosted with GapB or GapC, respectively, and antibody-cross-reaction between the two groups 
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was observed (Figs. 4.2.4.1A and B).  In addition, the total IgG and IgG1 serum titers against 
GapC/B increased in all the groups (Except placebo) regardless of the antigen used for priming 
or boosting (Fig. 4.2.4.1C) a result similar to what was reported before [472]. In the trial reported 
here however, only the group primed with pTPA2-gapC and boosted with GapC (Group 3a, Fig. 
4.2.4.1C) showed a significant increase of GapC/B-specific IgG2a titers. Priming with pBISIA-
TPA followed by a boost with GapC/B (Group 1a) also results in an increase of the total IgG, 
IgG1 and IgG2a titers against all the recombinant proteins compared to the placebo group (Fig. 
4.2.4.1).  This finding is not totally unexpected. Due to the time period between the protein boost 
and assay days (21 days, Table 3.6.2.1) one would expect an immune response to the GapC/B 
chimera and as observed before [491], we would also anticipate a response against the individual 
proteins. Compared to the titers in group 1a, the GapB-specific titers in group 2a are higher and 
the GapC-specific titers in group 3a are significantly higher whereas the GapC/B-specific titers 
in group 4a are not statistically different from the titers in group 1a (But significantly different 
than the placebo group). These results suggest that the humoral immune responses observed are 
solely due to the boost with the recombinant proteins. 
 
The results of the tests designed to check for cell-mediated immunity present a similar 
picture to the results observed before and after two immunizations with GapB and GapC (Fig. 
4.2.5.1). The number of antigen-specific IL-4-, IFN-γ-secreting cells and stimulation indexes 
were all significantly elevated with respect to the placebo group.  As observed before for the 
serum titers (Fig. 4.2.4.1),  the best IL-4 and IFN-γ  responses are obtained after priming with 
pTPA2-gapC and boosting with GapC (Even  in animals vaccinated with any form of GapB, 
presumably due to cross-antigenic reaction), followed by the responses obtained in the group 2a. 
The stimulation index in splenocytes isolated from mice primed with either pTPA2- gapB or 
pTPA2-gapC and boosted with cognate antigens shows significant differences after stimulation 
with their respective recall antigens compared to the stimulation index obtained in cells from 
animals primed with pBISIA-TPA and boosted with GapC/B. The animals primed with pTPA2-
gapC/B and boosted with GapC/B however show lower cell-mediated responses to GapC/B 
although the number of IL-4 and IFN-γ secreting cells from the group 4a animals is slightly 
higher, but not significant, than the number of cells in group 1a (Fig. 4.2.4.1A and B).  Due to a 
limit in the number of animals, we were unable to include groups of mice primed with the vector 
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alone and boosted with GapB and GapC and thus we could not assess the the effect of a single 
immunization with the protein antigens versus priming with DNA and boosting with the 
antigens. Thus, taking all these results together it appears that the immune responses to GapB, 
GapC and GapC/B are due to the boost vaccination with the recombinant antigens. 
 
The lower immune responses obtained in mice after priming with the plasmid-encoded 
antigens could be due to several factors including codon bias (Although the S. aureus antigens 
were detected on the surface of MAC- T cells (Fig.4.2.2.2)), uptake of antigens by APC or the 
type of CpG present on the plasmid. CpG oligonucleotides are small DNA molecules that belong 
to the family of pathogen-associated molecular patterns (PAMP). CpG motifs bind to the toll-like 
receptor (TLR9) molecules and upon recognition, cell-signalling pathways are induced resulting 
in a pro-inflammatory response and predominantly a Th-1-like immune response (reviewed in 
[492]. Analysis of the TLR9 receptor sequences shows greater homology between cattle and 
human than cattle and mice receptors. This degree of homology results in different CpG motifs 
able to stimulate mice and bovine leukocytes (reviewed in [493]. In addition to showing different 
TLR9-receptors specificities, cattle  appear to diverge from the Th-1/Th-2 paradigm in that  the 
majority of T cell clones appear to fall into the Th-0 type expressing both IL-4 and IFN-γ [494] 
whereas in mice, the Th-1- and Th-2- mediated responses are often mutually exclusive and 
reciprocally regulated by the cytokines they secrete in vivo [495, 496]. Despite the differences, 
in both species the Th-1 and Th-2 responses have been linked to the expression of specific 
cytokines for example IFN-γ is linked to IgG2 in cows and IgG2a and IgG3 in mice and  IL-4 to 
IgG1 and IgE production  in both species [497, 498]. Immune response against other S. aureus 
antigens were obtained after DNA immunization in mice [479, 487] and cows [445, 446]. 
Virulence studies performed in mice indicate that immunization with the MecA protein protects 
the animals from a bacterial challenge [487] and vaccination with plasmid DNA encoding the 
clumping factor A (CflA) resulted in a balanced Th-1/Th-2 immune response; however it did not 
protect mice from an intraperitoneal challenge although the immunized serum reduced the ability 
of S. aureus to bind to fibrinogen [479]. In cows, a balanced Th1/Th2 immune response was 
obtained after immunization with plasmid DNA encoding the S. aureus protein A and followed 
by a boost with the recombinant protein [446], vaccination with protein alone proved to be less 
effective in mounting an immune response when compared to a DNA priming/protein boost 
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regime and no information on protection against a challenge was provided. Another study 
indicates that priming the immune system with a mixture of two plasmids, one encoding the 
tandem fibronectin-binding repeats D1D3, an internal ribosomal entry site and the CflA protein 
and the second encoding bGM-CSF followed by a boost with the recombinant D1D3 and CflA 
proteins offered partial protection against a S. aureus challenge of dairy cows [445].  Using viral 
antigens immunization with plasmids possessing a similar backbone to the one reported here was 
effective to elicit a strong humoral and cell-mediated immune response in cattle [490].  Plasmids 
encoding the CpG ODN 2135, HCMV IEI promoter, intron A region,  Tpa secretion signal  and 
viral antigens have been shown to elicit significant Th-1/Th-2 balanced immune responses in 
cattle [489, 490, 499-502] and with lesser activity in mice [503].  In this work, we conclude that 
adding genes encoding S. aureus surface located antigens to these plasmids allows us to extend 
their range of use although it remains to be determined whether these plasmids will be effective 
in mounting an immune response against the S. aureus GapB and GapC proteins in dairy cows. 
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4.3. Optimizing the Immune Response in the Mammary Gland of Cows.  
  
4.3.1. Introduction 
 
In large animals, protection from intramammary infections is mainly achieved by the 
systemically induced inflammatory and adaptive immune responses that recruit immune cells 
and molecules into the mammary gland through multiple steps that requires expression of several 
mediators and receptors to achieve transfer of these immune effectors from blood to the 
mammary gland. Moreover, quick recruitment with increased numbers of immune cells 
(especially neutrophils) and molecules (example IgG2) are required to either prevent or control 
intramammary infection. The human mammary gland is part of the mucosal immune system 
where immunization through mucosal surfaces will induce protection in the mammary gland 
whereas in large animals it is not clearly known whether the mammary gland is part of mucosal 
immune system. For bovine mastitis, it is well known that phagocytic neutrophils together with 
pathogen specific opsonising antibodies (mainly IgG2) are the major immune effectors in the 
mammary gland [251]. The recognition of invading pathogens and prompt inflammatory 
responses that recruit neutrophils into the mammary gland are important immune responses 
required for prevention of intramammary infections [504-506]. Dendritic cells, blood vessel 
endothelial cells, mammary epithelial cells, milk macrophages and T and B lymphocytes of the 
peripheral immune system also play important roles in the local inflammatory response helping 
to recruit opsonising antibodies and neutrophils from blood into milk for rapid phagocytic 
clearance of opsonised pathogens [251]. Milk and its components have significant diluting and 
blocking effects on recruited immune effectors. To avoid dilution of immune effectors in milk 
during intramammary infection, intramammary immune effectors should be recruited in higher 
numbers. In healthy udders the major cell types are macrophages in dry and lactating cows, and 
neutrophils in colostrum. Lymphocytes account for 10-27% of cells during lactation [507]. The 
numbers of lymphocytes are high in the secretion of involuted udders but their numbers are less 
during the periparturient period [508-510]. In the normal population of udder milk, αβ T-
lymphocytes are higher than γδ T-lymphocytes. The αβ T-lymphocytes are predominantly CD8+ 
and show the phenotype of memory cells [245, 360, 511]. Milk macrophages are the first cells to 
encounter invading mastitis pathogens and they are also reported to be involved in phagocytosis 
[512].  
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As a means to improve bovine intramammary immunity we hypothesize that enhancing 
local intramammary immunity by targeting vaccine delivery to the supramammary lymph node 
through an appropriate  route of injection will strengthen the intramammary immunity by 
increasing local production of immune effectors  especially IgA production in the 
supramammary lymph node.  Immunoglobulin A is predominant in milk of humans and rodents, 
whereas IgG is the dominant immunoglobulin in milk of ruminants and pigs [513]. It has been 
shown that IgA producing plasma cells home to secretory epithelial cells after an initial stimulus 
with their antigen in the mucosal lymphoid tissue [343]. We hypothesize that local injection in 
the area drained by the supramammary lymph node might increase IgA production in the 
mammary gland more efficiently than from IgA producing B-lymphocytes that home to the 
mammary gland from distant gut associated lymphoid tissue. In this objective, we tested both the 
route of injection (Subcutaneous versus intradermal) and the site of injection (Parotid lymph 
node area for systemic response versus supramammary lymph node for local response) in the 
mammary gland. This hypothesis was tested by two intradermal (ID) and subcutaneous (SQ) 
vaccinations with GapC/B chimeric antigen 21 days apart, into the area drained by the 
supramammary lymph node (SMLN).  The trial design is shown in Table 3.7.1. As controls, 
immunizations in the area drained by the parotid lymph node (PL) were carried out. The placebo 
group (Group 1) (Table 3.7.1) was injected only with adjuvant (VSA3). This comparison of 
target sites was carried out in dairy cows during the involution period. This is the time when 
local production of IgA has the greatest impact on the total Ig levels in mammary secretions. The 
total IgG, IgG1, IgG2 and IgA levels were determined in serum and mammary secretions.  
 
 
4.3.2. Humoral Immune Response in Serum and Mammary Gland of Cows 
 
        
Compared to the placebo group, subcutaneous vaccination in the supramammary lymph 
node area resulted in significantly higher serum (p<0.01 for all immunoglobulins isotypes 
indicated) and milk (p-values <0.05, <0.01, <0.05, and <0.01) GapC/B total IgG, IgG1, IgG2 and 
IgA titers respectively.  Similarly intradermal vaccination in the supramammary lymph node area 
resulted in significantly higher serum (p-values <0.001, <0.01, <0.001 and <0.001) and milk (p-
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values <0.001, <0.001, <0.001 and <0.01) GapC/B IgG, IgG1, IgG2 and IgA titers respectively. 
Compared to the placebo, intradermal vaccination with GapC/B chimeric protein in the parotid 
lymph node area induced significantly higher serum (p-values <0.001, <0.001, <0.01 and 
<0.001) and milk (p-values <0.001, <0.01, <0.01 and <0.05) GapC/B total IgG, IgG1, IgG2 and 
IgA titers respectively. On the other hand, subcutaneous injection of GapC/B near the parotid 
lymph node areas did not stimulate significantly higher (p>0.05) GapC/B total IgG, IgG2 and 
IgA titers in milk and serum; however, it induced significantly higher (p<0.05) GapC/B IgG1 
titers in both milk and serum (Fig. 4.3.2.1). 
  
 
Figure 4.3.2.1. Serum titers to GapC/B.  
Humoral immune responses to GapC/B were measured 42 days after the first immunization.  The 
vaccine groups are indicated on the X-axis while the serum titers of total IgG, IgG1, IgG2, and 
IgA are shown in their respective panels. Each symbol represents one animal in the group. The 
bars across the symbols are mean + SD of the titers. The asterisks above the column represent 
statistically different titer levels (* = p < 0.05; ** = p<0.01; *** = p< 0.001) between groups. 
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Figure 4.3.2.2. Milk titers to GapC/B. 
Anti-GapC/B titers in milk were measured 42 days after the first immunization.  The vaccine 
groups are indicated on the X-axis while the titers of total IgG, IgG1, IgG2 and IgA are shown in 
their respective panels. Each symbol represents one animal in the group. The bars across the 
symbols are mean + S.D. of the titers.   The asterisks above the column represent statistically 
different titer levels (* = p < 0.05; ** = p<0.01; *** = p< 0.001) between groups. 
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4.3.3. Discussion 
 
In this trial both subcutaneous and intradermal immunizations with the GapC/B protein 
near the supramammary lymph node and intradermal immunization near parotid lymph node 
areas resulted in significantly increased serum and milk titers of total IgG, IgG1, IgG2, and IgA 
in all vaccinated groups as compared to the placebo. The GapC/B IgG1 serum and milk titers 
were significantly higher in all vaccinated group as compared to the placebo group.  These 
results indicated that local vaccination at the area drained by supramammary lymph nodes has a 
small advantage over vaccination at the distant anterior parotid lymph node area.  Both 
intradermal and subcutaneous injections at supramammary lymph nodes induced significantly 
higher GapC/B IgG, IgG1, IgG2 and IgA titers in both milk and serum. Intradermal vaccination 
at the parotid lymph node area also induced significantly higher GapC/B IgG, IgG1, IgG2 and 
IgA titers in both milk and serum; however, subcutaneous vaccination in the parotid lymph node 
area resulted in significantly high IgG1 titers in serum and milk. The IgG immunoglobulin is 
synthesized by lymph node-resident B-cells, collected from serum and transcytosed through the 
endothelial and epithelial cell layers by a prolactin-sensitive mechanism [514] whereas IgA 
immunoglobulin is produced locally in the gland after IgA expressing  B-lymphocytes  that had 
contact with antigen home to secretory epithelia [513]. Based on this fact we expected 
differences in the IgA titer in milk between supramammary and parotid lymph nodes areas in the 
vaccinated groups; however, there were no differences in GapC/B titers in intradermal 
vaccination at both sites. This may be due to several reasons. For example, vaccination near the 
supramammary and parotid lymph nodes might induce the production of IgA with equal 
magnitude in spite of the fact that the supramammary lymph node is the draining lymph node 
near the mammary gland. On the other hand, local production might be high but secretion into 
milk and serum might be limited or not efficient and there might be local differences in efficient 
presentation of antigen to immune effector cells. It is very important to understand the 
mechanism involved in the local IgA production in the bovine mammary gland, especially in 
how IgA secreting B-cells home to the lamina propria of the mammary gland after contact with 
antigen. Also receptors and mediators involved in the signalling pathways need to be known to 
design better immunization strategy for increasing local production of IgA. Moreover, receptors 
and mediators involved in the process of IgA secretion from local sites into milk need to be 
clearly defined to target them for enhancement of local production of IgA in milk. 
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4.4. Monitoring Duration of Immune Responses in Cows.  
 
 
4.4.1. Introduction 
 
The physiology of a mammary gland is continuously changing throughout the animal’s 
reproduction cycle to meet the requirement for the nourishment of the newborn. The resistance 
and susceptibility to intramammary infection also varies at different stages of the reproduction 
cycle. In dairy cows the mammary gland is susceptible to intramammary infections during early 
non-lactating and during periparturient periods whereas in the mid to late lactation period the 
mammary gland is relatively better protected.  The number of neutrophils and the concentration 
of immunoglobulins are high both during the early non lactating period and during prepartum; 
however the udder is not protected against bacterial infections [515]. The reasons for increased 
susceptibility to mastitis during these periods are not clearly understood, two factors that might 
contribute are cessation of hygienic milking time practices which greatly help in avoiding 
colonization of the teat end and udder skin during early lactation, and the anti-inflammatory 
effects of hormones that induce parturition (calving) such as cortisol. Detailed understanding of 
the profile of intramammary immunity over the reproduction cycle is of paramount importance 
for better design of protective vaccines against intramammary infections.  Antigen is only one 
component of the vaccine. Adjuvants, which increase the magnitude of the immune responses, 
play a critical role in vaccine efficacy. Novel adjuvants that rapidly induce Th-1 responses as 
well as opsonizing antibodies production by B cells of immunized cows are also very important. 
Most veterinary vaccines are still formulated with oil-based adjuvant and are delivered in a 
fashion which stimulates humoral, but not local immunity. Therefore, it is necessary to find 
novel adjuvants that can increase the magnitude of the immune response. CpG ODN (cytosine-
phosphate-guanosine oligodeoxynucleotides) and PCPP (Poly [di (carboxylatophenoxy) 
phosphazene) are some synthetic molecules that have potential to be used as adjuvants. CpG 
oligonucleotides are small DNA molecules that belong to the family of pathogen-associated 
molecular patterns (PAMP). Unmethylated CpG dinucleotide in a specific base sequence 
conferred immunostimulatory activity to bacterial DNA (Krieg et al., 1995). Synthetic 
oligodeoxynucleotide (ODNs) containing this same sequence also had immunostimulatory 
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activity (Krieg et al., 1995). The CpG motif binds to the Toll-like receptor 9 (TLR9) molecules 
and upon recognition, cell-signalling pathways are induced resulting in pro-inflammatory 
responses and predominantly Th-1-like immune responses (reviewed in [458, 492]. Poly 
[di(carboxylatophenoxy) phosphazene] (PCPP) is a water soluble synthetic biodegradable 
products  that has been proven to be immunostimulatory in mice[516]. The PCPP has been 
shown to have adjuvant activity with many viral and bacterial antigens in mice [516-518]. It has 
been shown to increase the IgM, IgG, IgG1 and IgG2a titers against influenza antigens and IgG 
against tetanus toxoid in mice [516, 519, 520]. Recently, it has been shown that the 
polyphosphazene-CpG ODN combination of adjuvants enhances immune responses in mice 
more effectively than either of the individual adjuvants [521]. These authors also showed that 
PCPP induced innate cytokine production, which might indicate a mechanism by which 
polyphosphazenes induce their adjuvant role. In another study, polyphosphazene polymer 6 was 
shown to have similar potent immune-adjuvant effect when formulated with CpG-ODN in mice 
[522]. Its adjuvant activity has not been tested in large animals although it has been reported to 
be a potent adjuvant in sheep when used at twice the dose for mice (Gorge Mutwiri personal 
communication). 
 
This animal trial was designed to test vaccine formulations containing the adjuvant 
PCPP, the immunomodulator CpG, CpG + PCPP as well as VSA3 (oil in water) and the duration 
of the immune response to the GapC/B antigen. Forty cows (Five groups of eight) (Table 3.8.1) 
were selected from a dairy herd based on their clinical history and low basal levels of antibody 
against the GapB and GapC proteins. Blood and milk samples were taken before the vaccination 
(Day 0) and at days 21, 42, 60, 90, 120,150, 180, 210, 240, 270, 300, 330 and 360, which cover 
one lactation cycle.  The antibody levels (total IgG, IgG1, IgG2, and IgA) in milk and serum 
were measured by ELISA. When the antibody levels decreased 20 fold as compared to the levels 
at day 42, animals were boosted.  This monitoring of humoral immune responses was conducted 
throughout the lactation cycle to establish if there was a consistent correlation between antibody 
titres from serum and mammary secretions. 
 
 
 
 99 
 
 
4.4.2. Humoral Immune Responses in Serum and Milk of Cows.  
 
 
The results from these experiment showed that in serum, except for day 120 (p<0.05), the 
total IgG titres on the rest of the sampling days were significantly higher than the titres on day 0 
(p<0.001).  The IgG1, IgG2 and IgA tites were significantly higher than the titers on day 0 on all 
the sampling days (p<0.001). In  animals vaccinated with the GapC/B chimera and CpG, PCPP 
or a combination of CpG + PCPP (Groups 3, 4, and 5 respectively) as adjuvants (Table 3.8.1),  
the serum levels of IgG, IgG1 and IgG2 to GapB, GapC, or GapC/B did not significantly 
increase with respect to pre-immunization levels. These results showed that the best formulation 
to confer a durable immune response to GapC/B in dairy cattle contains 30% VSA3 as adjuvant 
and the duration of humoral immune responses using GapC/B as antigen is approximately four 
months. In this experiment since all animals are not at the same stage of lactation (calving was 
not synchronised) the starting and ending of our immune response monitoring vary from 
individual animal to animal. Some of our animals dried off while others were still in lactation. 
This situation created a problem for accurate statistical analysis of intramammary immune 
response trend over the longitudinal period of one lactation cycle.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
D
0 
tIg
G
D
21
 tI
gG
D
42
 tI
gG
D
60
 tI
gG
D
90
 tI
gG
D
12
0 
tIg
G
D
15
0 
tIg
G
D
18
0 
tIg
G
D
21
0 
tIg
G
D
24
0 
tIg
G
D
27
0 
tIg
G
D
30
0 
tIg
G
D
33
0 
tIg
G
D
36
0 
tIg
G
D
0 
Ig
G
1
D
21
 Ig
G
1
D
42
 Ig
G
1
D
60
 Ig
G
1
D
90
 Ig
G
1
D
12
0 
Ig
G
1
D
15
0 
Ig
G
1
D
18
0 
Ig
G
1
D
21
0 
Ig
G
1
D
24
0 
Ig
G
1
D
27
0 
Ig
G
1
D
30
0 
Ig
G
1
D
33
0 
Ig
G
1
D
36
0 
Ig
G
1
D
0 
Ig
G
2
D
21
 Ig
G
2
D
42
 Ig
G
2
D
60
 Ig
G
2
D
90
 Ig
G
2
D
12
0 
Ig
G
2
D
15
0 
Ig
G
2
D
18
0 
Ig
G
2
D
21
0 
Ig
G
2
D
24
0 
Ig
G
2
D
27
0 
Ig
G
2
D
30
0 
Ig
G
2
D
33
0 
Ig
G
2
D
36
0 
Ig
G
2
D
0 
Ig
A
D
21
 Ig
A
D
42
 Ig
A
D
60
 Ig
A
D
90
 Ig
A
D
12
0 
Ig
A
D
15
0 
Ig
A
D
18
0 
Ig
A
D
21
0 
Ig
A
D
24
0 
Ig
A
D
27
0 
Ig
A
D
30
0 
Ig
A
D
33
0 
Ig
A
D
36
0 
Ig
A
100
101
102
103
104
105
106
107
Se
ru
m
 G
ap
C
/B
 ti
tr
es
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2.1. Duration of immune responses (Serum titers). 
The mean logarithm (+ S.D.) of serum titers from animals vaccinated with the GapC/B chimera 
formulated in VSA3 (Group 2) and obtained at days 0, 21, 42, 60, 90, 120, 150, 180, 210, 240, 
270, 300, 330 and 360 are shown. Animals were vaccinated on days 0, 21, 134 and 270 shown 
by arrows. Except for day 120 (p<0.05), the total IgG titers on the rest of the sampling days were 
significantly different than the titers on day 0 (p<0.001).  The IgG1, IgG2 and IgA titers were 
significantly different from day 0 on all the sampling days (p<0.001).  The antibody type and the 
sample days are indicated on the X axis.  The serum levels at day 120 were below the threshold 
(20 fold the serum levels of day 42) and the animals received a boost on day 134 (14 days after 
day 120).  The rest of the groups showed low serum levels at all the times tested. The arrows 
indicate the vaccination days.   
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Figure 4.4.2.2. Duration of immune responses (Milk titers). 
The mean logarithm (+S.D.) of milk titres from animals vaccinated with the GapC/B chimera 
formulated in VSA3 (Group 2) and obtained at days 0, 21, 42, 60, 90, 120,150, 180, 210, 240, 
270, 300, 330 and 360 are shown.  Animals were vaccinated on days 0, 21, 134 and 270 shown 
by arrows. The antibody type and the sample days are indicated on the X axis.  The milk titer 
levels at day 120 were below the threshold (20 fold the milk titer levels of day 42) and the 
animals received a boost on day 134 (14 days after day 120).  The rest of the groups showed low 
milk titer levels at all the times tested. The arrows indicate the vaccination days. 
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4.4.3. Discussion 
 
 
These results showed that in serum except for day 120 (p<0.05), the total IgG titers on the 
rest of the sampling days were significantly higher than the titers on day 0 (p<0.001).  The IgG1, 
IgG2 and IgA titers were significantly higher than the titers on day 0 on all the sampling days 
(p<0.001).  The best formulation that confers a durable humoral immune response to GapC/B in 
dairy cattle is that containing 30% VSA as an adjuvant.  This experiment is not sufficient to 
provide conclusive answers for the profile of immune responses throughout one lactation period 
using GapC/B as an antigen because we didn’t monitor the cellular immune response. However, 
since the IgG2 titers can be an indication of cellular responses, by implication we expected the 
existence of cellular immune responses against GapC/B. Results from this experiment also 
showed that the duration of humoral immune response is approximately four months. The serum 
levels of GapB, GapC, or GapC/B did not significantly increase with respect to pre-
immunization levels in animals vaccinated with CpG, PCPP or a combination of CpG + PCPP 
(Groups 3, 4, and 5, respectively) (Table 3.8.1). This might be due to interference between 
GapC/B and CpG. Polyphosphazines are known to enhance immune responses in mice, however 
their effect in large animals requires further evaluation.  
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4.5. Role of GapC in the Virulence of Bovine Staphylococcus aureus Mastitis. 
 
 
4.5.1. Introduction. 
 
S. aureus produces a wide array of cell surface and extracellular proteins involved in 
virulence. Expression of these virulence factors is tightly controlled by numerous regulatory loci, 
including agr, sar, sigB, sae, and arl, as well as by a number of proteins with homology to SarA. 
The sar locus regulates the expression of the agr locus which encodes an elaborate quorum-
sensing system that was hypothesized to differentially regulate the expression of cell wall 
associated proteins and secreted exoproteins in response to the density of bacterial populations 
[208]. Amongst the cell-wall associated proteins of mastitis-isolates of S. aureus are the GapB 
and GapC proteins with homology to GAPDH [75].  Based on evidence collected which 
indicated that GAPDH is involved in other non-glycolytic functions, we hypothesized that 
staphylococcal GAPDH by the virtue of its surface localization may function as an adhesin for S. 
aureus colonization of host tissue surfaces including the bovine mammary gland. To evaluate 
this hypothesis, in vitro adhesion and invasion assays of S. aureus RN6390 and its isogenic gapC 
mutant H330 into MAC- T cells were conducted.  
 
4.5.2. In vitro Adhesion and Invasion Assays of Staphylococcus aureus Strain RN6390 and 
its Isogenic GapC Mutant Strain H330 into Mammary Epithelial Cell Line (MAC-T). 
 
Results from in vitro adhesion and invasion assays on MAC- T cells, from 8 different 
experiments, each in triplicate, showed that the number of RN6390 bacteria that adhered 
(attached) to MAC-T cells  at 37 °C (Fig. 4.5.2.1) and  4 °C (Fig. 4.5.2.2) was significantly 
(p<0.05) higher than that of the isogenic GapC mutant strain H330. Similarily, the number of 
RN6390 invaded (internalized) into MAC-T cells at 37 °C and 4 °C was significantly (p<0.01) 
higher than that of  the isogenic GapC mutant strain H330. This suggests the involvement of 
GapC as a S. aureus cell-surface receptor for attachment to bovine mammary epithelial cells. The 
wild type strain RN6390 also killed MAC-T cells and was released into the supernatant 2, 3 and 
4 hs after incubation in fresh media without antibiotics while the GapC mutant strain did not kill 
MAC-T cells since no viable counts were obtained after 2, 3 and 4 hs of incubation in fresh 
media without antibiotics (Fig. 4.5.2.3 and Fig. 4.5.2.4). Although viable, there was no apparent 
 104 
 
intracellular growth of the GapC mutant and this might have contributed to the lack of cell lysis 
(Fig. 4.5.2.3). To determine whether attachment and internalization requires metabolically active 
cells, the adhesion and invasion assays were conducted at 4 °C and the result showed that the 
number of RN6390 and H330  cells that attached and/or  internalized at 4 °C were  significantly 
different and comparable to the numbers at 37 °C (Fig. 4.5.2.2).   Although the numbers of 
bacteria of the GapC mutant strain H330 that attach and/or internalize into MAC-T cells were 
significantly less than the number of wild type bacteria the absence of GapC did not prevent the 
attachment and internalization. This could be due to the presence of several other molecules on 
the surface of S. aureus that are also known to serve as adhesins  such as fibronectin binding 
proteins A and B [69, 70], fibrinogen binding proteins (Clumping factor A and B) [72, 73, 523], 
collagen binding protein [71], vitronectin binding protein [66, 524],  elastin binding protein [74], 
extracellular adherence protein (Eap) [525] and many  other surface components (Table 1.2.1.1). 
It has been shown that in other S. aureus strains deletion of the extracellular adherence protein 
[167, 526] did not affect binding of the mutant strain to host matrix components. These authors 
also suggested that the absence of a significant effect might be due to the presence of other 
adherence proteins such as fibronectin binding proteins, fibrinogen binding proteins and many 
other adhesins on the surface of S. aureus. In another similar study deletion of extracellular 
adherence proteins decreased internalization of S. aureus into human fibroblast and epithelial 
cells [68] and complementation of  extracellular adherence protein restored internalization of the 
mutant strain into these cells [68].  In another study deletion of fibronectin binding proteins in S. 
aureus strain 8325-4 [527] reduced the adherence of the isogenic mutant strain  to MAC-T cells 
by 40% and internalization by more than 95% [132]. Similarily, Brouillette et al. [528] reported 
that S. aureus strain DU5883 lacking fibronectin binding protein showed 30% reduction in its 
ability to attach to MAC- T cells as compared to its isogenic wild type strain 8325-4. More 
importantly these authors showed that the presence of fibronectin binding proteins in S. aureus 
strain 8325-4 increased the colonization of the lactating mammary gland in the mouse model of 
mastitis as compared to mutant strain DU5883 under in vivo conditions. Taken all these findings 
together it is possible to conclude that colonization of host tissue surfaces including bovine 
mammary gland by S. aureus is achieved by multiple cell surface adhesins and inactivation of 
one or some of them would not abrogate bacterial attachment to host tissue surfaces because of 
compensatory effects by others.   
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Figure 4.5.2.1. Number of RN6390 bacteria and its isogenic GapC mutant strain H330 attached 
and internalized into MAC- T cells at 37 oC. 
The number of attached and/or intracellular bacteria (±S.D.) of wild type strain RN6390 at 37 °C 
was significantly higher than that of isogenic GapC mutant strain. T-A/I: Total number of 
attached and internalized bacteria; I: Internalized bacteria. The bars refer to mean of the total 
counts. The symbols above the bars indicate statistical differences between the groups (*: 
p<0.05; **: p<0.01). 
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Figure 4.5.2.2. Number of RN6390 bacteria and its isogenic GapC mutant strain H330 attached 
and internalized into MAC- T cells at 4 oC. 
The numbers of attached and/or internalized bacteria of wild type strain RN6390 at 4 oC was 
significantly higher than that of isogenic GapC mutant strain. T-A/I = Total number of attached 
and intracellular bacteria. The bar refers to mean of total counts. The symbols above the bars 
indicate statistical differences between the groups (*= p<0.05; **: p<0.01). 
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Figure 4.5.2.3. Number of intracellular bacteria recovered at different time points. 
The number of intracellular bacteria does not significantly change over time. T-A/I = Total 
number of attached and intracellular bacteria, I= Intracellular. The bars refer to the mean of total 
counts.
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Figure 4.5.2.4. Number of intracellular bacteria released into supernatants after incubation in 
fresh media without antibiotics.  
The thick bar indicates the mean of bacterial counts after 3hs while the thin bar indicates the 
mean of the bacterial count after 4hs of incubation. The mutant strain H330 was recovered from 
the supernatant which indicates that it did not kill MAC- T cells but stay in the intracellular area.    
 
 
4.5.3. Pilot Challenge Experiment Using the Staphyloccocus aureus Strains RN6390 and its 
Isogenic GapC Mutant H330 on Ovine Mammary Gland 
 
The ability of the GapC mutant S. aureus strain H330 to infect MAC-T cells has been 
determined in vitro.  The results from this experiment showed that the adhesion and invasion 
ability of H330 into MAC-T cells was significantly lower than that of the isogenic wild type 
strain RN6390 suggesting that in an in vitro model the GapC mutant would be less pathogenic. 
To confirm this hypothesis we conducted a challenge trial. Ovine mammary glands were infected 
with RN6390 and H330 and we monitored the responses over 4 days. Because of very high 
expenses that we could not afford to do this experiment in cows, we decided to conduct it in 
ovine mammary glands. We have conducted pilot challenge experiments to determine optimum 
challenge dose for RN6390 and H330 in the ovine mammary gland. For the pilot trial we 
screened 6 Suffolk breed dairy sheep in the first week of lactation and selected 3 animals based 
on SCC and milk bacteriological culture results (Table 4.5.3.1).  These animals (72M, 81P and 
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20P) were challenged with high (106), medium (104) and low (102
Table 4.5.3.1 Pre-screening of animals for intramammary infection for pilot challenge trial 
 
 
) CFU/ml doses of S. aureus 
strain RN6390 into the right side udder halves and H330 into left side udder halves respectively 
in a total volume of 1 ml. 
 
 
Anl. 
ID 
Udder Bacterial count and colony description SCC Remarks 
20P R White transparent colony, 1 CFU/200 µl Gram-positive 
rod. 
1.76 X 10  
 
Selected 
8 
L Small size colony, 1 CFU/200 µl, Gram-negative cocci. 1.95 X 108 
72M R No growth. 1.95 X 10  
selected 
7 
L Small size colony, Gram  negative cocci, 2 CFU/200 µl 2.27 X 107 
81P R No growth 1.24 X 10  
Selected 
8 
L Small size colony, about 5 CFU/200 µl, Gram-  
negative cocci 
1.36 X 108 
154M R White circular colony, 2 CFU/200 µl, Gram-positive 
cocci, staphylococci and small grayish colony of about 
3 CFU/200 µl, Gram-negative cocci. 
5.62 X 10  
Not  
selected 
7 
L Similar colonies as above, staphylococci 1 CFU/200 
µl, Gram negative cocci 2 CFU/200 µl. 
1 X 108 
194M R  Small grayish, Gram-negative colonies ca. 20 
CFU/200 µl and 2 CFU/200 µl of staphylococci. 
7.2 X 10  
Not 
selected 
7 
L 3 CFU/200 µl of Gram-negative cocci, 1 CFU/200 µl 
of staphylococci, 
6.95 X 107 
238P R 3 CFU/200 µl of  staphylococci 1.59 X 10 Not selected 8 
 L 2 CFU/200 µl of Gram-negative cocci and 1 CFU/200 
µl of staphylococci. 
1.83 X 108 
 
Abbreviations:  L= Left side udder, R= Right side udder, Anl.=  Animal, Anl. ID = animal 
identification number 
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Table 4.5.3.2. Pre-screening of animals for intramammary infection for in vivo challenge trial 
 
Anl. 
ID 
Udder Milk culture bacterial count SCC Body temp. 
in  °C 
Remark 
156 R No growth 4.27 X 10  
39.8 
6  
selected 
 
 
(Group 1) 
L ‘’ 3.67 X106 
157 R ‘’ 7.62 X 10  
39.9 
7 
L ‘’ 6.79 X 106 
158 R ‘’ 2.83 X 10  
39.7 
8 
L ‘’ 2.46 X 106 
159 R ‘’ 2.02 X 10  
39.5 
6 
L ‘’ 1.60 X 107 
160 R ‘’ 2.07 X 10  
39.4 
8 
L ‘’ 5.52 X 107 
161 R ‘’ 2.69 X 10  
39.7 
6  
selected 
 
(Group 2) 
L ‘’ 3.13 X 106 
162 R ‘’ 3.65 X10  
39.8 
7 
L ‘’ 7.27 X 106 
163 R 5 CFU/ml Gram  negative rod 2.87 X 10  
39.6 
6 
L 7 CFU/ml Gram  negative rods 2.133 X 106 
164 R No growth 3.24 X 10  
39.3 
6 
L ‘’ 8 X 108 
165 R 3 CFU/ml Gram negative cocci 1.29 X 10  
39.1 
8 
L 2 CFU/ml Gram negative cocci 2.47 X 106 
3R R 2 CFU/ml  Gram negative cocobacilli 6.67 X 10  
39.6 
6 Not 
selected L 50 CFU/ml Gram negative coccobacilli 5.66 X107 
 
26T 
R No growth 1.35 X 10  
39.2 
7 Not 
selected L 3 CFU/ml Gram positive cocci 2.95 X 106 
 
116P 
R 2 CFU/ml    Staphylococci 4.29 X 10  
39.3 
6 Not 
selected L 59 CFU/ml  Staphylococci 1.42 X 107 
 
20T 
R No growth 3.85 X 10  
39.4 
6 Not 
selected L 3 CFU/ml Gram positive cocci 1.64 X 107 
 
61S 
R 19 CFU/ml  Gram positive cocci 1.48 X 10  
39.0 
8  
Not 
selected 
L 3 CFU/ml Gram positive cocci 1.37 X 106 
 
Abbreviations: L= Left side udder, R= Right side udder, Anl.=  Animal, Anl. ID = animal 
identification number 
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Table 4.5.3.3. Summary of pre- and post-challenge bacterial and somatic cell counts in both trials.  
Anl.  
ID 
Udder Prechallenge 
bacterial count 
Prechallenge 
Somatic cell 
count/ml 
Challenge 
strain and 
dose/ml 
Post challenge bacterial 
count/ml 
Post challenge 
somatic cell 
count/ml 
 
20P 
    24hrs 48hrs 24hrs 48hrs 
R No growth 1.07 X 10 RN6390 
4.30  X 10
8 6.83 X 10
2  
8.3 X106 1.14X 
10
7 2.87X 
108 8 
L 2 CFU/200µl of 
Gram  negative cocci 
1.27 X 10 H330: 3.90 
X 10
8 6.1 X 10
2  
LDL 5 6.76 X 
10
1.86 X 
106 6 
 
72M R No growth 1.67 X 10 RN6390: 
4.5 X 10
7 5.1X10
6 
6.6 X108 2.66 X 
10
7 5.76 X 
108 8 
L No growth 2.54 X 10 H330: 
3.7 X 10
7 166 
6 
LDL 7.27 X 
10
4.10 
X106 6 
81P R No growth 4.31 X 10 RN6390: 
2.0  X 10
7 2.6 X 10
4 
1.1 X 108 9.79X108 9.12 X 
10
8 
8 
 L 1 CFU/200µl Gram  
negative cocci 
5.50 X 10 2.15 X 107 LDL 4 LDL 1.96 X 
10
5.6 X10
7 
6 
156 R No growth 4.27 X 10 H330: 
4.16 x 10
6 ‘’ 
6 
9 4.59 X 
10
1.02X10
6 
6 
L ‘’ 3.67 X10 ‘’ 6 ‘’ LDL 4.51 X 
10
2.95X10
6 
6 
157 R ‘’ 7.62X 10 ‘’ 7 ‘’ ‘’ 1.36 X 
10
8.12X10
7 
6 
L ‘’ 6.79X10 ‘’ 6 ‘’ ‘’ 3 X10 2.89X106 6 
158 R ‘’ 2.83 X 10 ‘’ 8 ‘’ 9X10 8.74 X 
10
3 1.7 X10
7 
6 
L ‘’ 2.46 X10 ‘’ 6 ‘’ LDL 4X10 6.66X106 6 
159 R ‘’ 2.02 X 10 ‘’ 6 ‘’ ‘’ 3.05 
X10
2.31X10
6 
6 
L ‘’ 1.608 X10 ‘’ 7 113 ‘’ 1.83 
X10
1.53X10
6 
6 
160 R ‘’ 2.07 X10 ‘’ 8 LDL ‘’ 2.51 
X10
1.75X10
7 
6 
L ‘’ 5.52X 10 ‘’ 7 ‘’ ‘’ 2.15X10 4.39X107 6 
161 R ‘’ 2.69 X 10 RN6390: 
140 
6 3.3X10 2X104 4.33 
X10
5 3.82X10
7 
8 
L ‘’ 3.13 X10 ‘’ 6 1.6 X10 1X104 5.54 X 
10
5 5.99X10
7 
8 
162 R ‘’ 3.65 X10 ‘’ 7 2.16 X10 2.16X105 2.27 
X10
6 2.21X10
7 
8 
L ‘’ 7.27 X 10 ‘’ 6 1.8X10 2.5 X105 5.19 
X10
6 7.08X10
7 
7 
163 R 5 CFU/ml Gram 
negative  rod 
2.87 X10 ‘’ 6 1.8X10 9X104 7.25X105 7.8X107 7 
L 7 CFU/ml Gram 
negative rods 
2.133 X10 ‘’ 6 2.16X10 1.6X103 9.11 
X10
5 6.93X10
7 
8 
164 R No growth 3.24 X10 ‘’ 6 2X10 8.3X105 4.35X105 6.6X108 7 
L ‘’ 8 X10 ‘’ 5 5X10 2.8X104 1.13X105 6.83X108 7 
165 R ‘’ 1.29X10 ‘’ 8 1X10 7.1X105 5 2.05 
X10
4.66X10
8 
8 
L ‘’ 2.47 X10 ‘’ 6 5X10 2.3 X104 2.66X106 1.75X107 8 
Abbreviations: L= Left side udder, R= right side udder, LDL= less than detectable level 
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Table 4.5.3.4. Peripheral blood mononuclear cells (PBMCs) count and number of intracellular 
bacteria after 24 hs of intramammary challenge 
 
Animal PBMCs/ml Number  of 
intracellular 
bacteria 
Temperature 
in °C 
20P 1.26 X 10 340 CFU/ml 7 40.9 
72M 9.11 X 10 1000 CFU/ml 6 39.9 
81P 8.43 X 10 60 CFU/ml 6 39.3 
 
The number of intracellular S. aureus recovered from bovine PBMCs is shown as well as the 
body temperature of the animals. 
 
4.5.3.1. Clinical Findings, Milk Bacteriological Culture Results and Somatic Cell Counts  
 
All three animals in the pilot challenge trial were healthy and their feed intake was 
normal before challenge. After 24 hs of intramammary infusions all three animals were sick, 
some of the clinical signs included loss of appetite, weakness, depression and slightly increased 
body temperature to 40.9 oC, 39.9 oC and 39.3 o
Milk bacteriological culture results showed that all three right side udder halves 
challenged with wild type strain RN6390 had high bacterial counts both at 24 hs and 48 hs post 
challenge whereas only two of left side udder halves (20P and 72M) had bacterial count of  10
C for  20P, 72M and 81P respectively.  The right 
side udder halves that received the wild type strain were swollen and bluish in color in all three 
animals which was an indication of gangrene development. Milk from all three right side udder 
halves of 20P, 72M and 81P animals had clots and was bloody in color. Milk from the left side 
udder halves that received H330 had no detectable changes in all animals. There were no 
clinically detectable changes in these udder halves. In this pilot experiment because of the 
limited number of animals, each of three animals received wild type bacteria into its right side 
udder and mutant into the left side udder.  Because of that we were not sure whether the response 
was only from wild type bacteria or if the mutant strain also contributed to the systemic effects. 
 
5 
and 102 CFU/ml  respectively at 24 hs post challenge (Table 4.5.3.3). After 48 hs post challenge 
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there were no bacterial counts from the three left side udders challenged by the mutant strain 
whereas counts from right side udders challenged with wild type strain was high in all udders 
and increased by 2 logs in the 20P udder that received a low dose of 102 CFU/ml. The absence of 
growth from udders challenged with the mutant strain at 48 hs might be due to removal of the 
mutant strain by the defense system. 
The somatic cell counts were relatively higher in all three animals even before challenge. 
However; their milk bacteriological culture results were negative except for 20P and 81P which 
have 2 and 1 CFU/ml of Gram negative cocci from the left side udder halves  respectively (Table 
4.5.3.3). It has been indicated that in ewes generally somatic cell counts  are high during early 
and late lactation and also that the SCC from healthy udders of ewes are variable and could reach 
up to 106 cells /ml of milk. In addition to this, the older ewes usually have high somatic cell 
counts compared to younger ones. In this case all three ewes are older and this might contribute 
to high somatic cell counts from these animals. Although they have high somatic cell counts 
before challenge, the somatic cell counts from udder halves challenged by mutant strain H330 
started dropping after 24 hs whereas counts from udder halves challenged with the wild type 
strain remained high throughout the follow up period of 48 hs (Table 4.5.3.3). 
 
Peripheral blood mononuclear cells (PBMCs) were isolated and the presence of 
interacellular bacteria was analysed. Results from this experiment showed that peripheral blood 
mononuclear cells from all three animals were found to have significant numbers of intracellular 
bacteria which is an indication of bacterial uptake by phagocytic cells (Table 4.5.3.4).  
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a. Udder halves challenged with 106 CFU/ml 
 
 
 
                                         
   
              
 
 
                   
 
b. Udder halves challenged with  104 
 
CFU/ml 
 
 
 
 
 
 
 
 
Righ half (72R):  
Challenge strain wild type RN6390, 
observed findings: udder half was 
swollen and bluish in color and milk 
was bloody.                                       
Left half (72L): 
Challenge strain GapC mutant H330, 
observed findings: no physically detectable 
changes in milk and udder half 
Right half (81R):  
Challenge strain RN6390, 
observed findings: udder half was 
swollen and bluish in color and 
milk was bloody.                                       
  
Left half (72L): 
Challenge strain H330, observed 
findings: no physically detectable 
changes in milk and udder halves. 
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a. Udder halves challenged with 102 CFU/ml 
       
 
 
 
 
 
 
 
Figure 4.5.3.1a-c. Clinical udder examination results after 48 hs of intramammary challenge with 
RN6390 and its isogenic GapC mutant strain H330. 
 
4.5.3.2. Gross Pathological and Histopathological Findings 
 
Gross pathological examination results of udder halves challenged with wild type strain 
RN6390 48 hs post challenge showed high accumulations of bloody exudates and the udder 
tissue was dark colored and swollen (Fig. 4.5.3.2a-c). The udder tissue challenged with the 
mutant strain had no grossly visible changes (Fig. 4.5.3.2a-c).  The examination results of 
hematoxylin and eosin stained udder tissues challenged with the  wild type strain showed 
massive infiltration of inflammatory cells, especially neutrophils (Fig. 4.5.3.3d-f).  In udder 
tissue challenged with high dose of 106 CFU/ml of the wild type strain RN6390 there was 
necrosis and masses of necrotic debris seen whereas in the udder tissue which received medium 
and low doses of 104 and 102 CFU/ml respectively, there were  large  infiltrations of 
inflammatory cells with less necrosis (Fig. 4.5.3.3d-f).  In udder tissue challenged with the 
mutant strain there were no visible histopathological changes (Fig. 4.5.3.3a-c). The examination 
results of Gram stained udder tissue challenged with the wild type strain revealed high number of 
Right half (20R):  
Challenge strain RN6390, observed 
findings: udder half was swollen and 
bluish in color and milk was bloody.                                       
Left half (20L): 
Challenge strain H330, observed findings: 
No physically detectable changes in milk 
and udder half.                            
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Gram positive cocci   (Fig. 4.5.3.4a-c) whereas there were no stainable bacteria in udder tissue 
challenged with the mutant strain.   
 
a. 72L
72R
b.81R
81L
c.  20R
20L
 
 
 
Figure 4.5.3.2a-c. Gross pathological changes in the right side udder halves that received wild 
type strain. 
 All udder halves challenged with wild type strain had high accumulation of bloody exudates. 
These udder halves were extremely swollen by high accumulation of bloody fluid as compared to 
the left udder halves that received the mutant strain. 
 
 
 
 
 
 
72L 
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a. 72L50X b. 81L50X                                             
c. 20L50X
 
Figure 4.5.3.3a-c. Haematoxylin and eosin stained mammary gland tissue experimentally 
challenged with GapC mutant strain H330.  
All three doses of the GapC mutant strain did not cause any change in the mammary gland tissue. 
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d.72R 50X: Necrotic debris of  
inflammatory cells disintegrated at 
the local area of inflammation. 
e. 81R 50X: Massive infiltration 
of neutrophils
f. 20R50X: Massive infiltration of 
inflammatory cells, mainly 
neutrophils.
 
Figure 4.5.3.3d-f. Haematoxylin and eosin stained mammary gland tissue experimentally 
challenged by wild type S. aureus strain RN6390. 
All three doses of wild type strain caused acute inflammation characterized by infiltration of 
inflammatory cells especially neutrophils. 
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 a. 72R50X: Gram positive coccci
were visible in the necrotic gland 
tissue.
b. 81R 50X: Gram  positive cocci
were visible in the gland tissue.
c. 20R50X: Gram  positive in the gland 
tissue. 
 
 
 
Figure 4.5.3.4a-c. Gram-stained mammary gland tissue from wild type strain RN6390 challenged 
udders.  
Gram-positive cocci are visible in all udders challenged by wild type strain.  
 
 
Conclusions from pilot challenge trial: 
 
1. The wild type S. aureus strain RN6390 is highly pathogenic for Sulffok ewes. The 
challenge doses of 106, 104 and 102
2. The GapC mutant strain H330 did not cause any detectable clinical or histopathological 
changes in the udder and milk. 
 CFU/ml were very high and animals developed 
severe acute mastitis that led to lameness and gangreneous udders within 24 hs.  
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Based on this result we decide to decrease the challenge dose for the wild type strain RN6390 to 
50 CFU/udder. 
 
4.5.4. Mastitis Challenge Trial with the Staphylococcus aureus Strain RN6390 and its 
Isogenic GapC Mutant Strain H330 on Ovine Mammary Gland (second trial) 
 
After the preliminary challenge trial we decided to conduct the challenge trial with 
increased animal numbers to determine whether these findings are statistically significant or not. 
We also decided to decrease the challenge dose for the wild type strain to 50 CFU/udder while 
that of the GapC mutant strain was maintained at 106
 
 CFU/udder.  The challenge protocol for the 
second trial is presented in (Table 4.5.3.2). The second trial was comprised of 10 Suffolk breed 
dairy sheep in the first week of lactation in two groups of five sheep per group.  All sheep in 
Group 1 were challenged with the GapC mutant S. aureus strain H330 whereas sheep in Group 2 
were challenged with the isogenic wild type strain RN6390. 
4.5.4.1. Clinical Findings, Post-Challenge Milk Bacteriological Culture Results and Somatic 
Cell Counts  
 
As expected, clinical findings in wild type strain-infused sheep were not as acute as in the 
pilot study because the challenge dose was lower; however, after 48 hs all animals infused with 
the wild type strain developed clinical mastitis characterized by swollen udders with a hard 
consistency, slightly discolored milk with moderate milk clots, slightly increased body 
temperature although all animals were feeding and none appeared depressed.  All animals 
infused with the mutant strain were healthy and there were no visible clinical signs of mastitis 
either locally in the mammary gland or systemically.  
 
In general, milk bacteriological culture results were similar to the results seen in the pilot 
study in terms of bacterial recovery, i.e. only very few numbers of mutant bacteria were isolated 
from the right side udder haves of animals 159 and 158 and the left side udder half of animal 156 
at 24 hs post challenge and none were isolated at 48 and 72 hs post challenge. All udder halves 
challenged with the wild type bacteria had high bacterial counts at 24 and 48 hs (Table 4.5.3.3) 
as well as at 72 hs (data not shown). The numbers of bacteria were slightly increased from 24 to 
48 hs and the total numbers of bacteria were less than the number of bacteria counted at the same 
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time point for the pilot study, which may have been due to the low challenge dose (Table 
4.5.3.3).  
 
Similar to animals in the pilot study, pre-challenge somatic cell counts were also high in 
some udder halves of these animals but relatively better than that of pilot study since most udder 
halves had counts in the normal acceptable range. Post-challenge somatic cell counts were 
increased and remained high throughout the monitoring period of 72 hs  in all animals 
challenged with the wild type strain RN6390 (Table 4.5.3.3). Similar to the pilot study, all udder 
halves challenged with the mutant strain had somatic cell counts that were slightly decreased, 
indicating that the mutant strain had no effect. 
 
4.5.4.2. Gross Pathological and Histopathological Findings 
 
In animals challenged by wild type bacteria, a gross pathological examination after 72 hs 
revealed high accumulations of bloody exudates in all udder halves whereas in animals infused 
with the mutant strain H330 the udder halves looked normal and there were no grossly visible 
changes in the udder tissue. 
 
 
 
 
 
 
                   
 
 
 
 
Figure 4.5.4.2. Gross pathological findings in udder halves challenged by wild type RN6390 (a 
and b) and mutant strain H330 (c and d). 
 
a.165 b.164 
c. 156 d.159 
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Histopathological examination of udder tissues challenged with the wild type strain 
RN6390 revealed moderate infiltration of inflammatory cells, especially neutrophils in the 
alveolar lumen. There was not as much tissue necrosis and damage as was seen in pilot study and 
also the numbers of inflammatory cells were not as high as in the pilot study. More importantly, 
there were macrophages and plasma cells which indicated progression of inflammation toward 
the chronic stage (Fig.4.5.4.3).  There were no visible changes in the hematoxylin and eosin 
stained gland tissue from the mutant strain challenged udder (Fig. 4.5.4.4). In the Gram-stained 
gland tissue from the RN6390 challenged udder, there were few Gram positive cocci as 
compared to the pilot study whereas no bacteria were observed in gland tissue from H330 
challenged udder (Fig. 4.5.4.5). 
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Figure 4.5.4.3a-d. Hematoxylin and eosin stained udder tissue from wild type strain RN6390 
challenged Udders.   
There were infiltrations of inflammatory cells mainly neutrophils which were visible in the 
alveolar lumen, however, their number was not as high as in the pilot challenge experiment. Also 
the tissue damage is moderate as compared to the pilot study. In panel a there are a few 
macrophages and plasma cells indicating progression toward chronic inflammation.  
 
 
 
a.164L: 50X 
d.165R:50X 
c.165L: 100X 
b.164R 
Macrophages Plasma cells 
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Figure 4.5.4.4a and b. Hematoxylin and eosin stained udder tissue from the mutant strainH330 
challenged udder. 
 No detectable infiltration of inflammatory cells was observed 
 
a. 156R: 50X b. 159R: 50X 
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Figure 4.5.4.5a-c. Gram-stained gland tissue from wild type strain RN6390 and mutant strain 
H330 challenged udder. 
 Compared to the pilot study there were fewer Gram-positive cocci in the gland tissue (panel a 
and b) whereas there were no visible bacteria in gland tissue challenged by mutant strain (panel 
c).  
 
 
 
a. 165L: 50X  b. 165R: 50X 
c. 156L: 50X 
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4.5.5. Discussion 
 
Staphylococcus aureus has several virulence factors mainly categorized as cell surface 
structural components, secreted toxins, enzymes and proteases (Table 1.2.1.1).  Some of these S. 
aureus cell surface structural components are considered adhesins which allow the bacteria to 
colonize the host through binding to specific and possibly non-specific ligands on the surface of 
host cells. These surface structural components are expressed during exponential growth of 
bacteria [50-54] and they are important for early attachment to the host cell surface which might 
allow the bacteria to escape the effects of natural and innate immune defenses through 
interference with recognition of epitopes or receptors. On the other hand, secreted virulence 
factors comprise toxins and enzymes (Table 1.2.1.1), which enable bacteria to invade and spread 
through the tissue of the host and they are collectively named invasins. In addition to these two 
broad categories of virulence factors S. aureus has many other mechanisms to adapt to the host 
environment such as immune evasion [56-58, 239, 529, 530], ability to attach and internalize into 
host cells and formation of small colony variants [531, 532]. The ability to attach in vivo [112-
114] and in vitro [113, 115-122] and internalize [113, 115, 116, 124-130] into host cells allows 
the bacteria to escape from humoral immune responses and from antibiotics by being hidden in 
the intracellular area. This might allow S. aureus to cause chronic recurrent intramammary 
infections of cows and endovascular infections in human. Moreover, its ability to develop 
resistance to most recent antibiotics such as vancomycin and also the ability to form electron 
transport defective slow growing small colony variants that are less pathogenic but more difficult 
to treat makes it a more powerfully equipped pathogen that might be difficult to treat in the 
future. To combat such a versatile pathogen it is very important to understand the detailed 
mechanisms involved in the pathogenesis of disease. We hypothesized that staphylococcal GapC 
by the virtue of its surface localization, may function as an adhesin for S. aureus colonization of 
mammary gland tissue during early access of S. aureus into the intramammary area. We had 
tested the adhesion and invasion ability of S. aureus strain RN6390 and its isogenic GapC mutant 
strain H330 (RN6390 gapC::tet) into MAC-T cells in vitro. Our results showed that the number 
of adhered and/or invaded RN6390 strain into MAC-T cells was significantly higher than that of 
the isogenic GapC mutant (H330) strain. This suggests the involvement of GapC as a S. aureus 
cell- surface receptor for attachment to bovine mammary epithelial cells. The wild type strain 
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RN6390 killed MAC-T cells and was released into the supernatant after 2, 3, and 4 hs   
incubation in fresh media without antibiotics. The GapC mutant strain did not kill MAC-T cells 
since no viable counts were obtained after 2, 3 and 4 hs of incubation in fresh media without 
antibiotics. Although viable, there was no apparent intracellular growth of the GapC mutant and 
this might have contributed to the lack of cell lysis. 
 
To determine whether the GapC mutant strain had a similar effect in vivo, we conducted a 
challenge trial on ovine mammary glands. Our results showed that the GapC mutant strain H330 
was unable to cause mastitis in sheep whereas the isogenic wild type strain RN6390 caused acute 
febrile infection that lead to lameness, complete loss of appetite, bloody milk and bluish and 
gangrenous mammary gland within 24 hs. Although the viable count of RN6390 and its isogenic 
GapC mutant strains in the inocula were nearly the same, low numbers of GapC mutant strain 
were recovered from milk compared to the very high counts seen with its wild type strain. This 
might be because of rapid removal of the mutant strain by the host immune system. The somatic 
cell count of some animals included in this study were relatively higher prior to the challenge 
which was in the acceptable range for sheep in the early lactation period; however, the post 
challenge count from udders challenged with the wild type strain remained elevated while counts 
of the mutant strain  dropped after 48 hs. Taking all our in vitro and in vivo results together we 
can conclude that GapC protein is an important virulence factor in the pathogenesis of S. aureus 
mastitis, at least in sheep. 
 
4.6. Regulation of Expression of gapB and gapC Genes. 
    
                                      
4.6.1. Introduction 
 
There are two major families of regulatory elements controlling the expression of 
virulence determinants in S. aureus. They include the sarA (staphylococcal accessory regulator) 
protein family and the two component regulatory system (TCRS), which comprises agr 
(accessory gene regulator), saeRS (S. aureus exoprotein expression), srrAB (staphylococcal 
respiratory response), arlSR (autolysis related locus) and lytRS systems [185-187]. These 
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systems are sensitive to environmental signals and consist of a sensor histidine kinase and a 
response regulator protein. We hypothesized that the expression of gapB and gapC of S. aureus 
might be controlled by agr and sar loci which are known to be global regulators of virulence 
genes in S. aureus. 
 
Microorganisms sense their immediate environment through their interactions with the 
environment and consequently respond to it by producing specific molecules that allow them to 
survive and multiply in that particular environment.  Pathogenic microorganisms upon entry into 
host tissue induce transcription and translation of their virulence genes to produce virulence 
factors that allow them to survive and multiply in the harsh environment of host tissue. The 
expression of virulence genes in pathogenic microorganisms has been shown to be influenced by 
pH, oxygen tension, temperature, nutrient availability, growth phase, iron and other factors [533-
536]. In S. aureus expression of virulence genes under in vitro condition by agr has been well 
characterized and regulation is known to be growth phase and cell density dependent.  However, 
under in vivo conditon the environmental stimuli that induce sar, agr and other regulatory genes 
transcription and translation are not well known.  The environmetal stimuli for sar expression is 
also not known. Few studies have shown that agr is repressed by alkaline pH and glucose [537, 
538] and the production of α-hemolysin is influenced by glucose, temperature and NaCl [539]. 
However, results from recent studies indicated that changes in S. aureus  genes expression 
previously believed to be due to a glucose effect  were instead due to a drop in pH as bacteria 
ferment glucose [536]. These authors also showed that many genes encoding extracellular 
virulence factors and genes involved in regulation of virulence factors are affected by a mildly 
acidic environment (pH 5.5).   It has also been shown that the expression of α-hemolysin, toxic 
shock syndrome toxin  and staphylococcal protein-A  was repressed by 1 M NaCl or 20 mM 
sucrose [540]. In another study the expression of staphylococcal respiratory response (srrA) and 
other unknown genes was shown to increase during anaerobic growth of S. aureus [541]. The 
role of external environmental factors as well as local microenvironmetal factors especially 
under in vivo condition in the induction of virulence gene transcription and translation need 
further investigation. 
To determine the role of sar and agr loci on the expression of gapC and gapB genes, total 
RNA was extracted from wild type strain RN6390 and its isogenic mutants agrA, sarA and 
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sarA/agr during exponential and stationary phases of growth.  Using specific primers for gapC 
and gapB, cDNAs was synthesized by RT-PCR and used in qRT-PCR reactions to determine 
expression of gapC and gapB genes.  The 16s rRNA gene is used as an internal control (section 
3.2.6).  We also decided to check whether protein expression correlated with mRNA expression 
and therefore, further analysed the expressions of GapB and GapC proteins under the same 
environmental conditions.  
 
 
4.6.2. Expression of gapC and gapB Genes in Wild type (RN6390) and its Isogenic agrA, 
sarA and Double (sarA/agr) Mutant Strains 
 
 
The results for the exponential phase-cultures showed that the expression of gapC in the 
AgrA and SarA/Agr double mutant strains was 1000-fold down-regulated whereas the 
expression of gapC in the sarA mutant strain was 10,000 fold down-regulated. The expression of 
gapB was 1000 fold down regulated in the AgrA mutant strain whereas the expression of gapB in 
the SarA mutant and double mutant strains did not change. The results of the stationary phase 
cultures indicated that the expression of GapC and GapB in the AgrA mutant strain did not 
change whereas the expression of gapC and gapB in SarA and SarA/Agr mutant strains was 4-
13- fold higher (Table 4.6.2.1). 
Table 4.6.2.1. Expression of gapC and gapB genes in wild type RN6390 and its isogenic agrA, 
sarA and double (sarA/agr) mutant strains 
 
 
4.6.3. Expression of gapB and gapC Genes under Different Environmental Conditions 
 
4.6.3.1. Expression of gapB and gapC Genes under Different Environmental Conditions during 
the Exponential Phase of Growth. 
 
Strain                                            Fold change 
  Exponential phase cultures Stationary phase cultures 
 16s rRNA gapB gapC gapB gapC 
RN6390 + 1 + 1 + 1 + 1 + 1 
agrA mutant + 1 - 100 - 100 + 0.17 + 0.77 
sarA mutant + 1 + 0.29 - 1000 + 5.46 + 4.44 
sarA/agr mutant + 1 + 0.29 - 100 - 5.50 + 13.84 
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i. Effect of pH    
                
                In TSB the expression of gapC in SA16 and SA6390 was slightly increased at pH 5 
and in SA6390 at pH 7.4 whereas gapB expression did not change in all strains. In whey, growth 
of all strains at pH 5 and pH 7.4 was poor in the first 7 hr of incubation. Due to this poor growth 
rate, it was not possible to isolate sufficient RNA. However, at 24 hrs all strains had grown to the 
stationary phase and thus I was able to purify RNA from these cultures (Table 4.6.3.1). 
 
ii. Effect of Growth Media 
 
In TMG the expression of gapB and gapC increased in SA10 and SA12 and did not 
change in SA16 and SA6390, whereas in TMS their expression increased only in SA10 and 
remained unchanged in SA12, SA16 and SA6390. In whey, expression of both gapB and gapC 
increased in SA10 and decreased in SA16 and SA6390 (Table 4.6.3.1). 
 
iii. Effect of Oxygen Tension 
 
 
  In anaerobic growth conditions, the expression of gapB and gapC was slightly increased 
in SA12, SA16 and SA6390 and decreased in SA10 whereas in microaerophilic growth 
conditions, their expression increased in SA12 and SA6390, did not change in SA10 and 
decreased in SA16. In high CO2
 
 
 
 
 
, expression of gapB and gapC increased in all strains except for 
a slight decrease of gapC expression in SA10 (Table 4.6.3.1).       
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Table 4.6.3.1. Expression of gapC and gapB genes under different environmental conditions 
after 7 hs of incubation (Late exponential growth phase) 
 The expression of gapC and gapB were measured at the late exponential phase of growth (7 hs) 
in different growth media (standard growth media (TSB), defined growth media (TMS and 
TMG) and whey),  at different pH (5 and 7.4) and oxygen tension (aerobic, anaerobic, 
microaerophilic and high CO2
Env. 
condition  
) in different S. aureus strains SA10, SA12, SA16 and SA6390.  
The 16s rRNA gene is used as internal control gene. The fold changes in all conditions 
mentioned is calculated as compared to standard growth media (TSB). 
    
 
Test media Fold change in gapB and gapC gene expression  in different S. aureus strains  
  SA10 SA12 SA16 SA6390 
  16s gapB gapC 16s gapB gapC 16s gapB gapC 16s gapB gapC 
pH TSB- pH5 1 .2 .6 1 + 1.3 + 1.1 1 .5 + 3.2 1 0.1 + 2.2 
TSB- pH7.4 1 .3 + 1.1 1 .61 + 1.4 1 0.3 .5 1 0.5 + 2.7 
Whey- pH5 1 - - - - - - - - - - - 
Whey-  pH7.4 1 - - - - - - - - - - - 
Growth 
media 
TSB (standard) 1 1 1 1 1 1 1 1 1 1 1 1 
TMG 1 + 7.7 + 8 1 + 111 + 123 1 .7 .8 1 1 + 1.7 
TMS 1 + 6.2 + 4.9 1 .1 - 10 1 + 1.2 .9 1 + 1.2 + 1.4 
Whey 1 + 8.2 + 8.2 1 + 1.7 1.1 1 - 1000 .3 1 - 10 .1 
Oxygen 
tension 
Aerobic 1 1 1 1 1 1 1 1 1 1 1 1 
Anaerobic 1 0.1 .1 1 + 1.4 + 1.6 1 + 1.4 + 1.4 1 + 2.8 + 1.5 
Micro- 
aerophilic 
1 0.8 + 1.4 1 + 2.8 + 2.4 1 0.2 0.4 1 + 2.6 +  6 
High CO 1 2 + 362 .5 1 + 4.2 + 25 1 + 1.1 1 1 + 16 + 11.3 
 
 
 
4.6.3.2. Expression of gapB and gapC Genes under Different Environmental Conditions during 
Stationary Phase of Growth. 
 
i. Effect of pH 
 
In TSB at pH 5 the gapB and gapC expression were increased in SA10 and SA16 
respectively and decreased in other strains whereas in whey at pH 5 gapB was increased in 
SA10, SA12 and SA6390 and decreased in SA16.  In whey at pH 5, gapC was slightly increased 
in SA16 and not changed in the other strains.  In TSB at pH 7.4, gapB expression decreased in 
SA16 whereas expression of both gapB and gapC did not change in the other strains. In whey at 
pH 7.4, gapB expression increased in SA10, SA12 and SA6390 and decreased in SA16 however 
expression of gapC was not changed in any of the strains (Table 4.6.3.2). 
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ii. Effect of Growth Media. 
 
In TMG and TMS the expression of gapB was increased in SA10, SA12 and decreased in 
SA16 and SA6390. The gapC expression was increased in SA10, SA12 and SA16 and decreased 
in SA6390. In whey, gapB was up-regulated in SA10 and down- regulated in SA16 and SA6390 
and remained unchanged in SA12. The gapC was down regulated in SA6390 and remained 
unchanged in SA10, SA12 and SA16 (Table 4.6.3.2). 
 
iii. Effect of Oxygen Tension. 
 
In anaerobic growth conditions gapB expression was increased in SA10 and remained 
unchanged in SA12, SA16 and SA6390 whereas gapC was not changed except for a slight 
increase in SA16. In microaerophilic conditions gapB expression was increased in SA10, SA12 
and SA16 and not changed in SA6390 whereas, gapC expression increased in SA12 and SA16 
and remained unchanged in SA10 and SA6390. In high CO2 conditions gapB was increased in 
SA10 and SA6390 and decreased in SA16 and not changed in SA12 whereas gapC was slightly 
up-regulated in SA10, SA16 and SA6390 and remained unchanged in SA12 (Table 4.6.3.2). 
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Table 4.6.3.2. Expression of gapC and gapB genes under different environmental conditions 
after 12 hs of incubation (Stationary growth phase). 
The expression of gapC and gapB were measured at the stationary phase of growth (12 hs) in 
different growth media (standard growth media (TSB), defined growth media (TMS and TMG) 
and whey),  at different pH (5 and 7.4) and oxygen tension (aerobic, anaerobic, microaerophilic 
and high CO2
 
 
 
) in different S. aureus strains SA10, SA12, SA16 and SA6390. The 16s rRNA 
gene is used as internal control gene. The fold changes in all conditions mentioned was 
calculated as compared to standard growth media (TSB). 
 
4.6.4. Expression of GapB and GapC Proteins under Different Environmental Conditions 
 
The expression of gapC and gapB genes of S. aureus strains SA10, SA12, SA16 and 
RN6390 were analyzed under different environmental conditions such as growth media, pH and 
oxygen tension at different time points. To determine whether the transcript expression level in 
each of these strains matched with the expression of the corresponding proteins the amount of 
cellular and extracellular GapB and GapC proteins were determined by western blots. 
 
The results from this experiment showed that there were significant amounts of GapC 
proteins in the supernatants of growth media (Fig. 4.6.4.1a-f) as well as in the whole cell lysates 
(Fig. 4.6.4.2a-e).  The GapB protein was not seen in the supernatants and whole cell lysates of 
the SA10 and RN6390 strains whereas its presence was seen in SA12 and SA16 under some 
Env. 
condition  
Test media Fold change in gapB and gapC genes expression  in different S. aureus strains  
  SA10 SA12 SA16 SA6390 
  16s gapB gapC 16s gapB gapC 16s gapB gapC 16s gapB gapC 
pH TSB- pH5 1 + 13 0.9 1 .7 .3 1 - 10 + 2 1 -1000 - 10 
TSB- pH7.4 1 + 1.4 + 1.1 1 .4 .7 1 - 100 .4 1 0.7 0.7 
Whey- pH5 1 + 17 + 1.4 1 1.5 0.8 1 - 10 + 3 1 + 73 0.9 
Whey-  pH7.4 1 + 57 1 1 + 78 0.5 1 - 10 + 1.6 1 + 1.5 0.5 
Growth 
 media 
TSB 
(standard) 
1 1 1 1 1 1 1 1 1 1 1 1 
TMG 1 + 46 + 2 1 + 3 + 1.3 1 - 10 + 831 1 .70 .8 
TMS 1 + 22 + 4 1 + 3 + 2 1 - 10 .6 1 - 10 - 10 
Whey 1 + 2.2 .6 1 .8 .3 1 - 100 .6 1 - 10 -  
Oxygen 
tension 
Aerobic 1 1 1 1 1 1 1 1 1 1 1 1 
Anaerobic 1 + 17 1.5 1 0.6 .4 1 - 10 + 1.8 1 1 .4 
Micro- 
aerophilic 
1 + 46 0.6 1 + 1.8 + 29 1 + 1.2 + 3.2 1 0.8 0.5 
High CO 1 2 + 12 + 1.9 1 .9 .8 1 - 10 + 4.9 1 + 2.6 + 1.5 
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growth conditions.  The amount of GapC protein in the supernatants and whole cell lysates of the 
tested strains did not correlate under some conditions with the amounts of messenger RNA 
previously determined under similar growth conditions. The amounts of GapC protein in the 
supernatant of growth media (Fig. 4.6.4.1a-f) were more consistent than the amount in the whole 
cell lysates (Fig. 4.6.4.2a-f). The amount of GapC protein in the supernatants of cells grown in 
TSB was consistently higher than its amount in other media tested (Fig. 4.6.4.1a).  The amount 
of GapC protein in the whole cell lysates grown in TSB under microaerophilic condition was 
much more consistent than any other conditions tested (Fig. 4.6.4.2f).   
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Media
GapB
GapC
55
36
M B C 12h 7h 12h 7h 12h 7h 12h
TMG
12 16 6390
TMS
10Strain
Fold                  gapB 3       .7     .01    1     .7     6.2    46.8
Change            gapC 1      .8      831   1.7  .8     4.9     2
55
36
M    B    C
Media TSB                                   TMG
12 hrs             7h   12h    7h
GapB
GapC
Strain 10     12    16     6390        10        12
Fold         gapB 1       1        1        1      7.7  46.8  7.7
Change   gapC 1       1        1        1        8     2      8
Figure 4.6.4.1a-f. GapB and GapC proteins from the supernatants of cells grown in different 
media.  
 
 
 
 
 
 
  
 
 
 
 
 
a. Supernatants from cells grown in TSB and TMG 
M= Marker, B= GapB (positive control), C= GapC (positive control), TSB= 
Trypticase sy broth. TMG = Tris minimal glucose media. 
 
 
 
 
 
 
 
 
 
b. Supernatants from cells grown in TMG and TMS  
M= Marker, B =GapB (positive control), C= GapC (positive control), TMS= Tris 
minimal succinate media, TMG = Tris minimal glucose media 
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55
36
7h 12h  7h  12h  7h    12h   7hM     B    C
Media TMS                          TSB-AN
Strain                      12             16        6390         10         
GapB
GapC
Fold               gapB .1     3     1   .01   1      .05  .12   
Change            gapC .07   2    .9   .6    1.4     .04   .15
55
36
M     B        C 12h   7h    12h  7h   12h    7h        12h
GapB
GapC
Media TSB- Anaerobic
Strain                      10       12            16           6390      
Fold                gapB 17.8  1.4   .65  1.4   .02  2.8      1   
Change          gapC 1.5   1.62  .43  1.4   1.9   1.5     .4 
 
 
 
 
 
 
 
 
 
 
c. Supernatants from cells grown in TMS and TSB-under anaerobic condition 
M= Marker, B =GapB (positive control), C= GapC (positive control), TMS= Tris 
minimal succinate media, TSB-AN = Trypticase soy broth, anaerobic conditions. 
 
 
 
 
 
 
 
 
d. Supernatants from cells grown in TSB under anaerobic condition 
M= Marker, B =GapB (positive control), C= GapC (positive control), TMS= Tris 
minimal succinate media, TSB-Anaerobic = Trypticase soy broth, anaerobic 
conditions. 
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55
36
GapB
GapC
Media whey    
Strain                     10   12   16  6390
M  B    C 12 hs
Fold             gapB 2.3  .81 .002 .02      
Change      gapC .63 .31 .61   .09
55
36
GapB
GapC
Media              TSB-microaerophilic
M   B   C
Strain          10              12               16     6390
7h    12h    7h  12h   7h  12h  7h
Fold         gapB .8     47    3    2     .3      1   2.6      
Change   gapC 1.4   .63    2   30    .4      3    6
 
 
 
 
 
 
 
 
 
e. Supernatantss from cells grown in TSB under microaerophilic condition 
M= Marker, B =GapB (positive control), C= GapC (positive control), TMS= Tris 
minimal succinate media, TSB-microaerophilic = Trypticase soy broth, 
microaerophilic conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
f. Supernatants from cells grown in whey 
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55
36
M     B    C
GapB
GapC
Media                           TMS
Strain                            SA10
Fold GapB .09      22.62          6.2
change GapC .65      4.43            4.9
3h    12h   3h   7h
GapB
GapC
Fold change          GapB .5   7 .5 7 46    6    111                         
GapC .5 8 .5      8      2    1.7 123
55
36
M      B     C
Media                                                     TMG
Strain                            SA10                        SA12
3h  7h    3h    7h    12h   3h  12h
Figure 4.6.4.2a–e. GapB and GapC proteins in the whole cell lysate grown in different media.  
 
 
 
 
 
 
 
 
 
 
 
 
a. Whole cell lysate from strains grown in TMG 
M= Marker, B= GapB (positive control), C= GapC (positive control), TMG= Tris 
minimal glucose media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. Whole cell lysate from strains grown in TMS 
M=Marker, B=GapB (positive control), C= GapC (positive control), TMG= Tris 
minimal glucose media. 
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55
36
M    B    C 3h    7h   12h    3h  7h  7h 12h
Media                                      TMS
Strain                             SA12                SA16
GapB
GapC
Fold                  gapB 1.8    .1    3     19      1        .01                                
change              gapC 0.75   .07  2     64    .93   .61
GapB
GapC
55
36
M    B    C
Media                       TSB
Strain                      12              16             6390  
7h   12h    7h    12h   7h      12h
Fold                    gapB 3       2      0.3     1     2.6    .81      
Change               gapC 2       30       .4     3       6     .5
 
 
 
 
 
 
 
 
 
 
 
c. Whole cell lysate from cells grown in TMS 
M=Marker, B=GapB (positive control), C= GapC (positive control), TMS= Tris 
minimal succinate media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M=Marker, B=GapB (positive control), C= GapC (positive control), TSB: 
Trypticase soy broth. 
d. Whole cell lysate grown in TSB- under microaerophilic condition 
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55
36
M     B       C 7h      12h
Media            TSB-under microaerophilic condition
Strain                               SA10
GapB
GapC
Fold            gapB .81    46.85
Change        gapC 1.4     .63
d.  
 
 
 
 
 
 
 
 
 
 
e. SA10 whole cell lysate in TSB under microaerophilic condition 
M=Marker, B=GapB (positive control), C= GapC (positive control), TSB: 
Trypticase soy broth. 
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4.6.5. Discussion 
 
 
In general SarA promotes the expression of the genes for most of the S. aureus cell 
surface structural components and down regulates some of them, whereas agr down regulates the 
expression of genes for S. aureus cell surface structural components but up regulates the gene 
expression of secreted products [52, 181]. In the agrA mutant strain the expression of gapB and 
gapC were decreased by 1000 fold in exponential phase cultures whereas their expressions did 
not change in post-exponential phase cultures. AgrA is a response regulator in the agr two 
component regulatory system and its absence decreased expression of both GapB and GapC 
proteins on the surface of S. aureus, however, their expression during post exponential phase 
were not affected. This might be due to the presence of other regulatory mechanism such as SarA 
and its homologues as well as a sigma factor which are known to control expression of several 
genes during the post exponential phase of growth. 
                            
                     In a sarA mutant strain the expression of gapB was not affected whereas the 
expression of gapC was more than 10000 fold down regulated in exponential phase cultures, 
however, in stationary phase cultures both gapB and gapC were slightly up regulated. This might 
indicate that the expression of gapC is more influenced by sarA than that of gapB. Similar to the 
post exponential situation with the agrA mutatnt strain there might be other regulatory genes, for 
example,  agr that compensate for the lost activity of sarA in the sar mutant strain. 
 
                 In the double mutant strain (sar/agr) the expression of gapC is decreased by about 
1000 fold in exponential phase cultures whereas gapB expression was not affected. In post 
exponential cultures the expression of both gapB and gapC were slightly up regulated.  Again, 
this might indicate that the expression of gapC is more controlled by the agr and sar regulons 
than is gapB. Generally gapC gene expression is more affected by these universal regulators than 
is gapB. 
 
The amount of GapC protein in the supernatant of tested growth media was relatively 
higher and more consistent than the amount seen in the whole cell lysate. The amount of GapC 
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protein in the supernatant as well as in the whole cell lysate of cultures in some of the growth 
media did not match with the corresponding amount of transcripts previously determined under 
similar environmental conditions. This can be due to several factors such as differences in the 
daily microenvironment, the presence of the proteins at different locations which might make its 
quantification inaccurate, as well as variation in the regulation of GapB and GapC under 
different environmental conditions.   The amount of GapC protein in the supernatants of cultures 
in most of the media tested and especially in the whole cell lysate and supernatant of cells grown 
in TSB- under microaerophilic condition was consistent. The GapB protein was not seen in some 
strains such as SA10 and RN6390; however, it is visible in SA12 under some growth condition.  
In general GapC was detectable in all strains tested and it seemed to be conserved in most S. 
aureus strains compared to GapB.  Overall there were no consistent correlations between strains 
as well as in individual strains under different environmental conditions tested. These findings 
were not surprising since S. aureus has multiple gene regulation mechanism which might vary 
among strains, environmental conditions and stages of bacterial growth [185, 187]   
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5. CONCLUSIONS 
 
1. From two surface GAPDH antigens of S. aureus that appear to be conserved among 
pathogenic strains, a chimeric gene encoding the GapC and GapB proteins as a single 
entity (GapC/B chimera) was constructed as the basis for a multivalent vaccine. 
2. Immunization with the recombinant GapC/B chimera resulted in significant humoral and 
cellular immune responses comparable to responses to the individual proteins. 
3. Vaccination with gapB, gapC and gapC/B  plasmid DNA did not result in a significant 
increase in cellular and humoral immune responses in C-57BL/6 mice  
4. Vaccination with gapB, gapC and gapC/B plasmid DNA followed by booster vaccination 
with GapB, GapC and GapC/B proteins induced significant cellular and humoral immune 
responses in C-57 BL/6 mice. 
5. Vaccination at the area drained by the supramammary lymph node resulted in better 
immune responses in the mammary gland of cows.  
6. The GapC/B protein with VSA-3 as adjuvant was the best formulation in terms of 
incuducing the highest immune responses in Holstein dairy cows. 
7. The duration of GapC/B intramammary immune responses were approximately four 
months in Holstein dairy cows. 
8. The number of wild type strain RN6390 that were attached and internalized into MAC- T 
cells was significantly higher than that of the isogenic GapC mutant strain H330. 
9. The internalized wild type strain RN6390 started killing MAC-T cells 4 hs post infection   
whereas the isogenic GapC mutant strain H330 did not kill cells within this period of 
incubation. 
10. The GapC mutant strain H330 was unable to cause mastitis in sheep whereas the isogenic 
wild type strain RN6390 caused acute febrile infection that lead to symptoms of mastitis 
within 24 hrs. 
11. The GapC protein is an important virulence factor in S. aureus mastitis 
12. The expression of the gapB and gapC genes in S. aureus is controlled by the universal 
virulence genes regulators, agr and sar.  
13. The expression of gapB and gapC genes in different species of S. aureus was not 
consistent under different pH, growth media and oxygen tensions. 
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